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General introduction, aim and 
outline of the thesis




Cardiovascular disease (CVD) is the leading cause of death worldwide. Accord-
ing to the World Health Organisation (WHO), 17.8 million individuals died from 
CVD in 2017, representing about 30% of all deaths, and this number continues 
to rise [1]. Unfavourable changes in lifestyle including an unhealthy diet, low 
physical activity, and tobacco use strongly predispose to CVD [2]. Other classical 
CV risk factors include elevated blood pressure (hypertension), elevated circu-
lating lipids (dyslipidaemia), obesity and impaired glucose regulation (insulin 
resistance). Worldwide, the prevalence of obesity has tripled since 1975, while 
an estimated 1.1 billion people have hypertension [3]. The vast majority of CVD, 
including stroke and myocardial infarction, are caused by atherosclerosis. Ce-
rebral small vessel disease is another important cause of CVD, accounting for 
one fourth of all ischemic strokes, and is also a major contributor to cognitive 
decline and dementia [4, 5]. Cerebral small vessel disease and atherosclerosis 
share several histopathological findings, and share several risk factors, including 
hypertension and smoking.
Reducing the burden of deaths and disability from CVD, including myocardial 
infarction, stroke, heart failure or limb ischemia, can be achieved by prevention, 
which involves a robust reduction of risk factors. This is achievable with gov-
ernment policies that promote a healthy lifestyle, as for example the ‘Nationaal 
Preventie-akkoord’ aims to reduce smoking and obesity in the Netherlands. Un-
fortunately, government policies to promote lifestyle adjustment are generally 
still lacking, especially in middle and low-income countries where CVD is high-
ly prevalent. Currently, in addition to lifestyle interventions, the best strategy 
to reduce the CVD burden is with pharmacological therapy targeting CV risk 
factors. Pharmacological therapy includes lipid-lowering therapy for dyslipidae-
mia, anti-hypertensive drugs for hypertension, and glycaemic control in diabe-
tes mellitus. Lipid-lowering therapy is the most effective drug-based treatment, 
resulting in a 25 to 40% CV risk reduction [6]. Put in other words, about 70% of 
the future CV events are not prevented by therapeutic strategies, so a consider-
able residual CV risk remains. As a consequence, many individuals still develop 
first or recurrent CV events until today.
Inflammation as cardiovascular risk factor
In the past twenty years, it has been firmly established that inflammation is 
an independent risk factor for CVD, that accounts in part for this residual risk. 
Chronic systemic inflammatory diseases, including auto-immune/inflammatory 
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diseases, have emerged as an independent risk factor for CVD over the last de-
cades [7]. This is illustrated by patients with rheumatic arthritis, who have an 
2-4x higher risk for CVD [8], and severe periodontitis that almost doubles the 
risk for CVD [9]. The focus of CVD research has drastically changed through these 
and other observations. The current research questions that are addressed in 
the CVD field aim to unravel the role of inflammation in the pathophysiology of 
atherosclerotic CVD, with the ultimate goal to identify novel pharmacological 
targets to treat or prevent CVD.
CVD research has shifted from the perspective that atherosclerosis is a passive 
lipid-storage driven disease to an active inflammation driven disease [7]. In fact, 
chronic low-grade arterial wall inflammation is now recognized as major driver 
of atherosclerotic plaque development. Novel visualisation techniques, such as 
fluorine 18 fluorodeoxyglucose positron-emission tomography ([18F]FDG PET) 
scanning, allow for the detection of vascular wall inflammation in vivo by radio-
active labelled glucose uptake in the vascular wall in humans. Individuals with 
(risk factors for) CVD show increased [18F]FDG-uptake in the large arteries and 
in hematopoietic tissues such as the bone marrow and spleen, and this strongly 
predicts future CV events [10, 11]. [18F]FDG PET scanning has thus demonstrat-
ed that chronic low-grade inflammation of the arterial wall is an important com-
ponent in the development of atherosclerosis.
Large randomized controlled trials have been conducted to determine whether 
anti-inflammatory therapies can reduce the risk of CV events. The Canakinum-
ab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) documented that 
targeting inflammatory pathways, specifically the cytokine interleukin-1β (IL-
1β), led to a 15% reduction in CV event risk in patients with CVD receiving lip-
id-lowering therapy, but also led to a slightly higher incidence of fatal infections 
[12]. As a consequence, canakinumab did not obtain US Food and Drug Adminis-
tration-approval for CVD. In addition, colchicine, an old anti-inflammatory drug 
mainly used to treat gout, led to a 25% lower risk of ischemic CV events among 
patients with a recent myocardial infarction in the Colchicine Cardiovascular 
Outcomes Trial (COLCOT) [13]. Colchicine also reduced CV events in patients 
with chronic coronary artery disease with 30% [14]. However, the risk for pneu-
monia also significantly increased in the colchicine-treated group. In contrast, 
methotrexate, a general inflammatory inhibitor used for rheumatic arthritis, 
psoriasis and Crohns disease, did not affect CV outcomes in the Cardiovascular 
Inflammation Reduction Trial (CIRT) [15]. Even though CV therapeutic research 
has advanced rapidly, these drugs inhibit immune pathways rather broadly and 
have considerable side effects such as the increased infection risk. Therefore, a 
deeper understanding of the inflammatory pathophysiological mechanisms in 
atherosclerosis is needed to identify specific targets for prevention and therapy 
in atherosclerosis. 
In this thesis, I aimed to further unravel the role of monocytes and monocyte-de-
rived macrophages in the pathophysiology of atherosclerotic and arterioloscle-
rotic CVD, in particular regarding a novel mechanism that can explain persistent 
activation of these cells, which is called trained immunity. In this introduction, 
I will first describe the (inflammatory) processes driving the initiation, develop-
ment and progression of the atherosclerotic plaque. Subsequently, I will discuss 
the role of monocytes and the concept of trained immunity as a novel mecha-
nism for persistent immune cell activation. 
The pathophysiology of atherosclerotic CVD
Atherosclerosis is the main underlying pathological process of CVD, a chronic, 
low-grade inflammatory disorder of the arterial wall, in which monocyte-de-
rived macrophages play a key role in driving non-resolving inflammation [16, 
17]. Atherosclerotic plaques can ultimately suffer from rupture or erosion, 
which triggers acute luminal thrombotic occlusion, leading to myocardial infarc-
tion, stroke, or acute limb ischemia. 
Figure 1. The development of the atherosclerotic plaque. Originally from: Libby, P., Ridker, P. & 
Hansson, G. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 
317–325 (2011). ISSN 1476-4687 (online).
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An atherosclerotic plaque is characterised by subendothelial accumulation of 
apolipoprotein-B-containing lipoproteins, immune cells, vascular smooth mus-
cle cells, fibroblasts, and extracellular matrix components (Figure 1). Athero-
sclerosis is initiated by the entry and retention of apolipoprotein-B-containing 
lipoproteins in the subendothelial vessel wall. This occurs in regions where the 
vascular wall is prone for endothelial dysfunction, for example where shear 
stress is low and laminar blood flow is disturbed. Subsequently, apoB lipopro-
teins, particularly after oxidative modification, acquire features of damage-as-
sociated molecular patterns (DAMPs) and thereby trigger an inflammatory 
response. This response further activates endothelial cells which initiates endo-
thelial adhesion molecule expression and secretion of signalling molecules that 
in turn promote innate immune cells, predominately monocytes, to enter the 
intima layer. The importance of monocytes in the initiation of atherosclerosis is 
illustrated by the observation that atherosclerosis development is reduced in 
animal models by preventing monocyte migration into the vascular wall [18]. In 
addition, lipoprotein-driven activation of monocytes can already occur within 
the circulation and leads to an increased influx of immune cells into the arterial 
wall [19]. Once in the intima layer, monocytes differentiate into pro-inflamma-
tory macrophages and continue to accumulate. Pro-inflammatory macrophages 
produce cytokines/chemokines upon stimulation with local DAMPs contributing 
to a non-resolving inflammatory response [20]. Subsequently, an adaptive im-
mune response is initiated that involves T-helper (Th) 1 cells, Th-2, Th-17 and 
B-cells in conjunction with other cell types that promote atherosclerotic lesion 
progression [21, 22]. 
Eventually, these inflammatory responses become chronic, non-resolving and 
can lead to plaque destabilisation. For example, apoptosis of lipid-laden im-
mune cells leads to the creation of a necrotic core and destruction of extra-
cellular matrix through secretion of matrix metalloproteinases (MMPs) leads 
to plaque thinning. Plaque destabilisation can ultimately result in rupture or 
erosion which causes arterial occlusion. 
Although the role of innate immune cells in atherosclerosis has been well es-
tablished, it still remains elusive why the strong inflammatory response in the 
arterial wall persists over time. Therefore, attention is shifting towards newly 
discovered pathophysiological mechanisms in atherosclerosis. We propose that 
trained immunity contributes to this persistent inflammation.
Trained innate immunity
Recently, it has been discovered that innate immune cells can build an immu-
nologic memory after a brief immunological challenge [23]. Acquiring memory 
has always been thought to be an unique feature of the adaptive immune sys-
tem, but innate immune cells such as monocytes also appear to be capable to 
build non-specific memory responses after initial stimulation. The first evidence 
of innate immune memory originates from studies in plants and invertebrates, 
which lack adaptive immunity. In plants, systemic acquired resistance leads to 
non-specific protection against a broad spectrum of pathogens after inoculation 
with a pathogen [24, 25]. Invertebrates such as Drosophila species (fruit flies) 
that lack T- and B-cells, rely completely on their innate immune system: still they 
are capable to build protective adaptive immune responses upon reinfection 
[26, 27]. Studies in mice have demonstrated the role of innate immune memory 
by showing that activated monocytes provide non-specific protection against 
candidiasis after treatment with the Bacillus Calmette-Guérin (BCG) vaccine 
[28]. Also, studies in severe combined immunodeficient mice (SCID mice, that 
lack T- and B-cells) have shown protective effects of BCG vaccination against a 
subsequent lethal challenge with Candida albicans, which, in the absence of T- 
and B-cells, truly reflects innate immune memory [29]. Proof-of-principle stud-
ies with BCG vaccination in humans, demonstrated that this vaccine induces an 
immunologic memory of innate immune cells, characterized by a non-specific 
activation of monocytes, that persisted for at least 3 months [29]. 
Figure 2. Schematic overview of trained innate immunity. Originally from: Netea, M.G., Domín-
guez-Andrés, J., Barreiro, L.B. et al. Defining trained immunity and its role in health and dis-
ease. Nat Rev Immunol 20, 375–388 (2020). Nature Reviews Immunology ISSN 1474-1741 (online).
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This innate immune memory has been termed trained immunity, and describes 
the long-term functional reprogramming of innate immune cells, including 
monocytes/macrophages, upon brief exposure to exogenous or endogenous 
compounds leading to an altered response after the second challenge (Figure 
2) [30, 31]. The increased pro-inflammatory cytokine production (e.g. TNFα and 
IL-6) upon restimulation after the initial challenge is the hallmark of trained im-
munity. Monocytes can adapt a long-term pro-inflammatory phenotype after 
brief exposure to various exogenous microbial products, such as BCG, or Can-
dida albicans and its cell-wall component β-glucan [32]. More recently, it was 
reported that trained immunity can also be induced by endogenous atherogen-
ic products, including oxidized low-density lipoprotein (oxLDL), lipoprotein (a) 
(Lp(a)), aldosterone, and catecholamines [33-36].
The primary function of trained immunity appears to be improving survival of 
the host by providing a quicker and stronger response against pathogens, by 
different mechanisms than the adaptive immune system. Although trained im-
munity provides a beneficial immune response in the context of (recurrent) in-
fections, this mechanism might actually be detrimental in the context of chronic 
inflammatory diseases in which increased inflammatory responses by innate 
immune cells contribute to the pathophysiology, such as in atherosclerosis [37].
Mechanisms of trained immunity
How do innate immune cells remember that they have been stimulated? Trained 
immunity is dependent on changes in intracellular metabolic pathways and is 
mediated by epigenetic modifications, resulting in a chromatin architecture that 
is persistently more accessible for gene transcription, and an enhanced cytokine 
production upon subsequent challenge [29, 38]. Changes in cellular metabolism 
are crucial to develop the enhanced responsiveness of trained innate immune 
cells. Increased aerobic glycolysis via activation of the AKT-mTOR-HIF1α path-
way is the hallmark of trained monocytes [39]. Pharmacological inhibition of 
glycolysis abrogates training, revealing how crucial cellular metabolism is for 
the trained immunity phenotype [40]. In addition, several metabolites of the 
tricarboxylic acid (TCA) cycle function as essential cofactors for epigenetics en-
zymes and thereby exert different immunomodulatory effects on innate im-
mune cell function [41-43].
Epigenetic regulation controls gene expression by posttranslational modifica-
tions of DNA, histones or non-coding RNA, creating a more openly or closely 
folded chromatin structure. Epigenetic reprogramming is tightly regulated by 
enzymes (‘writers’, ‘readers and ‘erasers’), but these molecular mechanisms 
are only partially understood in trained immunity. Three key epigenetic marks 
accompany trained immunity. These histone modifications include  monometh-
ylation of lysine residue 4 at histone 3 (H3K4me1) at distal enhancer sites, his-
tone 3 lysine 4 trimethylation (H3K4me3) at promotor sites, and histone 3 lysine 
27 acetylation (H3K27Ac) at promotors and enhancers of stimulated genes in-
volved in trained immunity [44]. These epigenetic modifications result in a chro-
matin architecture that is more accessible for transcription factors to promote 
(pro-inflammatory) gene transcription. 
In short, innate immune cells can adopt a trained immunity phenotype with in-
creased pro-inflammatory cytokine production by profound metabolic and epi-
genetic reprogramming. But monocytes are short lived, which raises the ques-
tion how it is possible that trained monocytes can be found in the circulation 
three months after BCG vaccination [29]. Does trained immunity occur at the 
level of myeloid precursor cells in the bone marrow?
Trained immunity in bone marrow progenitors
The effects of BCG vaccination on ex vivo cytokine production last for 3 to 12 
months after vaccination [29]. Considering that the lifespan of monocytes is 
only 5-7 days [45, 46], it is surprising that the effects of BCG vaccination are still 
present in circulating monocytes several months after initial administration. The 
observation that trained immunity lasts longer than the lifespan of circulating 
monocytes therefore suggests that it shapes the haematopoietic stem and pro-
genitor cells (HSPCs) in the bone marrow to mediate its long-term effects.
Several studies have examined reprogramming of HSPCs as possible explanation 
for the long-term effects of trained immunity. Recent studies have shown that 
β-glucan and BCG can indeed reprogram the myeloid progenitor cells in the 
bone marrow to generate trained immunity within the myeloid cell compart-
ment (i.e. the neutrophil and monocyte lineage) [47]. In a mouse model, BCG 
vaccination reprograms HSPCs towards myelopoiesis, which leads to protective 
trained immunity [48]. The induction of trained immunity modulates metabo-
lism of HSPCs with adaptations in glucose metabolism in the bone marrow and 
increased myelopoiesis [49]. The role of endogenous atherogenic stimuli in this 
context has also been studied. A Western type diet in atherosclerosis prone LDL 
receptor -/- mice induced functional, transcriptional and epigenetic reprogram-
ming of myeloid progenitor cells, which persisted for at least four weeks after 
switching back to chow diet, indicating a cell-intrinsic memory of HSPCs [50].
Trained immunity as mechanism in atherosclerosis
Given the observations that trained monocytes and macrophages have a 
pro-atherogenic phenotype and that endogenous atherogenic products can in-
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duce trained immunity, we proposed that the mechanism of trained immunity 
contributes to atherogenesis. Initial studies on the role of trained immunity in 
atherosclerosis showed that isolated human monocytes also adopt a long-term 
pro-inflammatory phenotype after brief exposure to pro-atherogenic stimuli in 
vitro, such as oxidized LDL and lipoprotein(a) [33, 34]. Later, this was also shown 
for aldosterone and the catecholamines adrenaline and noradrenaline, which 
are all associated with CVD [35, 36]. 
The relevance of these findings was corroborated in vivo in patients with risk 
factors for atherosclerosis or with established atherosclerosis. It was reported 
that patients with elevated levels of lipoprotein(a) had a pro-inflammatory phe-
notype of circulating monocytes associated with epigenetic remodelling [34]. 
Similarly, circulating monocytes of patients with familial hypercholesterolemia 
have a trained immunity phenotype characterized by  transcriptional and epi-
genetic reprogramming, which was not reversed by three months of lipid-low-
ering therapy. [51]. Finally, patients with severe coronary atherosclerosis have 
a pro-inflammatory phenotype of circulating monocytes, which associated with 
an increased glycolytic metabolism and with epigenetic remodelling at the level 
of histone modifications [52]. 
In summary, evidence is accumulating that trained immunity can be induced by 
atherogenic stimuli and thereby contributes to the development of atheroscle-
rosis in patients with classical risk factors for CVD. In this thesis, I will expand 
this hypothesis by investigating the role of trained immunity in patients with 
non-classical risk factors for atherosclerosis, such as chronic periodontitis, and 
in patients with cerebral small vessel disease. Furthermore, we have explored 
bone marrow progenitor cell reprogramming in severe atherosclerosis. Final-
ly, we explored the athero-protective effects of physical exercise on innate im-
mune cell function in patients with increased cardiovascular risk.
The aim and outline of this thesis
The aim of this thesis was to investigate the contribution of innate immune cell 
activation, in the context of trained immunity, to the pathogenesis of athero-
sclerosis and related cardiovascular disorders (Figure 3). Monocyte reprogram-
ming in individuals with atherosclerosis or increased CV risk is further explored. 
The overlap in systemic inflammation and shared risk factors for atherosclerotic 
CVD, made me hypothesize that trained immunity might also contribute to the 
pathophysiology of cerebral small vessel disease. 
As an introduction to the topic, a detailed overview of the mechanism of trained 
immunity, including epigenetic reprogramming, and its possible contribution to 
atherosclerosis is given in chapter 2. 
Part 1: Monocyte activation in atherosclerosis
The first part of the thesis elucidates several mechanisms of monocyte repro-
gramming in individuals with atherosclerosis or increased CV risk. 
In chapter 3, we explored whether the concept of trained immunity is relevant 
in individuals with periodontitis. Periodontitis is an independent risk factor for 
atherosclerosis, and preclinical studies have revealed activation of monocytes 
and vascular wall inflammation in individuals with periodontitis. We studied 
whether periodontitis-associated bacteria induce trained immunity in vitro and 
translated these findings to study the pro-inflammatory monocyte phenotype 
of individuals with severe periodontitis in vivo. In addition, periodontal tissue 
and vascular wall inflammation was quantified with [18F]FDG PET-CT scanning.
Figure 3. Schematic overview of the chapters of this thesis.
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Trained immunity shapes the bone marrow progenitor cells to mediate its long-
term effects in mice. Based on these observations, we hypothesized in chapter 4 
that functional, metabolic and transcriptional reprogramming of HSPCs also oc-
curs in human atherosclerosis. To test this hypothesis, we extensively analysed 
bone marrow of patients with established severe coronary atherosclerosis and 
patients in whom coronary atherosclerosis was excluded. 
In chapter 5, we explored the hypothesis that interventions that can prevent 
CVD, by reversing innate immune cell activation: we investigated whether re-
duction of sedentary behaviour and increasing physical activity in individuals 
with increased CV risk could reduce their pro-inflammatory monocyte pheno-
type. Besides the functional monocyte phenotype, we also assessed the effects 
on intracellular metabolism of monocytes.
Part 2: Monocyte phenotype in individuals with cerebral small vessel disease
The second part of the thesis examines the monocyte phenotype in individuals 
with related cardiovascular disorders. In chapter 6 and 7 we studied the circu-
lating monocyte phenotype in the context of cerebral small vessel disease. In 
a cohort of elderly individuals with cerebral small vessel disease, a common 
condition in elderly that is one the major causes of cognitive decline, dementia 
and stroke, we examined their monocyte phenotype in relation to long-term 
disease progression (chapter 6). Next, we explored their monocyte function and 
transcriptome during acute progression of cerebral small vessel disease by us-
ing repeated, detailed MRI techniques (chapter 7).
A summary of the results of these studies and conclusions of this thesis are 
detailed in chapter 8.
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Introduction 
Innate immunity is the first in line and one of the most important components 
of host defense. Recently, a paradigm shift has occurred through the discov-
ery of memory properties in innate immune cells [1, 2]. In contrast to adaptive 
immune responses, the innate immune system has traditionally been viewed 
as primitive and generic, lacking the ability to differentiate individual species 
of pathogen or the quantity of encounters. However, an unequivocal body of 
clinical and experimental evidence now argues for a shift in our understanding 
of the innate immune system [2], underscored by its capacity to confer broad 
immunological protection. 
Innate immune cells, such as monocytes/macrophages and natural killer cells 
(NK-cells), can recollect a previous foreign encounter and therefore mount im-
munological memory. This biological process of innate immune memory has 
been called trained immunity [3], and is illustrated by the observation that 
stimulation of innate immune cells with a pathogen augments the subsequent 
immune response to similar or unrelated immunological stimuli [1, 4]. The en-
hanced immune response is associated with a profound change in the intracel-
lular metabolism and epigenetic regulation at the level of histone modifications 
[5, 6].
Besides the primary function of the innate immune system to mediate first 
line host defense against a broad spectrum of pathogens and to regulate tis-
sue homeostasis, recent studies have argued that functional reprogramming 
of innate immune cells may also play an important role in immune-mediated 
diseases [7-9]. Monocytes and macrophages are involved in the pathogenesis 
of many highly prevalent chronic disorders, including insulin resistance (obesity 
as well as diabetes mellitus), tumor growth, and autoimmune or autoinflam-
matory diseases such as rheumatoid arthritis and inflammatory bowel disease. 
Furthermore, innate immune cells play a central role in the development of 
atherosclerosis, a chronic low-grade inflammatory condition of the vessel wall 
with macrophages being the most abundant immune cells in the atherosclerotic 
lesion that regulate plaque progression and stability [10, 11]. The involvement 
of innate immune cells in atherosclerosis, as well as in other immune-mediated 
diseases, illustrates the pivotal role of the innate immune system in common 
inflammatory disorders with a high medical and economic burden.
To exploit the concept of trained immunity to improve vaccination strategies or 
prevent atherosclerosis and other chronic inflammatory diseases, it is crucial 
to unravel the underlying mechanism. This review provides a comprehensive 
state-of-the-art framework on the intracellular events that coordinate trained 
Abstract
Significance
A growing body of clinical and experimental evidence has challenged 
the traditional understanding that only the adaptive immune system can 
mount immunological memory. Recent findings describe the adaptive 
characteristics of the innate immune system, underscored by its ability 
to remember antecedent foreign encounters and respond in a nonspecif-
ic sensitized manner to reinfection. This has been termed trained innate 
immunity. Although beneficial in the context of recurrent infections, this 
might actually contribute to chronic immune-mediated diseases, such ath-
erosclerosis. 
Recent Advances
In line with its proposed role in sustaining cellular memories, epigenetic 
reprogramming has emerged as a critical determinant of trained immu-
nity. Recent technological and computational advances that improve un-
biased acquisition of epigenomic profiles have significantly enhanced our 
appreciation for the complexities of chromatin architecture in the contexts 
of diverse immunological challenges. 
Critical Issues
Key to resolving the distinct chromatin signatures of innate immune mem-
ory is a comprehensive understanding of the precise physiological targets 
of regulatory proteins that recognize, deposit, and remove chemical modi-
fications from chromatin as well as other gene regulating factors. Drawing 
from a rapidly expanding compendium of experimental and clinical stud-
ies, this review details a current perspective of the epigenetic pathways 
that support the adapted phenotypes of monocytes and macrophages. 
Future Directions
We explore future strategies aimed at exploiting the mechanism of trained 
immunity to improve the prevention and treatment of infections and im-
mune-mediated chronic disorders.
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immunity, namely intracellular metabolism and epigenetic rewiring of gene 
transcription. Understanding the specific immunometabolic pathways and epi-
genetic signatures of innate immune memory is crucial for the development of 
novel therapeutic approaches for infectious and chronic inflammatory diseases. 
Memories are not just about the past
Unlike acquired immunity, which primes the adaptive immune system for an 
enhanced response to subsequent encounters with the same pathogen, innate 
immune memory instructs an altered future response that is nonspecific. Non-
specific immunological memory has long been known to occur in plants [12] 
and invertebrate animals [13-15], both of which lack an adaptive immune sys-
tem, suggesting an ancient biological process [16]. The first indication of the po-
tential importance of this phenomenon for vertebrate host defense came from 
the broad protection conferred against unrelated diseases by pioneering vac-
cination programs. As early as the 1930’s Bacillus Calmette-Guérin (BCG), one 
of the world’s most administered vaccines against Mycobacterium tuberculosis, 
was found to greatly improve the survival of infants beyond the tuberculosis 
mortality burden [17-22]. The nonspecific beneficial effects of BCG vaccination 
were further demonstrated by randomized clinical trials reporting reduced mor-
tality from various infections in low birth weight children in Africa [23, 24].
Perhaps the most striking example in humans supporting a nonspecific training 
of the immune system was a series of studies revealing a heightened ex vivo im-
mune response to the fungal pathogen Candida albicans in human volunteers 
recently vaccinated with BCG [4], consistent with previous reports of BCG-me-
diated protection against disseminated candidiasis in experimental animals [25, 
26]. The enhanced immune response was detected not only for the lympho-
cyte-derived IFNγ, but also for monocyte-derived TNFα and IL6. Furthermore, 
the heterologous protection conferred by BCG training was replicated in mice 
with known deficiencies in adaptive immune responses [4]. 
Appreciation for the importance of innate immune memory has since expand-
ed beyond vaccines to include various microbe-associated molecular patterns 
(MAMPs). For example, protection against lethal C. albicans infection in mice by 
prior administration of a nonlethal dose is dependent on the enhanced proin-
flammatory and microbicidal function of trained monocytes and macrophages 
[1]. Similar effects are observed for human primary monocytes trained in vi-
tro with the C. albicans cell wall component β-1,3-(D)-glucan (β-glucan), which 
show enhanced secondary response to stimulation with various Toll-like recep-
tor (TLR) agonists such as the bacterial lipoprotein Pam(3)CSK4 (TLR2) and lipo-
polysaccharide (LPS) endotoxin (TLR4). This in vitro model [27] exemplifies the 
main properties of trained immunity: infection with one pathogen augments 
the subsequent immune response to unrelated immunological stimuli. In strik-
ing contrast, primary stimulation by a high dose of LPS has been long known 
to induce a persistent refractory state in with reduced capacity to respond to 
restimulation by a process called LPS-induced tolerance [28]. Conceptually also 
a form of innate immune memory, inappropriately activated immune tolerance 
is responsible for the immunoparalysis induced by Gram-negative sepsis [29, 
30]. The adapted phenotypes induced in vitro are highly reproducible across 
cells prepared from unrelated donors and indicative of a specific program of cell 
differentiation [6]. The distinct and opposing functional programs of training 
and tolerance provide a useful contrast for understanding the extremes of a 
spectrum of adaptive characteristics that can be acquired by the innate immune 
system in response to diverse immunological challenges (Fig 1).
Figure 1. Innate immune memory underlies a spectrum of adaptive characteristics that are ac-
quired in response to diverse immunological challenges. Monocyte (Mo) memories of past en-
counters with microbial and nonmicrobial products can elicit vastly different responses to future 
exposures upon differentiation to macrophages (Mϕ). Trained immunity, induced by Bacillus 
Calmette–Guérin (BCG), β-glucan, or oxidized low-density lipoprotein (oxLDL), defines an  immu-
nological  memory that calibrates an enhanced non-specific response to subsequent infections 
by enhancing the inflammatory and antimicrobial properties of innate immune cells. In contrast, 
primary stimulation with lipopolysaccharide (LPS) induces a persistent refractory state known as 
tolerance, with markedly reduced capacity to respond to restimulation.
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Trained immunity is a double-edged sword
Despite its benefits in the context of infections, long-term activation of the in-
nate immune system may play a maladaptive role in the pathogenesis of chronic 
inflammatory diseases [31]. One example of such a disease is atherosclerosis, 
the result of a chronic, low-grade vascular inflammation in which the immune 
system plays a central role. A complex interplay between endothelial cells, 
smooth muscle cells and circulating immune cells creates a proinflammatory 
microenvironment in the vascular wall supporting the formation of an athero-
sclerotic plaque [32]. In this process, the most abundant inflammatory cells are 
monocytes and macrophages. By migrating into the vessel wall, monocytes de-
termine early plaque development, and following differentiation into macro-
phages they ingest lipid particles to become foam cells [31]. Moreover, local 
damage associated molecular patterns such as modified LDL particles and pro-
teoglycans stimulate membrane bound receptors such as TLR2 and TLR4 [33]. 
The subsequent secretion of proinflammatory cytokines and chemokines fur-
ther fuels the proinflammatory environment associated with the development, 
progression, and (in)stability of atherosclerotic plaques [31]. 
Training of human primary monocytes with MAMPs induces a marked eleva-
tion in the production of proinflammatory cytokines and chemokines that are 
strongly implicated in the development and progression of atherosclerotic 
plaques [9]. Vaccination with BCG accelerates atherosclerosis in rabbits fed a 
cholesterol-rich diet [34]. In contrast, other studies have reported a protective 
effect in atherosclerosis-prone mice [35, 36], which might be due to its cho-
lesterol-lowering action. Perhaps most compelling are recent observations that 
nonmicrobial products, including lipoproteins that are known drivers of cardio-
vascular disease, can also induce trained immunity (Table 1). In vitro stimulation 
of human primary monocytes with a low concentration of oxidized low-density 
lipoprotein (oxLDL) programs a sustained atherogenic macrophage phenotype 
characterized by elevated expression of CD36 and SR-A scavenger receptors 
leading to enhanced foam cell formation, as well as amplified proinflammatory 
cytokine production and matrix metalloprotease expression [7]. Similarly, brief 
exposure to lipoprotein(a) induces a proinflammatory phenotype in monocytes 
restimulated in vitro [8]. Indeed, circulating monocytes isolated from patients 
with symptomatic atherosclerosis exhibit a proinflammatory phenotype com-
pared with cells isolated from healthy controls [37]. This effect was also ob-
served in patients with an increased cardiovascular risk due to elevated circulat-
ing levels of lipoprotein(a) [8].
These findings convey the concept that trained immunity is a biological process 
with broad implications for cardiovascular disease [31]. Such a model implies 
that monocytes are stimulated by environmental signals in the circulation that 
could induce epigenetic reprogramming, thereby increasing their responsive-
ness to secondary stimulation, for instance within the arterial wall or athero-
sclerotic plaque. The ability for macrophages to adopt unique properties as a 
function of their microenvironment raises important considerations for mac-
rophage populations in atherosclerotic lesions that are hypoxic, as well as rup-
ture-prone versus stable plaques. Furthermore, accelerated atherosclerosis 
remains the principal cause of morbidity and premature mortality in patients 
with diabetes mellitus [38], and a role for trained immunity in diabetic versus 
normoglycaemic environments warrants exploration [9, 31]. Several other fac-
tors associated with metabolic disease such as free fatty acids, uric acid, and ad-
vanced glycation end-products elicit inflammatory responses in monocytes via 
pattern recognition receptor stimulation, raising the unexplored possibility that 
they too could induce functional reprogramming and innate immune memory 
in the context of cardiovascular complications [9, 39]. 
Cellular metabolism determines the phenotype of innate immune cells
The extensive range of physiological macrophage functions in host defense and 
maintenance of tissue homeostasis necessitates a broad spectrum of precisely 
regulated states of macrophage activation. While it has long been appreciat-
ed that changes in oxygen and glucose consumption accommodate the meta-
bolic requirements of activated macrophages, the importance of intracellular 
metabolism for shaping the immune response has only recently emerged [48]. 
Moreover, engagement of distinct metabolic pathways not only follows energy 
requirements but also distinguishes and supports discrete macrophage pheno-
types. This metabolic reprogramming is best exemplified by the polarization of 
classically activated (M1 or M[IFNγ]) and alternatively activated (M2 or M[IL-4]) 
macrophages. Paralleling their respective pro- and anti-inflammatory pheno-
types, these subtypes are characterized by distinct arginine metabolism as well 
as differences in fatty acid synthesis and usage (recently reviewed [49]). While 
glycolytic metabolism is upregulated across both polarized states, activation of 
the pentose phosphate pathway (PPP) is only observed in classically activated 
macrophages, where it supports inflammatory responses by generating amino 
acids for protein synthesis, nucleotides for proliferation, as well as NADPH for 
the production of reactive oxygen species necessary for phagocytic killing [48].
Though energetically less efficient than mitochondrial oxidative phosphoryla-
tion (OXPHOS), the relatively rapid expandability of glycolysis allows faster pro-
duction of ATP in order to meet cellular requirements [48, 50]. In alternatively 
activated macrophages these biochemical processes remain coupled: enhanced 
Chapter 2 Epigenetics and trained immunity
36 37
glycolytic generation of pyruvate fuels the tricarboxylic acid (TCA) cycle and par-
allels the induction of OXPHOS [51]. This contrasts sharply with inflammatory 
macrophages, which are characterized by impaired OXPHOS and anabolic re-
purposing of the TCA cycle [48, 49]. This metabolic shift is comparable to the 
Warburg effect characteristic of cancer metabolism that amends tumor cells to 
hypoxic environments by upregulating glycolytic gene expression via the hypox-
ia-inducible factor 1 alpha (HIF1α) transcription factor [52, 53]. Furthermore, 
instead of feeding into the TCA cycle to ultimately fuel OXPHOS, pyruvate is 
fermented to lactate by HIF1α-dependent pathways. A similar process drives 
the glycolytic switch in inflammatory macrophages despite the availability of 
oxygen [48, 51]. 
Cellular metabolism orchestrates innate immune memory
A metabolic switch comparable to that of classically activated macrophages 
underlies the adapted phenotype induced by β-glucan training. Stimulation of 
human monocytes with β-glucan induces glycolysis paralleling elevated glucose 
consumption and increased pyruvate to lactate conversion [41]. Moreover, 
markedly reduced oxygen consumption in β-glucan-trained macrophages indi-
cates a concomitant reduction in OXPHOS [41]. Recent studies reported long-
term upregulation of glycolytic rate-limiting enzymes in circulating monocytes 
from individuals vaccinated with BCG and demonstrated that genetic variation 
in hexokinase 2 and phosphofructokinase modulates induction of trained im-
munity [5]. Contrasting the classical Warburg switch induced by β-glucan, the 
immunometabolic profile of BCG training is characterized not only by increased 
glycolysis and lactate production, but also by augmented oxygen consumption 
[5]. However, inhibition of the electronic transport chain did not alter the repro-
gramming of macrophages in BCG-training, demonstrating the secondary role 
of OXPHOS in development of the adapted phenotype [5]. By contrast, inhi-
bition of glycolysis with 2-deoxyglucose abrogated BCG training. Furthermore, 
inhibition of the Akt/mTOR/HIF1α pathway at several stages abolished training 
by β-glucan and BCG in vitro as well as experimental animals [5, 41]. Emphasiz-
ing the relevance of this pathway in humans, administration of the antidiabetic 
drug and indirect mTOR inhibitor metformin decreased the ability for circulat-
ing monocytes to mount a trained response ex vivo to β-glucan exposure in 
healthy individuals [42]. Interestingly, the PPP was also found to be upregulat-
ed in β-glucan trained cells. However, evidence so far suggests that the role of 
the PPP in trained immunity is relatively small, since inhibition of this pathway 
had no effect on the adapted phenotype [42]. The relevance of this metabolic 
rewiring in the context of atherosclerosis is illustrated by the consistent finding 
that glycolytic enzymes are upregulated in monocytes and monocyte-derived 
macrophages isolated from patients with established atherosclerosis [37, 54].
Table 1. Inducers of innate immune memory in monocytes
Primary stimulus Type of immune 
response
Cellular metabo-









Kleinnijenhuis et al., 
(2012) PNAS 109:17537-
17542 [4]
Arts et al., (2016) Cell Rep 
17:2562-2571 [5]
Candida albicans              Trained immunity Quintin et al., (2012) Cell 
Host Microbe 12: 223-
232 [1]
Saccharomyces cere-
visiae via fungal chitin
Trained immunity Rizzetto et al., (2016) J 
Biol Chem 291:7961-72 
[40]




Cheng et al., (2014) Sci-
ence 345:1250684 [41] 
Saeed et al., (2014) Sci-
ence 345:1251086 [6]
Arts et al., (2016) Cell 
Metab 24: 807-819 [42]
Oxidized low-density 
lipoprotein (oxLDL)
Trained immunity ↑ Glycolysis Bekkering et al., (2014) 
ATVB 34:1731-8 [7]
Lipoprotein(a) Trained immunity Van der Valk et al., (2016) 
Circulation 134:611-24 [8] 
Fumarate Trained immunity Arts et al., (2016) Cell 
Metab 24: 807-819 [42]
TLR-agonists
TLR 4: LPS Trained immunity/ 
tolerance 
Novakovic et al., (2016) 
Cell 167:1354-1368 [43]
Foster et al., (2007) Na-
ture 447: 972-978 [28]
Ifrim et al., (2014) Clin 
Vaccine Immunol 21: 534-
545 [44]
Lachmandas et al., (2016) 
Nat Immunol 2:16246 [45]
TLR 2: Pam3CSK4 Immunotolerance
TLR 3: Poly(I:C) Trained immunity/
tolerance





Trained immunity Ifrim et al., (2014) Clin 









Borriello et al., (2017) 
Front Immunol 7:680 [46]
Hoeksema et al., (2015) J 
Immunol 194:3909-3916 
[47]
Chapter 2 Epigenetics and trained immunity
38 39
Despite the metabolic skewing of β-glucan-trained macrophages towards gly-
colysis, concentrations of the TCA cycle metabolites citrate, succinate, malate, 
fumarate, and 2-hydroxyglutarate are increased in comparison to naïve mac-
rophages [42]. This suggested that the TCA cycle was not entirely adjourned 
and led to the speculation that these specific metabolites were being replen-
ished through glutaminolysis [42]. Indeed, increased glutamine metabolism was 
one of the consistent immunometabolic changes in macrophages trained with 
β-glucan and BCG [5, 41, 42], and plays an important role in immune activation 
[55]. Demonstrating the importance of this process, the glutaminase inhibitor 
BPTES blocked the induction of trained immunity by β-glucan [42] and BCG [5] 
in vitro and in experimental animal models [42]. 
Immunometabolic pathways important for the functional reprogramming of im-
mune cells extend beyond those involved in glucose metabolism and oxidative 
phosphorylation. Cells trained with β-glucan displayed upregulation of more 
than half of the genes involved in cholesterol biosythesis, identifying this path-
way together with glutaminolysis and glycolysis as one of the most essential for 
innate immune training [42]. Underlining the importance of the cholesterol syn-
thesis pathway even further, treatment with the HMG-CoA-reductase atorvas-
tatin attenuated β-glucan induced innate immune training in a murine model 
[42]. Since, next to sterols, the essential lipids in the human cell membrane are 
phospholipids and glycolipids, fatty acid synthesis is also an important pathway 
in immune cell function [49]. Indeed recent data indicate that inflammatory 
stimuli such as LPS and cytokines trigger an increase in fatty acid synthesis in 
macrophages [Arts et al., 2017 Cell Metab (in press)]. However, in contrast to 
the abrogation of training when cholesterol synthesis was inhibited, blockade of 
fatty acid synthesis did not alter the proinflammatory macrophage phenotype 
induced by β-glucan training [42]. 
Molecular mechanisms of macrophage memory
For a monocyte, memories of past encounters with microbial products can be 
truly transformative insofar as they can elicit vastly different future respons-
es to microbial ligands. The gross implication of training or tolerance is a fun-
damental phenotypic shift involving changes to major metabolic and signaling 
pathways that facilitate the overall cellular memory. Underlying much of this 
reprogramming are widespread transcriptional changes associated with meta-
bolic pathways, many of which occur early in the training regimen and precede 
the adapted phenotype [42]. 
Because distinct cell types and subtypes of multicellular organisms arise from 
identical genetic material, gene control and expression are fundamental deter-
minants of differentiation and phenotype. However much remains to be under-
stood about how genetic information is interpreted by individual cells in health 
and disease. Only when we unravel the DNA strands to appreciate the constitu-
ent assembly of chromatin can we begin to recognize the complexity of genome 
organization and regulation [56].
Chromatin reorganization and innate immune memory
Epigenetic regulation of gene expression
Gene transcription is tightly controlled by the interplay and long-range commu-
nication of regulatory events at gene promoters proximal to the transcription 
start site and distal genetic elements called enhancers [57]. Accessibility of the 
DNA to protein transcription factors (TFs) and other transcriptional machinery 
at these regulatory regions is essential for gene expression. The dynamic poly-
mer of DNA and nucleosomal histone proteins known as chromatin facilitates 
functional compartmentalization of the genome to assemble structurally open, 
transcriptionally permissive configurations or condensed, repressive domains 
[58]. Since the initial description of the nucleosome particle as the repeating 
unit of chromatin in 1977 [59], it has become increasingly clear that core nucle-
osome components are distinguishable by posttranslational chemical modifica-
tion and instructive of chromatin architecture [60, 61].
Histone modifications influence chromatin structure and function
The octameric nucleosome is composed of four core histone proteins: two H3 
and H4 homodimers and two H2A/H2B heterodimers, encircled by approximate-
ly 147 bp of DNA [58]. Unstructured N-terminal histone tails that extend from 
nucleosomes are substrate for posttranslational enzymatic modifications, which 
are cooperatively associated with various states of transcriptional competen-
cy and chromatin organization. Amid a vast repertoire of histone modifications 
[62], acetylation (lysine residues) and methylation (arginine and lysine residues) 
are the most broadly studied and extensively characterized (Fig 2). The capacity 
for histone modifications to designate functional genomic regions and support 
transcriptional processes significantly amplifies the information potential of the 
genetic code through mechanisms that modulate chromatin structure and func-
tion. Their influence on higher order chromatin accessibility is predominantly 
facilitated by establishing high-affinity binding sites for the recruitment of chro-
matin readers: core transcriptional machinery, as well as multisubunit protein 
complexes that actively restructure, relocate, install, or evict nucleosomes [63]. 
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Histone acetylation
Histone acetylation, for example at lysine-9 (H3K9ac) and lysine-27 (H3K27ac) 
of H3 histones, almost exclusively demarcates transcriptional competency [64]. 
In addition to promoting open chromatin architecture by neutralizing the elec-
trostatic charges on the histone tail and subsequently altering interactions with 
adjacent nucleosome components [65], acetylated histones are recognized and 
bound by bromodomains – a structural motif found in specialized chromatin 
reader proteins [66]. Components of many histone acetyltransferase (HAT) com-
plexes harbor bromodomains, which anchor the HAT complexes to acetylated 
chromatin, allowing them to propagate the acetyl signature to adjacent nucle-
osomes. Similarly the bromodomain components of ATP-dependent chromatin 
remodeling complexes are critical for their recruitment to acetylated promoters 
[65]. Another class of histone-acetyl readers known as the bromodomain and 
extra-terminal (BET) domain-containing family of proteins can regulate gene 
expression by recruiting transcription factors as well as chromatin remodeling 
complexes, and are increasingly implicated in transcriptional responses associat-
ed with inflammation [31] and innate immunity [67, 68]. Histone modifications 
are reversible, and their presence on the chromatin is determined by oppos-
ing activities of enzymatic writers and erasers. Histone deacetylase (HDAC) en-
zymes remove acetyl groups from histone tails. Thus HAT/HDAC activity balance 
is an important determinant of gene regulation, and has accordingly emerged 
as a potential therapeutic target for the treatment of various diseases [69-72].
Histone methylation
Contrasting histone acetylation, the position of the modified residue with-
in the histone tail determines the functional readout of histone methylation. 
Regulatory elements of repressed genes are often characterized by H3 histones 
methylated at lysine-9 and lysine-27. Conversely, methylation of lysine-4 and 
lysine-36 is associated with the assembly of transcriptionally permissive chro-
matin structures. Enzymes that catalyze the transfer (lysine methyltransferase 
[KMT]) and removal (lysine demethylase [KDM]) of histone methylation demon-
strate remarkable specificity toward amino acid positions within the histone 
tail [73] Furthermore, specific enzymes and complexes determine the extent of 
individual lysine methylation: mono- (m1), di- (m2), or trimethylated (m3) his-
tone lysine residues are differentially distributed across chromatin and attribut-
ed discrete functional roles in gene regulation. Transcriptional activity positively 
correlates with the degree of H3-lysine-4 trimethylation (H3K4m3) at gene pro-
moters [74]. On the other hand, monomethylation of this residue (H3K4m1) is a 
stereotypical feature of enhancers [75]. Specialized protein domains, including 
the chromodomain, tudor domain, MBT domain, and the PHD finger domain 
Figure 2. Posttranslational chemical modifications distinguish chromatin architecture and tran-
scriptional competency. As the repeating structural unit of chromatin, the nucleosome consists of 
approximately 147 bp of DNA wrapped around an octamer of the core histone proteins H2A, H2B, 
H3, and H4. Unstructured N-terminal histone tails are substrate for a variety of posttranslational 
modifications, which are dynamically written to and erased from specific amino acid residues by 
specialized enzymes. Shown here are lysine modifications that occur on the tails of H3 and H4 
histones. Histone lysine acetylation (orange hexagons) is ubiquitously associated with transcrip-
tional competency and is regulated by the competing activities of histone acetyltransferase (HAT) 
and deacetylase (HDAC) enzymes. By contrast, the extent of modification as well as the position 
of the modified residue within the histone tail determines the functional readout of histone lysine 
methylation (purple hexagons). The influence of histone modifications on higher order chromatin 
accessibility is predominantly facilitated by establishing high-affinity binding sites for the recruit-
ment of protein complexes that actively remodel chromatin. K lysine; KMT lysine methyltransfer-
ase; KDM lysine demethylase.
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interpret methylated histones by recruiting various chromatin-remodeling com-
plexes [76, 77]. 
DNA methylation regulates gene expression
The epigenetic methyl modification is unique in the way that in addition to his-
tones, it can also be written directly to the DNA template. Again, the genomic 
location of the modification is key to the functional outcome. Postreplicative 
methylation of the 5-carbon ring of cytosine nucleotides (5-methylcytosine, 
5mc) immediately adjacent to guanine residues (CpG) is primarily associated 
with promoter silencing by two main mechanisms. First, 5mc is mechanistically 
interpreted by proteins possessing the methyl-CpG-binding domain, which in 
turn recruit transcriptional repressors and chromatin remodeling complexes to 
establish transcriptionally incompetent chromatin [78]. Second, 5mc can physi-
cally modulate the binding of transcription factors to gene regulatory elements 
[79]. On the other hand, 5mc regulates gene splicing, transcriptional elonga-
tion, and distal regulatory activities of highly transcribed genes [80]. Recent ad-
vances in methyl-capture and sequencing technologies have propelled efforts 
to characterize the DNA methylome across various tissues and disease states, 
including myeloid differentiation [81, 82], macrophage polarization [83] and cy-
tokine production [84]. 
Epigenetic cross-talk 
The emerging picture of epigenetic regulation is one of remarkable complexity. 
Protein complexes that read chromatin marks can further recruit certain classes 
of epigenetic enzymes that cooperatively shape the chromatin landscape. For 
example, binding of heterochromatin protein 1 (HP1) via its chromodomain to 
H3K9m2/3 promotes further repressive methyl marks by enlisting additional 
KMTs, as well as DNA methyltransferases [85, 86]. Together with the activities of 
short (miRNAs) and long (lncRNAs) noncoding RNA, histone and DNA modifica-
tions are collectively defined as epigenetic [87]. Through complex interactions 
with TF networks and other transcriptional machinery, epigenetic modifications 
collaboratively support the functional exchange between repressed and active 
states of chromatin to contextualize gene expression. 
Chromatin modifications associated with macrophage differentiation and 
identity 
Epigenome-wide variations underlying cellular function and fate are definable 
at unprecedented resolution by current analytical technologies. To this end, 
the importance of histone modifications to cellular identity is underscored by 
the massive reconfiguration of lysine methylation and acetylation patterns at 
gene regulatory elements during naïve monocyte to macrophage differentia-
tion [6, 43]. Crucially, the intersection of transcriptome and epigenome profiles 
revealed a positive correlation between transcriptionally permissive H3 histone 
modifications and the activity of regulatory elements [6]. The most dynamic of 
these changes were observed for H3 acetylation, with one report describing 
approximately equal numbers of promoters exhibiting significant enrichment or 
depletion of H3K27ac [6, 43]. 
A similar pattern of H3K27ac was observed at distal enhancer regions upon dif-
ferentiation, with 1894 and 2142 regions displaying significant loss and gain of 
this modification, respectively, [6] in accordance with the function of enhancers 
as key determinants of cell identity especially within the myeloid lineage. The 
complement of active enhancer elements in a given tissue are typically co-occu-
pied by combinations of lineage-determining TFs enforcing tissue and cell-type 
specific programs of gene expression [88, 89]. Enhancers are distinguished from 
promoters by their specific enrichment of H3K4m1 [75] and can be classified 
as active or poised depending on the presence or absence of H3K27ac [88]. A 
comprehensive study of hematopoiesis in mice revealed that a significant pro-
portion of lineage-specific enhancers are established de novo in parallel with 
H3K4m1 enrichment. Furthermore, clear distinctions were observed across the 
respective enhancer repertoires following the definitive differentiation step 
from monocyte to macrophage [90]. Enrichment of H3K27ac during human 
macrophage differentiation is often accompanied by increased deposition of 
H3K4m1. By contrast, a majority of sites that lose H3K27ac retain their H3K4m1 
signature and remain sensitive to cleavage by DNase I due to their open chro-
matin architecture [6]. 
Epigenomic patterns distinguish training and tolerance
Because many studies reporting adaptive characteristics of the innate immune 
system predate the modern era of molecular biology, insufficient understand-
ing at the molecular level meant that the magnitude of this process was per-
haps underappreciated. While much detail remains to be elucidated, several 
studies published in recent years demonstrate the essential role of epigenetic 
reprogramming in innate immune memory across various phyla [13, 16, 91-93]. 
These seminal findings not only shed light on the molecular mechanisms under-
lying the capacity for monocytes to integrate micro environmental experiences 
into their programs of gene expression that is a type of chromatin-based memo-
ry, but also emphasize the potential reversibility of innate immune phenotypes 
[43]. 
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Several studies describe the enrichment of H3K4m3 at promoters associated 
with trained immunity, for instance at genes encoding proinflammatory cyto-
kines and intracellular signaling molecules following stimulation with β-glu-
can [1, 6], as well as at promoters of genes implicated in atherogenesis in cells 
trained with oxLDL [7]. Furthermore, the heterologous benefit of BCG vacci-
nation is associated with persistent H3K4m3 enrichment at the promoters of 
genes encoding TNFα, IL6, and TLR4 [4]. Similarly, H3K4m3 distinguishes attenu-
ated (tolerizable) and induced (non-tolerizable) genes in immune tolerance. Al-
though promoters of both classes of genes are trimethylated at H3K4 upon LPS 
stimulation, this mark is selectively maintained at non-tolerizable promoters 
following restimulation [28]. The positive correlation of H3K4m3 and transcrip-
tional activity is well described across various organisms and cell types [14, 75, 
94]. Accordingly, inhibition of this modification using the pan-methyltransferase 
inhibitor 5´-methylthioadenosine (MTA) precludes the adapted phenotypes in-
duced by β-glucan [44], BCG [4], and oxLDL [7]. 
While quantifying H3K4m3 can be informative of transcriptional competency 
or activity at discrete loci, it hardly exhausts the broad regulatory potential for 
histone modifications in innate immune memory. Recent deep sequencing anal-
yses revealed distinct epigenomic signatures characteristic of trained immuni-
ty and tolerance [6, 41, 43]. By generating epigenome-wide maps of H3K4m1, 
H3K4m3, H3K27ac, and DNase I sensitivity, Saeed et al., [6] defined distinct 
clusters of genomic regions reflecting putative transcriptional regulatory el-
ements. Importantly, several of these clusters are differentially modulated in 
β-glucan training and LPS tolerance. This is most apparent at approximately 500 
promoters that concurrently gain H3K27ac and H3K4m3 exclusively in β-glu-
can-trained cells [6]. Paralleling naïve monocytes, β-glucan treatment results in 
partial establishment of macrophage-specific regions within the first 24 hours 
of the in vitro training protocol. In contrast, LPS-treated cells exhibited stunted 
differentiation and delayed establishment of chromatin marks. This temporal 
observation is consistent with a failure of LPS-tolerized macrophages to deposit 
active histone marks at promoters of tolerized loci in response to a second LPS 
stimulation, including genes associated with lipid metabolism and phagocytic 
pathways [43]. 
Most remarkable however, is the epigenetic distinction observed across the re-
spective repertoires of distal enhancers within these phenotypic extremes of 
the innate immune memory spectrum [6, 43]. LPS and β-glucan pretreatment 
induced a distinct set of enhancers generating signal-dependent differences in 
gene expression. While some enhancer regions (1212) showed consistent en-
richment of H3K27ac across both treatment conditions, more than 40% of all 
dynamic enhancers gain de novo H3K27ac exclusively in cells trained with β-glu-
can. On the other hand, acetylation of a much smaller subset of enhancers is 
restricted to LPS-tolerized cells [6]. Taken together, these studies suggest that 
β-glucan induces comprehensive epigenetic rewiring of promoters and en-
hancers, while LPS tolerance is characterized by a subtle epigenetic signature 
closely reflecting that of naïve macrophages.     
The epigenome modulating effects of β-glucan were further exemplified by the 
exciting finding that it can partially reverse LPS tolerance. Exposure of LPS-tol-
erized cells to β-glucan for 24 hours in vitro restored their capacity for cytokine 
production [43]. Importantly, this reversal of immunoparalysis to a more re-
sponsive phenotype was also observed in monocytes isolated from volunteers 
with experimental endotoxemia restimulated with β-glucan ex vivo. The effects 
of β-glucan were demonstrated by the reinstitution of the transcriptional re-
sponse to LPS at otherwise tolerized genes. This process was associated with 
the restoration of H3K27ac at enhancers previously precluded by LPS exposure, 
demonstrating the ability for β-glucan to effectively erase and reprogram innate 
immune memory. These findings indicate that β-glucan-induced receptor path-
ways remain at least partially responsive in LPS tolerized cells, and could lead to 
novel immunomodulatory strategies for the clinical management of sepsis [43]. 
DNA methylation in innate immune memory
Despite its historically robust associations with genome organization and tran-
scriptional regulation, much less is known about the potential role of DNA 
methylation in innate immune memory. Epigenome-wide analyses have demon-
strated a general loss of 5mc during ex vivo monocyte to macrophage differen-
tiation [43, 95]. The vast majority of differentially methylated regions occurred 
at distal enhancers, with only a small fraction enriched at gene promoters. In 
terms of macrophage subtypes, a distinct methylation pattern was observed for 
LPS-treated cells. On the other hand, the methylome of β-glucan-treated cells 
more closely resembled that of naïve macrophages [43]. 
Like its histone counterpart, 5mc is enzymatically reversible. The first step of 
this process requires oxidation of 5mc by the ten-eleven-translocation (TET) 
family of dioxygenases [96] to generate 5-hydroxymethylcytosine (5hmc). This 
variant can then be further processed to 5-formylcytosine and 5-carboxylcyto-
sine - newly characterized epigenetic marks that appear to be associated with 
silenced [97], poised [98], or activated [99] enhancer elements. The importance 
of 5mc and 5hmc dynamics in the course of innate immune memory remains 
an open question. The answer necessitates an ability to accurately distinguish 
these variants of cytosine methylation. The method used by the aforemen-
Chapter 2 Epigenetics and trained immunity
46 47
tioned study [43], bisulfite sequencing, is the gold standard for 5mc analysis and 
involves the conversion of unmethylated cytosine residues to uracil. Important-
ly, 5mc and 5hmc are both resistant to bisulfite conversion [100], meaning that 
DNA demethylation could be underestimated using this method. By extension, 
such a method of analysis confounds the discovery of 5hmc-specific functions 
in genome regulation. To this end, a recent study highlights advantages and 
caveats of commonly used epigenome-wide 5hmc profiling technologies and 
demonstrates that the interpretation of 5hmc data is significantly influenced by 
the sensitivity of the method used [100].     
Transcriptional and epigenetic memory
The biological consequences of this epigenetic reprogramming are numerous 
and varied. Where they intersect is at the level of transcriptional regulation, 
however the precise mechanisms of this control require further investigation. 
Amongst the catalogue of gene expression changes associated with innate im-
mune memory is a subset of genes whose pattern of expression reveals a pro-
found transcriptional memory. Within this cluster, a broad distinction can be 
drawn between genes that are primed for transcriptional activation, and those 
that are persistently altered.
A recently emerged paradigm of primed transcriptional memory centers on the 
induction of de novo or latent enhancers [89]. In unstimulated macrophages, 
these genomic regions are unbound by transcription factors and are largely de-
void of the histone modifications characteristic of distal regulatory elements. 
However they acquire signature epigenetic features of enhancers such as an 
open chromatin architecture marked by H3K4m1 and H3K27ac in response 
to specific stimuli. Upon removal of the activating stimulus, Ostuni et al. [89] 
demonstrated the persistence of H3K4m1 despite loss of H3K27ac at a fraction 
of decommissioned de novo enhancers. Moreover, the enhancers that retained 
the H3K4m1 signature exhibited a stronger response to rechallenge (Fig 3). This 
chromatin-dependent transcriptional memory may at least partly explain the 
differential activation of enhancer repertoires supporting the unique pheno-
typic properties adopted by macrophages as a function of anatomical location 
[101], and similar mechanisms are likely to shape chromatin architectures as-
sociated with innate immune memory. Indeed the dynamics and genomic lo-
cations of H3K4m1-marked enhancers differs significantly between β-glucan 
training and LPS tolerance [43]. Furthermore, these findings are reminiscent of 
previous descriptions of H3K4m1-dependent metabolic memory in monocytes 
and other cell types [58].
Contrasting primed memory, persistent memory is characterized by transcrip-
tional activity that is sustained beyond removal of the activating stimulus. 
Monomethylation of H3K4 underlies persistent, high glucose mediated proin-
flammatory gene expression that is refractory to glycaemic  correction in vas-
cular endothelial models of glycaemic  variability and diabetic mice [102]. This 
epigenetic signature, written by the Set7 lysine methyltransferase, was later 
Figure 3. Latent enhancers prime a transcriptional memory in macrophages. Constitutively un-
marked distal regulatory elements acquire signature epigenetic features of enhancers such as 
an open chromatin architecture marked by H3K4m1 and H3K27ac in response to specific stimuli. 
Upon removal of the activating stimulus, regions that retain the H3K4m1 enrichment mediate a 
faster and more robust response to restimulation, supporting a role for this specific modification 
in the epigenetic memory of macrophages.
Figure 4. Training with β-glucan induces a 
program of persistent transcriptional mem-
ory. Persistent transcriptional memory is 
characterized by transcriptional activity that 
is sustained beyond removal of the activating 
stimulus. Intersection of transcriptome data 
derived from macrophages at early (24 h,) and 
late (6 days) time points post β-glucan stim-
ulation described by Novakovic et al., (2016) 
(GSE85246) reveals a cluster of 121 genes 
whose transcriptional response is maintained 
for the duration of the experiment.
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observed in monocytes of diabetic patients [103]. Intersection of the transcrip-
tome data from early and late timepoints described by Novakovic et al. [43] 
reveals a cluster of genes whose transcriptional response to β-glucan is main-
tained for 5 days in culture (Fig 4). This includes genes downregulated 24 hours 
after stimulation that are also downregulated on day 6, as well as genes upreg-
ulated on day 1 that remain in a state of heightened transcriptional activity for 
the duration of the experiment. Of course this is a simplification as the activity 
of some genes may oscillate between altered and basal transcriptional states at 
intermediate time points. Nonetheless this model may provide a useful frame-
work to understand changes in gene expression associated with metabolic and 
other pathways that occur early in the process of trained immunity and support 
the phenotype of fully differentiated, trained macrophages. Discernment of the 
epigenetic proponents of persistent gene expression will not only inform about 
mechanisms that sustain the memories of macrophages, but also long-term 
epigenetic programming of myeloid cells.
The heterologous protection conferred by vaccination with BCG far exceeds the 
lifespan of innate immune cells in the circulation [4]. The remarkable finding 
that the trained phenotype and gene-specific H3K4m3 enrichment can be ob-
served 3 months and even up to 1 year after vaccination has inspired interest 
in the physiological mechanisms mediating innate immune memory at the lev-
el of immune progenitor cells. Myeloid cell progenitors can mediate long-term 
TLR2-induced tolerance [104], however much less is known about this process 
in trained immunity. Evolutionary conservation of innate immune memory 
across various phyla provides valuable opportunities to understand this bio-
logical process in humans [105]. Using an experimental infection model, Torre 
et al. recently demonstrated that the induction of innate immune memory in 
planarians (phylum Platyhelminthes) is driven by a specific population of plu-
ripotent stem cells [91]. While much controversy surrounds the transmissibility 
of histone modifications across generations in vertebrates, the role of DNA (de)
methylation in myeloid differentiation is actively investigated [81, 106]. Further-
more, the heritability and potent gene regulating functions of 5mc underscores 
the enthusiasm surrounding the role of this modification in sustaining cellu-
lar memories [107]. Future studies should aim to characterize the DNA methy-
lomes of myeloid progenitors and terminally differentiated cells in the broader 
context of innate immune memory.
In light of the epigenetic changes and different modes of transcriptional mem-
ory that define innate immune memory, a key challenge is to understand the 
operational epigenetic machinery [108]. Several epigenetic enzymes have been 
recently associated with macrophage function (recently reviewed [88]), howev-
er their roles in training and tolerance remain untested. One study reported sig-
nificant upregulation of Set7 in response to β-glucan training [6]. While the im-
portance of the MLL1 KMT to epigenetic enhancer signatures in macrophages 
has been recently described for processes such as TLR4 signaling [109, 110], the 
potential role of Set7 remains to be established. As an interesting link to meta-
bolic regulation, genes encoding KDMs JMJD1A and JMJD2B are transcriptional-
ly activated by HIF1α in response to hypoxia in primary epithelial cells as well as 
transformed cell lines [111, 112]. In this search for epigenetic regulators anoth-
er potentially important clue was revealed by the study of Torre et al., [91]. The 
trained phenotype of planarians is dependent on a KMT that shares homology 
with human Set8. This enzyme specifically methylates lysine 20 on H4 histones 
[113], a modification that is yet to be explored in the innate immune memory 
of vertebrates [105].  
Recent evidence suggests that the identities of some of the factors responsi-
ble for the myriad epigenetic changes governing innate immune memory may 
be revealed through a deeper understanding of upstream signaling events that 
sustain epigenetic pathways and shape the deposition of chromatin marks [2]. 
Epigenetics and immunometabolism
Inhibition of either glycolysis or mTOR signaling interrupts the characteristic 
chromatin modification pattern and adapted phenotype of trained immunity, 
confirming a role for metabolic changes in epigenetic reprogramming. Further 
linking metabolic rewiring of cellular metabolism with innate immune memo-
ry, evidence increasingly supports the integration of metabolic information and 
transcriptional control via the enzymatic consumption of metabolites in epi-
genetic reactions [58]. Specifically, the enzymatic activities of many chromatin 
modifiers are regulated in part by concentrations of metabolic intermediates 
[114]. Fluctuating metabolite concentrations therefore potentiate continual ad-
justment of gene expression by modulating the epigenome to influence chro-
matin dynamics [58].
It is therefore reasonable to speculate that the profound metabolic changes 
associated with trained immunity could sustain epigenetic patterns or drive 
further alterations to the chromatin landscape at important regulatory regions 
through an interesting interplay between metabolites and gene regulation. Crit-
ical metabolic intermediates such as NAD+ and acetyl-CoA, which are altered 
in β-glucan trained monocytes [2, 41], serve as cofactors or substrates for nu-
merous HDACs and HATs respectively (Fig 5). The methylome is also sensitive 
to metabolic variation through changes to cellular levels of α-ketoglutarate, an 
essential cofactor for several lysine and cytosine demethylating enzymes [58, 
115]. Importantly, TCA cycle intermediates succinate and fumarate can inhibit 
certain demethylation reactions [116]. The striking elevation of succinate and 
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fumarate induced by the metabolic rewiring of trained macrophages therefore 
represents a plausible mechanism behind the integration of immunometabolic 
and epigenetic programs in trained immunity.
Drawing upon these molecular interactions, we recently demonstrated that the 
accumulation of fumarate as a function of glutamine replenishment of the TCA 
cycle connects immune pathways with epigenetic programs by inhibiting the 
H3K4 demethylase KDM5 and thereby elevating the enrichment of H3K4me3 at 
the promoters of genes encoding proinflammatory cytokines [42].
Moreover, exogenous fumarate itself induces a trained macrophage phenotype 
in terms of cytokine production that is again abolished by inhibition of gluta-
minolysis and glycolysis. At the epigenomic level, fumarate training echoes a 
proportion of the chromatin patterns induced by β-glucan, implicating its prob-
able involvement in at least partially mediating the effects of classical training 
stimuli. Perhaps most remarkable is the observation that fumarate positively 
regulates transcription of genes encoding KDM5 isoforms, in addition to the 
epigenetic activity of these enzymes. From this interplay emerges a regulatory 
dichotomy with relevance for trained immunity: KDM5 activity and the down-
stream increases in cytokine production mediated by fumarate were attenuated 
by α-ketoglutarate [117].
Another important observation transpiring from this study was the induction of 
H3K27ac in cells trained with fumarate [42]. This raises two main possibilities. 
First, fumarate could positively regulate expression of genes encoding HATs, or 
reciprocally, negatively regulate HDAC gene expression by inhibiting demethyl-
ation of active chromatin marks. Second, fumarate inhibits KDM5 demethylas-
es to regulate the chromatin-modifying activities of HATs or HDACs by altering 
their posttranslational lysine methylation status (see below).
Finally, other metabolites could directly influence epigenetic regulation by 
mechanisms that are yet to be thoroughly characterized. A pertinent example 
is succinylation - a posttranslational modification of proteins in which a succinyl 
group is added to a lysine residue from succinyl-CoA [118]. In accordance with 
the marked increases observed for succinate in trained immunity, lysine suc-
cinylation is considered an inflammatory signal for innate immune cells [53]. 
Importantly this modification is written to several sites of histone tails in human 
and yeast cells [119]. Although details of the functional consequences of his-
tone succinylation are currently undescribed, this modification induces a struc-
tural chromatin change greater than the change caused by lysine acetylation, by 
converting a positively charged residue to a negative charge [119]. Future stud-
ies are predicted to strengthen this regulatory connection between chromatin 
biology and the metabolic characteristics of innate immune memory. 
Figure 5. Chromatin modifications unite immunometabolism and gene expression. The activities 
of many chromatin-modifying enzymes are regulated in part by concentrations of intermediates 
of energy metabolism. Repurposing of the TCA cycle modulates the epigenome of trained immu-
nity. Members of the sirtuin family of histone deacetylase (HDAC) enzymes are sensitive to intra-
cellular NAD+/NADH ratios. Acetyl-CoA is the essential acetyl group donor to lysine acetylation 
(by histone acetyltransferases, HATs), linking intermediary carbon metabolism with chromatin 
dynamics and transcription. Histone lysine demethylating events are influenced by the elevat-
ed levels of succinate and fumarate associated with metabolic rewiring of trained macrophages. 
In particular, fumarate inhibits lysine demethylases (KDMs) thereby elevating the enrichment of 
H3K4m3 at the promoters of genes encoding proinflammatory cytokines.
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Multiple roles for lysine methylation in innate immune memory
The very definition of epigenetics has drawn its share of recent criticism [120], 
though perhaps largely from argument that is more semantic than biologic and 
stemming from an etymology rooted in developmental biology and heredity 
[121]. It is now clear that epigenetic processes are not restricted to roles in de-
velopment but also shape the phenotypes of nondividing cells. Certainly more 
deserving of attention is the controversy surrounding the hierarchical signifi-
cance of epigenetic modifications in gene expression. A stringent interpretation 
of the histone code hypothesis [73] tends to attribute regulatory primacy to 
chromatin modifications whilst appreciating that TFs bind specific DNA sequenc-
es to activate nearby genes. However, rather than displace the long-standing 
importance of TFs, the emerging picture is one where epigenetic enzymes and 
chromatin modifications synergize with traditional regulators of transcription. 
To this end, a conceptual framework that encompasses the molecular tagging 
of chromatin components to designate functional genomic regions and support 
transcriptional responses to distinct signaling cues is consistent with the current 
understanding of gene regulation.
While not entirely overlooked, the role of TF networks for the induction of 
innate immune memory has not received the same attention as chromatin 
modifications. Approximately 12% of known TFs are variably expressed during 
macrophage differentiation, tolerance, and training [6]. Furthermore, discrete 
binding motifs within condition-specific dynamic epigenomic regions indicates 
the importance of particular TFs for the distinct transcriptional programs of 
trained and tolerized macrophages [6, 43]. 
Although pre-treatment with a pan-methylation inhibitor impedes the epigen-
etic rewiring and consequently blocks the adapted phenotype of trained cells 
[4, 7, 44], histones and DNA are not the only gene-regulating factors modulated 
by methylation. Posttranslational methylation has in recent years emerged as 
a ubiquitous and pivotal determinant of TF stability and trans-activity, reveal-
ing the dual regulatory roles of KMTs and KDMs in histone-dependent and -in-
dependent mechanisms of transcription (Fig 6) [122, 123]. Similar regulatory 
functions are attributed to posttranslational lysine acetylation [124, 125]. Of 
particular relevance to the induction of innate immune memory for its potential 
influence on cellular metabolism is the posttranslational methylation recent-
ly shown to regulate HIF1α function. Set7-mediated methylation of HIF1α di-
minishes its occupancy on glycolytic gene promoters, thereby inhibiting gene 
expression [126]. Importantly this modification is reversed by lysine-specific 
histone demethylase 1 (LSD1) [127], an epigenetic enzyme that is influenced 
by cellular levels of flavin adenosine dinucleotide and is therefore sensitive to 
metabolic variation [128]. It is currently unknown if similar methyl-dependent 
regulation of HIF1α, or other TFs that direct the overall metabolic shift, impacts 
the induction of trained immunity.
This avenue of inquiry could also reveal novel regulatory mechanisms immedi-
ately associated with the trained cell’s response to secondary stimuli. The ra-
pidity and magnitude of macrophage responses to TLR stimulation is facilitated 
by the expeditious deployment of stimulus-responsive TFs such as AP-1, NFκB, 
and STAT family members to regulatory elements of inflammatory genes [2]. As 
described above, these transcriptional responses are intensified in trained im-
munity by the sustained accessibility of chromatin owing to specific epigenetic 
patterns. However the same pathways that support chromatin modifications 
may also influence TF dynamics. Much like histones, the functional consequenc-
es of TF lysine methylation are site-specific (Table 2). 
In addition to their interactions with modified histones, binding of TFs can in 
fact facilitate the localization of epigenetic enzymes to sites of chromatin mod-
ification [129]. A recent finding suggests that the stress-responsive TF ATF7 is 
a key regulator of long-term maintenance of epigenetic changes that enhance 
macrophage resistance to pathogens [130]. In resting cells, ATF7 suppresses a 
group of innate immune-related genes by recruiting the H3K9 KMT G9a. In re-
sponse to LPS stimulation, ATF7 is phosphorylated by p38 kinase and released 
from the chromatin. This causes a concomitant decrease in transcriptionally 
Figure 6. Lysine methylation regulates gene expression by chromatin-dependent and chroma-
tin-independent mechanisms. In addition to chromatinized histone substrates, epigenetic lysine 
methyl writers can exert their influence on gene expression by specific methylation of amino acid 
residues on the surface of non-histone proteins. The functional consequences for substrates such 
as key transcription factors include changes in protein stability and activity that modulate down-
stream transcriptional outcomes.
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repressive H3K9m2 levels culminating in a partially disrupted chromatin struc-
ture. Once ATF7 is depleted from the chromatin it is not entirely reinstated back 
at the original binding sites, thus maintaining the expression of target genes 
for long periods as a type of epigenetic and transcriptional memory [130, 131].
Interestingly, many chromatin modifying enzymes are themselves regulated 
by posttranslational modifications including lysine methylation and acetyla-
tion, suggesting a highly ordered and dynamic network of components capable 
of writing and erasing modifications at both the chromatin template as well 
as each other. For example, the enzymatic activity of a specific HAT known as 
p300/CBP associated factor is posttranslationally regulated by methylation and 
acetylation at numerous lysine residues [132, 133]. Individual epigenetic en-
zymes therefore possess the potential to indirectly control multiple chromatin 
modifications. Mapping the inter-enzyme modification network of chromatin 
regulators has considerable capacity to expand our understanding of gene reg-
ulation [129].
Table 2. Lysine methylation regulates transcription factor function
Transcription 
factor
Methylated lysine Regulatory function KMT KDM
HIF1α K32 repression Set7 [126, 127] LSD1 [127]
K391 degradation LSD1 [134]
NFκB-p65 K37 activation Set7 [135]
K218 activation NSD1 [136] FBXLII [136]
K221 activation NSD1 [136] FBXLII [136]
K310 repression SETD6 [137]
K314 degradation Set7 [138]
K315 degradation Set7 [138]
STAT3 K49 activation EZH2 [139]
K140 repression Set7 [140] LSD1 [140]
K180 activation EZH2 [141]
STAT1 K685 (predicted) Set7 [142] 
KMT lysine methyltransferase; KDM lysine demethylase
Conclusion and future prospective
The defining premise of innate immune memory rests on the cell’s ability to 
retain and recall information about previous exposures. This cellular memory 
is facilitated by major shifts in metabolic and transcriptional pathways. It is be-
coming increasingly clear that such changes are inextricably and bidirectional-
ly linked through epigenetic mechanisms. These findings add to the growing 
body of literature supporting a prominent role for the epigenome in recording 
adaptive experiences. In particular they shed light on the potential mechanisms 
underlying primed and persistent transcriptional memory in innate immune 
training and tolerance. Furthermore, stable and heritable epigenetic changes 
have the capacity to explain the long-term memory effects of trained immunity 
observed months after BCG vaccination [4].  
Trained immunity is a fundamental property of the mammalian immune re-
sponse, and is increasingly investigated as an adjuvant to potentiate next-gen-
eration vaccines [143]. In recent years there has been a shift by some in the 
field to understand the broader therapeutic possibilities. For example, induc-
ers of trained immunity such as BCG and β-glucan represent current [144, 145] 
and prospective approaches to the clinical management of various cancers. The 
restoration of cytokine production in experimental endotoxemia by β-glucan 
at the level of histone modification and transcriptional reactivation highlights 
the potential of epigenetic therapy in the broader context of immune paralysis 
[43]. On the other hand, innate immune reprogramming may have adverse ef-
fects in various pathological contexts, particularly under chronic inflammatory 
conditions in which trained immunity is induced by endogenous ligands. The 
enhanced and maladaptive immune responsiveness foreshadows important 
consequences as well as novel therapeutic opportunities for the development, 
progression, and stability of atherosclerotic lesions [146]. Further exploration 
may uncover new clinical strategies to treat vascular complications arising from 
the deleterious hyperactivity of innate immune cells sustained by features of 
metabolic syndrome and the diabetic milieu [9]. Indeed hyperglycemia can in-
duce long-term epigenetic modulation of inflammatory gene expression [103, 
147].
Clinical exploitation will be enhanced by the rapidly accumulating knowledge 
of the molecular mechanisms underlying the metabolic and epigenetic rewiring 
of adaptive innate immune responses. Pharmacological modulation of metab-
olism has shown potential in other pathophysiological situations. For example, 
inhibition of glycolysis limits pathological neovascularization [148]. The emerg-
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ing picture of trained innate immunity outlines a process driven by complex 
interactions between metabolic and epigenetic factors. Not surprisingly, the 
immune-modulating effects of metabolic inhibitors are at least partly mediated 
by epigenetic changes. Such studies have already disclosed important clues to 
the identities of the nuclear machinery responsible for maintaining chromati-
nized signatures of innate immune memories [42], providing early framework 
for the development of clinical strategies that target epigenetic regulators. Sev-
eral drugs that inhibit epigenetic enzymes are already approved for clinical use 
in the fields of oncology and haematology [149]. Small molecular histone mimic 
BET inhibitors (iBET) have shown promise for treatment of inflammation [150]. 
Though effective in blocking LPS-induced tolerance when co-administered in 
human monocytes, iBET treatment was unable to reverse memories of previous 
LPS stimulation [43].
While offering arguably greater precision for the adjustment of discrete tran-
scriptional events, direct pharmacological manipulation of the epigenetic pro-
ponents of trained immunity raises some important considerations. As de-
scribed above for the pan-methyl inhibitory properties of MTA, certain HDAC 
inhibitors exhibit broad substrate specificity. Even compounds that target spe-
cific enzymes may have unintended effects, as the complex interplay between 
epigenetic enzymes and traditional transcriptional machinery forecasts the po-
tential pleiotropic impact of epigenetic drugs across a broad spectrum of pro-
tein substrates and gene regulatory processes [151, 152]. The complexities of 
pharmacological epigenetic modulation are further exacerbated by cell type–
specific roles of the chromatin modifying machinery. For example, macrophage 
and endothelial cell HDAC3 play opposing roles the development of atheroscle-
rosis in mice [153, 154]. For these reasons, recent technological and scientific 
advances such as single-cell transcriptomic and epigenomic profiling will form 
the cornerstone of future research efforts. 
Indeed we are only beginning to scratch the surface of a remarkably intricate 
system of long-term gene regulation and transcriptional memory. In combina-
tion with DNA sequence profiling, epigenomics could determine the functional 
significance of genetic variants to innate immune function [145], including those 
occurring in regulatory and noncoding regions. Epigenomic and transcriptomic 
profiling could also unravel the contributions of miRNA and lncRNA to trained 
immunity, which remain largely unexplored but of significant regulatory poten-
tial [2]. Furthermore, TF substrates of epigenetic enzymes can be inferred from 
chromatin and gene expression profiles and protein substrate motifs [142]. Suc-
cessful future therapeutic approaches to the manipulation of innate immune 
memory of infectious and autoinflammatory diseases will emerge only from a 
comprehensive understanding of key molecular events and epigenetic interac-
tions. 
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Introduction
Periodontitis (PD) is an independent risk factor for cardiovascular disease (CVD) 
[1, 2]. Unravelling the mechanistic link between PD and CVD is of great public 
health importance due to their high prevalence and economic burden [3-5]. 
Despite ongoing research, a comprehensive understanding of this association 
is still lacking [6].
PD and CVD are chronic low-grade inflammatory diseases, driven by the acti-
vation of innate immune cells. In atherosclerosis, which is the main cause of 
CVD, monocytes and macrophages play a key role in the initiation, progression, 
and destabilization of atherosclerotic plaques [7]. In PD, microbial dysbiosis and 
local inflammation co-develop in a reciprocally reinforced manner [8]. Porphy-
romonas gingivalis is a keystone periodontal pathogen driving microbial dysbi-
osis in PD [9, 10], and is also suggested to be involved in atherosclerotic CVD. It 
was isolated from human atherosclerotic plaques [1], and reported to modulate 
immune cell function [11, 12].  In mice, P. gingivalis-induced PD led to athero-
sclerosis with enhanced vascular wall inflammation [12]. We now propose that 
a novel mechanism of innate immune cell activation, called trained immunity, 
contributes to the association between PD and CVD.
Trained immunity describes the observation that monocytes/macrophages can 
build immunological memory after encountering a pathogen, resulting in a per-
sistent hyperresponsive phenotype. Increased cytokine production capacity is 
the hallmark of trained immunity. It provides host protection against recurrent 
infections, but in chronic inflammatory diseases, such as atherosclerosis, it can 
contribute to the disease pathophysiology [13]. Trained immunity can be in-
duced by brief exposure to micro-organisms, but also with endogenous athero-
genic stimuli. In human monocytes, exposure to oxidized low-density lipopro-
tein (oxLDL) induces a persistently enhanced cytokine response and increased 
foam cell formation [14]. Trained immunity develops through distinct epigene-
tic and metabolic reprogramming [13].
In view of the association between PD and CVD, we now hypothesize that P. 
gingivalis as a keystone periodontal pathogen can induce trained immunity in 
vitro, and that monocytes isolated from patients with PD have a hyperrespon-
sive phenotype that accelerates atherosclerosis development.
Abstract
Periodontitis (PD) is an independent risk factor for cardiovascular disease 
(CVD), but the mechanistic link is not fully understood. In atherosclerot-
ic CVD, monocytes can adopt a persistent hyperresponsive phenotype, 
termed trained immunity. We hypothesized that PD-associated bacteria 
can induce trained immunity in monocytes, which subsequently acceler-
ate atherosclerosis development. We combined in vitro experiments on 
human primary monocytes and in vivo techniques in patients with PD to 
test this hypothesis. 
When adherent peripheral blood mononuclear cells (PBMCs) were tran-
siently exposed in vitro to Porphyromonas gingivalis for 24 hours, and re-
stimulated with LPS or P3C six days later, IL-6 and TNFα production was sig-
nificantly increased (TNFα/P3C, p<0.01). In an exploratory study, patients 
with severe PD (63±6 years, n=14) and control subjects with no-to-mild 
PD (54±10 years, n=14) underwent venepuncture and 2’-deoxy-2’-[18F]flu-
oro-D-glucose positron-emission-tomography ([18F]FDG PET/CT) scanning. 
Circulating leukocytes, and interleukin 6 (IL-6) and IL-1Ra concentrations 
were generally higher in patients compared to controls (leukocytes: p<0.01; 
IL-6: p=0.08; IL-1Ra: p=0.10). Cytokine production capacity in PBMCs after 
24h stimulation revealed no differences between groups. [18F]FDG PET/CT 
imaging showed a trend for increased [18F]FDG-uptake in the periodon-
tium (SUVmean, p=0.11) and in femur bone marrow (SUVmean, p=0.06), but no 
differences were observed for vascular inflammation. Positive correlations 
between severity of PD, measured by DPSI and pocket depth, with circulat-
ing inflammatory markers and tissue inflammation were found.
In summary, P. gingivalis induces long-term activation of human mono-
cytes in vitro (trained immunity). Patients with severe PD did have signs 
of increased systemic inflammation and hematopoietic tissue activation. 
However, their circulating monocytes did not show a hyperresponsive phe-
notype. Together we suggest that trained immunity might contribute to 
local periodontal inflammation which warrants further investigation.





P. gingivalis strains ATCC 33277 and W83 (kindly provided by ACTA, Amster-
dam, The Netherlands) were cultured on blood agar plates under anaerobic 
conditions at 37⁰C. At day 7, colonies were transferred to anaerobe basal broth 
(CM0957, ThermoFisher, Waltham, USA) and cultured for 24h until they reached 
mid-log growth (OD690 0.5). Gram staining confirmed purity of the cultures. The 
bacterial cultures (diluted to OD690 0.1) were heat-inactivated at 60°C for 60 min.
PBMC isolation
Buffy coats were obtained from healthy donors after written consent (Sanquin 
Blood Bank, Nijmegen, the Netherlands). Peripheral blood mononuclear cells 
(PBMCs) were isolated using density centrifugation over Ficoll-Paque PLUS (GE 
Healthcare Biosciences, Chicago, USA). Cells were resuspended in Dutch modi-
fied RPMI culture medium (Invitrogen, CA, USA) supplemented with 2 mmol/L 
glutamine, 10 mg/mL gentamicin and 1 mmol/L pyruvate.
Trained immunity model
A validated trained immunity experimental design was used [15]. After 1h incu-
bation with 5x105 PBMCs per well, cells were washed thrice to remove non-ad-
herent cells in flat-bottom 96-well plates (Corning, NY, USA). Adherent mono-
cytes were stimulated with 1x104/mL P. gingivalis W83, 1x104/mL P. gingivalis 
ATCC, or RPMI only. After 24h incubation, the cells were washed with warm 
PBS and incubated in culture medium with 10% pooled human serum. At day 6, 
cells were restimulated with RPMI, 10 ng/mL Escherichia coli lipopolysaccharide 
(LPS; serotype 055:B5 Sigma-Aldrich, St. Louis, USA), and 10 μg/mL Pam3CysK4 
(P3C; EMC Micro collections, Tübingen, Germany). At day 7, supernatants were 
collected and stored at −20°C. In separate experiments, P. gingivalis stimulation 
was combined with freshly oxidized LDL (10 µg/mL, prepared as described pre-
viously [16]).
Cytotoxicity
Cytotoxicity was determined after 24h of incubation with P. gingivalis using a 
lactate dehydrogenase cytotoxicity assay (LDH; CytoTox 96 Non-Radioactive Cy-
totoxicity Assay, Promega, USA) on fresh supernatants.
Foam cell formation
Foam cell formation was evaluated after 4h starvation and 24h oxLDL (25 µg/
mL) exposure at day 6 of the trained immunity experiment. On day 7, Oil Red 
O staining was performed on adherent macrophages. Intracellular ApoB con-
centration was measured using enzyme-linked immunosorbent assay (ELISA) as 
described in [17].
Cytokine measurements
Cytokine production in supernatants was determined using ELISA for TNFα and 




Participants (40-80 years) were recruited among patients of the Dentistry de-
partment of Radboud University Medical Center, the Netherlands. Exclusion 
criteria were previous CVD, auto-immune or auto-inflammatory diseases (in-
cluding diabetes mellitus), chronic immunomodulatory drug use, chronic kidney 
disease (MDRD<45 ml/min) or liver disease (ALAT>135 U/l). Additionally, partic-
ipants with an infection (>38,5°C or antibiotic treatment), hospital admission, 
or vaccination within 1-month prior study entry were excluded. We attempted 
to match control participants based on age, sex, body mass index (BMI) and 
smoking. The study protocol was approved by the Institutional Review Board 
Arnhem/Nijmegen, the Netherlands (NL61840.091.17). All participants gave 
written informed consent.
Clinical periodontal assessment
The Dutch Periodontal Screening Index (DPSI) and probing pocket depth (PPD) 
were recorded by an experienced periodontist [AP]. Subjects with DPSI scores 
0, 1, 2 were classified as having no PD (category A), those with DPSI score 3- as 
having mild PD (category B), and subjects with DPSI scores 3+ and 4 as having 
severe PD (category C) [18]. The presence of alveolar bone loss on paired bite-
wings, defined as >2 mm distance between the cement-enamel junction and 
alveolar bone crest [19] was used to confirm the clinical diagnosis. Subjects with 
DPSI category C (scores 3+, 4) and advanced alveolar bone loss were assigned to 
the patient group, i.e. participants with severe PD. Subjects with DPSI category 
A (scores 0-2) and category B (score 3-) without radiographic alveolar bone loss 
were assigned to the control group, i.e. participants with no-to-mild PD.
The clinical diagnosis of PD is in concordance with the New Periodontal classi-
fication of 2018 [20]. Defined by the classification of 2018, study subjects had 
advanced PD stage IV (21%), severe PD stage III (57%), and moderate PD stage 
II (21%), whilst control subjects had gingivitis (43%) and initial PD stage I (57%).
Cardiovascular risk assessment
Blood pressure was measured according to AHA guidelines [21]. Fasting total 
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cholesterol (Tchol), high-density lipoprotein cholesterol (HDLc), and triglycerides 
(TG) were measured using standardized methods, and LDL cholesterol (LDLc) 
was calculated with the Friedewald formula.
PBMC isolation and stimulation
PBMCs were isolated by Ficoll-Paque density gradient centrifugation (GE Health-
care) and resuspended in supplemented RPMI. Cell composition was evaluated 
by Sysmex analyser (Sysmex). Per well, 5x105 PBMCs were stimulated for 24h 
in triplicate in round-bottom 96-well plates (Corning) with the following stimuli 
to assess the innate immune response: RPMI, 10 ng/mL LPS and 10 μg/mL P3C. 
Simultaneously, to assess the adaptive immune response, PBMCs were stim-
ulated in duplicate for 7 days with RPMI, 1×106/mL Candida albicans conidia 
(UC820 strain), or 1x106/mL Staphylococcus aureus (ATCC 29213 strain) both 
with 10% human pool serum. After the incubation periods of 24h and 7 days, 
supernatants were stored after plate centrifugation at −80°C.
Cytokine measurements
Cytokine and chemokine concentrations were determined in supernatants us-
ing ELISA for TNFα, IL-6, IL-8, IL-10, IL-1β, IL-17 and IL-22 (DuoSet ELISA, R&D), 
and interferon gamma (IFNγ) (Sanquin). Plasma hsCRP concentrations were ob-
tained (DuoSet ELISA, R&D). Circulating IL-1β, IL-1Ra, IL-6 and IL-18 concentra-
tions were sensitively measured using SimplePlex cartridge on the Ella platform 
(Protein Simple, San Jose, USA).
Flow cytometry
Circulating immune cells and monocyte subpopulations were determined by 
their expression markers using a CYTOflex flow cytometer (Beckman Coulter) 
(gating strategy in Appendix Figure 1). Single cells were analyzed by manual 
gating using Kaluza v2.1 software (Beckman Coulter) and unsupervised compu-
tational methods in parallel using FlowJo v10.6.2 software (Beckton Dickinson), 
see supplement for methods.
[18F]FDG PET and low-dose CT scanning 
After adhering to a 24h low-carbohydrate diet and 6h of fasting, participants un-
derwent 2’-deoxy-2’-[18F]fluoro-D-glucose positron-emission-tomography ([18F]
FDG PET) with low-dose non-contrast enhanced CT on a dedicated Siemens Bi-
ograph 40 mCT scanner (Siemens Healthineers, Erlangen, Germany). Analyses 
were performed on reconstruction settings according to the European guideline 
[22]. See supplement for details.
Periodontal [18F]FDG-uptake was determined in two volumes of interest (VOI): 
left and right periodontium in the maxilla and mandible (Figure 2A, Appendix 
Figure 2). Vascular [18F]FDG-uptake was determined in seven regions of interest 
(ROI); the aorta ascendens, aorta descendens, abdominal aorta, the left and 
right common carotid arteries, and the left and right iliac arteries (Figure 2B, 
illustration). ROIs were positioned in uncalcified areas of vascular wall. Hemato-
poietic [18F]FDG-uptake was assessed in the spleen, lumbar vertebrae L2 and L3, 
and in the left and right medullary cavity of the femur (Figure 2C, illustration). 
The mean standardized uptake value (SUVmean) was extracted from each ROI af-
ter correction for weight and [18F]FDG dose (MBq). Next, the target-to-back-
ground ratio (TBR) was calculated as the ratio of the vascular wall SUVmean and 
the thoracic arterial blood pool SUVmean. TBR of hematopoietic tissue was ex-
pressed as ratio of the liver SUVmean. All images were analysed blinded for par-
ticipant identifiers using Inveon Research Workspace v4.2 software.
Statistical analysis
In vitro data are reported as mean±SEM. P. gingivalis-trained cells were com-
pared to RPMI-incubated control cells using Wilcoxon signed-rank test. In vivo 
continuous variables are reported as mean±SD or median[interquartile range], 
depending on the data distribution. Normal distribution of the data was checked 
with the Shapiro-Wilk test, when the p-value reached <0.05 this assumption 
was violated. Patients and controls were compared for continuous variables 
using independent samples T-test (if normally distributed) or Mann-Whitney 
U test (if not normally distributed). Categorical variables are presented as per-
centage(number) and were compared using Χ2-test. For all study outcomes, a 
one-way ANCOVA was conducted to control for age differences between pa-
tients and controls. Beforehand, outliers were removed with >±3SD of Z-scores 
and thereafter log(10)-transformed. A two-sided p-value <0.05 was considered 
statistically significant. All data were analysed using SPSS v25.0 (Chicago, USA).
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Results
P. gingivalis induces trained immunity in vitro
The in vitro experiments with P. gingivalis ATCC and W83 strains are illustrated in 
Figure 1A. The production of IL-6 and TNFα after restimulation was significantly 
increased compared to the RPMI-incubated control cells (Figure 1B, p<0.05). 
Restimulation with P3C, a TLR2 agonist, resulted in the strongest augmentation 
of the cytokine response with a two-fold induction.
In P. gingivalis-trained macrophages, foam cell formation seemed to be in-
creased as visualized by Oil Red O staining (Figure 1C). Quantification of the 
intracellular lipid uptake (ApoB) did not show differences (p=0.20, data not 
shown).
Both oxLDL and P. gingivalis can be found in low concentrations in the periodon-
tium [23]. Costimulation with P. gingivalis and oxLDL resulted in a strong ampli-
fication of cytokine production upon restimulation compared to the RPMI-ex-
posed control. The induction of trained immunity by combined stimulation was 
not stronger compared to oxLDL training alone, although there was a trend for 
ATCC to further potentiate LPS-induced TNFα release (Figure 1D, p=0.12). Co-
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Patients with severe periodontitis have increased systemic inflammation which 
correlates with tissue inflammation
Baseline characteristics 
We included participants with severe PD (DPSI 3.9±0.2, n=14, ‘patients’) and par-
ticipants with no-to-mild PD (DPSI 2.9±0.3, n=14, ‘controls’) (Table 1). Patients 
were older than controls (63±6 versus 54±10 years, p<0.05), and had a higher 
previous tobacco exposure (15.8±18.2 versus 4.5±5.7 pack years, p<0.05). Cur-
rent smoking behaviour was similar. Age is known to impact immune cell func-
tion [24], therefore we corrected all comparisons for age.
Table 2. Circulating cell types and cytokines/chemokines. 
Cell types Controls Patients
WBC, 106/mL 5.6 [4.5-6.2] 6.1 [5.5-7.1]**
Neutrophils, 106/mL 3.3 [2.7-3.8] 3.1 [3.0-4.3]
Lymphocytes, 106/mL 1.7 [1.5-2.1] 1.8 [1.6-2.2]^
Monocytes, 106/mL 0.4 [0.3-0.5] 0.5 [0.4-0.6]
Monocytes, % 7.1 [6.1-8.5] 7.1 [6.5-8.5]
Classical monocytes, %gated 81 [75-84] 82 [75-86]
Intermediate monocytes, %gated 4.9 [4.2-7.0] 6.0 [5.1-9.5]
Nonclassical monocytes, %gated 13 [12-16] 11 [10-18]
CCR2+ monocytes, %gated 84 [80-88] 86 [80-89]
CD11b+ monocytes, %gated 86 [66-96] 91 [88-94]
CD41+ monocytes, %gated 7.5 [6.0-8.8] 7.4 [5.7-9.2]
Cytokines & chemokines
IL-1β, pg/mL 0.17 [0.14-0.24] 0.17 [0.13-0.21]
IL-1Ra, pg/mL 171 [145-239] 247 [188-428]^
IL-6, pg/mL 1.4 [0.9-1.9] 2.0 [1.6-3.0]^
IL-18, pg/mL 159 [120-189] 182 [136-244]
hsCRP, µg/mL 0.7 [0.3-1.8] 0.7 [0.4-1.3]
Circulating cells/markers are reported as median with [interquartile ranges] in control partici-
pants (n=14) and participants with periodontitis (n=14). 10 samples under IL-1β lowest detection 
limit of 0.16 pg/mL. One sample under IL-6 lowest detection limit of 0.70 pg/mL. P-values are age 
corrected using ANCOVA. ^ indicates P<0.10,*: p<0.05, **: p<0.01. WBC: white blood cell counts.
Table 1. Baseline characteristics
Demographics Controls (n=14) Patients (n=14)
DPSI, 0-4 2.9 ±0.3 3.9 ±0.2**
Mean PPD, mm 3.7 ±0.6 5.0 ±1.3**
Deepest PPD, mm 4.6 ±0.7 6.4 ±1.6**
Age, years 54 ±10 63 ±6*
Sex, % men 57 (8) 36 (5)
BMI, kg/m2 24.9 ±3.5 28.0 ±6.5
SBP, mmHg 130 ±17 137 ±17
DBP, mmHg 80 ±7 89 ±12
Hypertension, % (n) 43 (6) 64 (9)
Alcohol consumption, 0-8 3.3 ±1.7 2.9 ±1.4
Current smoking, % (n) 14 (2) 7 (1)
Smoking, packyears 4.5 ±5.7 15.8 ±18.2*
Anti-hypertensive treatment, % (n) 14 (2) 29 (4)
Lipid lowering therapy, % (n) 7 (1) 29 (4)
Fasting glucose, mmol/L 5.1 ±0.4 5.4 ±0.4
Creatinine, mmol/L 79 ±12 75 ±10
Tchol, mmol/L 4.96 ±0.47 5.18 ±0.76
LDLc, mmol/L †2.65 ±0.44 2.90 ±0.67
HDLc, mmol/L 1.41 ±0.47 1.44 ±0.37
TG, mmol/L 1.92 ±1.19 1.90 ±0.88
nHDLc, mmol/L †3.52 ±0.73 3.76 ±0.84
Demographics are reported as mean ±SD or (number of participants) in control participants (n=14) 
and participants with periodontitis (n=14). Anti-hypertensive treatment includes beta-blockers, 
ACE-inhibitors, ARB’s and thiazide diuretics. Alcohol consumption is the sum of alcohol consump-
tion frequency (0-4, ranging from never:0 to >4x/week:4) and alcohol consumption quantity per 
occasion (0-4, ranging from 1-2 drinks:0 to >10 drinks:4) based on the Alcohol Use Disorders Iden-
tification Test questions. † Data is missing for 1 participant. * indicates p<0.05, **: p<0.01. PPD: 
probing pocket depth.
Systemic inflammatory markers
Higher circulating leukocytes (median 6.1 versus 5.6 106/mL, p<0.01) and a 
trend for higher lymphocytes numbers (1.8 versus 1.7 106/mL, p=0.06) were 
found in patients compared to controls after age correction. In addition, a ten-
dency for higher concentrations of circulating pro-inflammatory IL-6 and an-
ti-inflammatory IL-1Ra cytokines were observed, but after age correction the 
statistical significance was lost (IL-6: 2.0 versus 1.4 pg/mL, p=0.08; IL-1Ra: 247 
versus 171 pg/mL, p=0.10) (Table 2).
Using flow cytometry, circulating immune cell populations were further identi-
fied based on their expression markers. Unsupervised t-Stochastic Neighbour 
Embedding (tSNE) analysis showed a clear separation of both groups with sev-
eral potentially interesting differences in cell populations (Appendix Figure 4C, 
arrows), however manual gating of these populations and statistical analysis 
revealed high similarity between groups (Table 2).
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Cytokine production capacity
No significant difference in the cytokine production capacity of PBMCs between 
patients and controls was observed (Table 3), for both 24h stimulation (i.e. in-
nate immune response) and 7day stimulation (i.e. adaptive immune response).
Periodontal, hematopoietic and arterial wall activation on [18F]FDG PET/CT
[18F]FDG PET/CT imaging results are displayed before (i.e. raw data) and after 
correction for age. Increased [18F]FDG-uptake in periodontium was observed in 
patients compared to controls (SUVmean 1.70 versus 1.49, p<0.05). After age cor-
rection, the statistical significance was diminished (Figure 2A, p=0.11). The SUV 
Table 3. Cytokine production capacity. 
24-hour stimulation Controls Patients
LPS stimulated PBMCs
TNFα, pg/mL 637 [414-1204] 324 [212-976]
IL-1β, pg/mL 5222 [3893-11317] 6950 [4808-11264]
IL-6, ng/mL 13.1 [7.9-15.8] 12.0 [6.9-20.8]
IL-8, ng/mL 107 [89-123] 110 [68-139]
IL-10, pg/mL 182 [91-295] 110 [59-236]
P3C stimulated PBMCs
TNFα, pg/mL 557 [88-1338] 338 [145-681]
IL-1β, pg/mL 4216 [3112-5929] 5230 [3982-6720]
IL-6, ng/mL 13.2 [11.3-17.4] 13.6 [10.8-17.6]
IL-8, ng/mL 148 [129-189] 146 [126-185]
IL-10, pg/mL 47 [47-131] 55 [47-97]
7-day stimulation
C. albicans stimulated PBMCs
IFNγ, pg/mL 1500 [727-1500] 1276 [625-1500]
IL-17, pg/mL 1509 [631-2811] 1033 [575-2137]
IL-22, pg/mL 5855 [2723-9233] 3803 [1120-9906]
S. aureus stimulated PBMCs
IFNγ, pg/mL 1500 [604-1500] 1040 [508-1500]
IL-17, pg/mL 171 [39-401] 77 [39-127]
IL-22, pg/mL 472 [108-661] 189 [85-787]
Cytokine production capacity of PBMCs in control participants (n=14) and participants with peri-
odontitis (n=14) after 24h stimulation to assess the innate immune response, and 7d stimulation 
to assess the adaptive immune response. Data are reported as median with [interquartile ranges], 
p-values are age corrected using ANCOVA.
Figure 2. Periodontal, vascular wall inflammation and haematopoietic tissue activation on [18F]
FDG PET/CT scan. Standard uptake value (SUV) of each region in control participants (white bars, 
n=14) and participants with periodontitis (black bars, n=14). Regions of interest are illustrated 
in the figure with black lines/blocks. A. Periodontal [18F]FDG-uptake (SUVmean), B. Vascular wall 
[18F]FDG-uptake (SUVmean), and C. Hematopoietic [
18F]FDG-uptake (SUVmean). Geometric mean with 
95% CI, p-values are age corrected with ANCOVA.
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in all arterial and hematopoietic regions were higher in patients, including the 
blood pool used to calculate target-to-background ratios (TBR). Age correction 
resulted in the loss of statistical significance for arterial wall [18F]FDG-uptake 
(Figure 2B). A trend for higher [18F]FDG-uptake in hematopoietic tissue of pa-
tients remained for the femur bone marrow (SUVmean 0.88 versus 0.58, p=0.06) 
(Figure 2C). 
The TBR values showed no statistically significant difference between patients 
and controls. Only a trend for femur bone marrow activation was observed in 
patients after age correction (TBRmean 0.40 versus 0.31, p=0.08) (Appendix Table 
1).
Periodontitis severity correlates with circulating markers and tissue inflammation
The severity of PD, either measured by DPSI or PPD, showed strong positive 
associations with circulating markers IL-6 and IL-1Ra, and with iliac artery vas-
cular wall and femur hematopoietic tissue [18F]FDG-uptake (Appendix Figure 5, 
Appendix Table 2). For example, the DPSI score strongly correlated with the 
number of circulating leukocytes (p<0.01) and mildly correlated with vascular 
wall inflammation in the iliac arteries (p=0.10). Also the mean PPD associated 
with circulating IL-6 concentrations (p<0.05), periodontal tissue inflammation 
(p<0.01) and splenic tissue activity (p<0.05). For circulating markers IL-1β and 
IL-18, and other vascular regions no association with PD was found.
Discussion
Our aim was to explore the induction of trained immunity as a plausible mecha-
nistic link between PD and atherosclerosis. In vitro, we showed that P. gingivalis 
induces trained immunity in human monocytes, in terms of an augmented cyto-
kine production capacity. In vivo, patients with severe PD had signs of systemic 
inflammation, with higher circulating leukocyte counts. However, their circulat-
ing monocytes did not show a hyperresponsive phenotype. Patients appeared 
to have periodontal and hematopoietic tissue activation as visualized by [18F]
FDG PET/CT, after age correction, which correlated with PD severity.
First, we set up an in vitro study using a validated trained immunity protocol 
[15]. Previously we showed that exposure of human monocytes to microbial 
stimuli, including Candida albicans and Bacille Calmette-Guérin (BCG), and en-
dogenous atherogenic stimuli, including oxLDL and catecholamines, leads to an 
augmented cytokine production in response to restimulation [25, 26] [14, 27, 
28]. In the current study, two different P. gingivalis strains were also capable 
of inducing trained immunity. The augmented cytokine production was most 
pronounced after restimulation with P3C, a TLR2 agonist, compared to LPS, a 
TLR4 agonist. This supports the reports that P. gingivalis drives a chronic in-
flammatory response via activation of TLR2 and inhibition of TLR4 in immune 
cells [8]. TLR2-mediated activation is relevant in the context of pathogen in-
duced atheroma formation in mice [29]. The induced two-fold increase in IL-6 
and TNFα production by P. gingivalis was comparable to the effect size of oxLDL 
and BCG [14, 26]. P. gingivalis did not significantly induce foam cell formation in 
macrophages, possibly due to the sample size. In mice, direct stimulation with 
P. gingivalis did increase foam cell formation [30]. Future experiments should 
elucidate the cellular mechanisms by which P. gingivalis induces trained immu-
nity. P. gingivalis can persist intracellularly in macrophages [31], it has to be 
determined yet if training by P. gingivalis requires phagocytosis. Together this 
suggests that trained immunity might fuel a self-perpetuating chronic inflam-
mation in the periodontium. 
Our second aim was to translate our in vitro findings to patients with periodon-
titis in vivo. In this study, participants were included with PD based on validated 
clinical index and radiographs. Although we aimed to match the patient and 
control group, age was significantly different and subsequently all results were 
corrected for age. In this exploratory study, we presented our data before (i.e. 
raw data) and after age correction. In contrast to the in vitro results of PG-in-
duced trained immunity, no difference in the cytokine production capacity of 
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circulating monocytes, which is regarded as major indicator of trained immuni-
ty, between individuals with severe PD and those without was observed. This is 
in contrast to previous studies that did show trained immunity characteristics 
in vivo: after BCG vaccination in vivo, isolated monocytes show a hyperrespon-
sive trained phenotype for several months after vaccination [26]. Also, isolat-
ed monocytes from subjects with dyslipidemia or pheochromocytoma show 
a trained phenotype, matching the in vitro observations that oxLDL and cate-
cholamines induce trained immunity [32]. There are various explanations for 
this discrepancy between the in vitro and in vivo findings in the current study. 
First, in comparison to BCG vaccination and pheochromocytoma that have sys-
temic effects, PD is a local disease which might not influence the phenotype 
of circulating immune cells. Secondly, the disease severity in our patient group 
might not be severe enough to exert a significant effect on distant immune cells. 
Thirdly, the in vitro training effect of P. gingivalis might be diluted in vivo by 
influences of other stimuli. Our results do not exclude, however, that trained 
immunity by P. gingivalis occurs locally in the inflamed periodontium, or within 
atherosclerotic plaques.
It is worth to emphasize that our patients with severe PD had signs of system-
ic inflammation, supporting the existing evidence for the presence of systemic 
inflammation in PD [2]. A trend for periodontal and hematopoietic tissue acti-
vation was observed. Moreover, positive correlations between the severity of 
PD and circulating inflammatory markers or vascular wall inflammation were 
found. The mild association with vascular inflammation was only observed in ili-
ac arteries, which is a region that is prone for early atherosclerotic plaque devel-
opment. There are only a few studies using PET-CT scanning that show that peri-
odontal [18F]FDG-uptake correlates with vascular wall inflammation [33], and 
that lipid-lowering therapy significantly decreases vascular wall inflammation 
as well as periodontal inflammation [34]. However, major limitations of these 
studies are that participants were retrospectively selected from other cohorts 
without clinical diagnosis of PD. 
What makes our study unique is that for the first time, key factors involved in 
the etiology and pathogenesis of PD, including P. gingivalis as keystone patho-
gen and the host innate immune response, were investigated together, in de-
tail, and prospective in relation to atherosclerotic inflammation. Highly sensitive 
methods for evaluation of innate immune cells were used, and [18F]FDG PET/CT 
scanning was applied for bone marrow, periodontal and vascular wall inflam-
mation. Limitations are the small sample size (n=14 per group) and that partici-
pants with severe PD were in supportive periodontal therapy, which resulted in 
a milder phenotype. Since participants did not have an untreated form of PD, 
it cannot be excluded this influenced our results, as periodontal therapy can 
reduce surrogate markers of CVD [2]. Together, this may explain the lack of dif-
ferences in cytokine production capacity and vascular wall inflammation. Larger 
cross-sectional studies with untreated cases of severe PD are needed to further 
explore trained immunity in this population.
Acknowledgements
We are grateful to Bastiaan Krom en Michel Hoogenkamp from ACTA Amster-
dam for kindly providing the P. gingivalis strains. Thanks to Servier medical art 
for providing illustrative artwork.
Funding
This work was supported by the European Union’s Horizon 2020 research and 
innovation program [grant number No 667837] and by the Dutch Heart Foun-
dation IN-CONTROL CVON grant [CVON2018-27] to [MGN, LABJ, NPR]; Neth-
erlands Organization for Scientific Research Spinoza Grant [NWO SPI 94-212] 
to [MGN]; ERC Advanced Grant (#833247) to [MGN]; Competitiveness Oper-
ational Programme grant of the Romanian Ministry of European Funds [HINT, 
ID P_37_762; MySMIS 103587] to [LABJ]; the ERA-CVD Joint Transnational Call 
2018 by the Dutch Heart Foundation [JTC2018, project MEMORY; 2018T093] to 
[NPR].
Author contributions
MPN contributed to conception, design, data acquisition and interpretation, 
performed all statistical analyses, drafted and critically revised the manuscript. 
AP and NPR contributed to conception, design, data acquisition and interpre-
tation, drafted and critically revised the manuscript. EMMS, EHJGA, PV and SB 
contributed to data acquisition and interpretation, and critically revised the 
manuscript. LABJ, MGN contributed to conception, design, and critically revised 
the manuscript. All authors gave their final approval and agree to be account-
able for all aspects of the work.
Disclosures
LABJ and MGN are scientific founders of TTxD.
Chapter 3 Trained immunity as a link between periodontitis and cardiovascular disease
86 87
References
1. Lockhart, P.B., et al., Periodontal disease and atherosclerotic vascular disease: does the 
evidence support an independent association?: a scientific statement from the Ameri-
can Heart Association. Circulation, 2012. 125: p. 2520-2544.
2. Sanz, M., et al., Periodontitis and cardiovascular diseases: Consensus report. J Clin Peri-
odontol, 2020. 47(3): p. 268-288.
3. Alwan, A.D., Global Status Report on non-communicable diseases 2010. 2011. 2011: p. 
9-32.
4. Borrell, L.N. and M. Talih, Examining periodontal disease disparities among U.S. adults 
20 years of age and older: NHANES III (1988-1994) and NHANES 1999-2004. Public 
Health Rep, 2012. 127(5): p. 497-506.
5. Petersen, P.E. and H. Ogawa, Strengthening the prevention of periodontal disease: the 
WHO approach. J Periodontol, 2005. 76(12): p. 2187-93.
6. Teles, R. and C.Y. Wang, Mechanisms involved in the association between periodontal 
diseases and cardiovascular disease. Oral Dis, 2011. 17(5): p. 450-61.
7. Moore, K.J. and I. Tabas, Macrophages in the pathogenesis of atherosclerosis. Cell, 2011. 
145(3): p. 341-55.
8. Hajishengallis, G., Periodontitis: from microbial immune subversion to systemic inflam-
mation. Nature Reviews Immunology, 2014. 15: p. 30-44.
9. Lamont, R.J., H. Koo, and G. Hajishengallis, The oral microbiota: dynamic communities 
and host interactions. Nat Rev Microbiol, 2018. 16(12): p. 745-759.
10. Hajishengallis, G., Immunomicrobial pathogenesis of periodontitis: Keystones, pathobi-
onts, and host response. Trends in Immunology, 2014. 35: p. 3-11.
11. Rodrigues, P.H., et al., Porphyromonas gingivalis Strain Specific Interactions with Hu-
man Coronary Artery Endothelial Cells: A Comparative Study. PLoS ONE, 2012. 7.
12. Miyajima, S., et al., Periodontitis-activated monocytes/macrophages cause aortic in-
flammation. Sci Rep, 2014. 4: p. 5171.
13. Netea, M.G., et al., Defining trained immunity and its role in health and disease. Nat Rev 
Immunol, 2020.
14. Bekkering, S., et al., Oxidized low-density lipoprotein induces long-term proinflammato-
ry cytokine production and foam cell formation via epigenetic reprogramming of mono-
cytes. Arterioscler Thromb Vasc Biol, 2014. 34(8): p. 1731-8.
15. Bekkering, S., et al., In Vitro Experimental Model of Trained Innate Immunity in Human 
Primary Monocytes. Clin Vaccine Immunol, 2016. 23(12): p. 926-933.
16. van Tits, L.J., et al., Oxidized LDL enhances pro-inflammatory responses of alternative-
ly activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis, 
2011. 214(2): p. 345-9.
17. Van Tits, L., et al., Increased levels of low-density lipoprotein oxidation in patients with 
familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. 
Lab Invest, 2003. 83(1): p. 13-21.
18. Van der Velden, U., The Dutch periodontal screening index validation and its application 
in The Netherlands. J Clin Periodontol, 2009. 36(12): p. 1018-24.
19. Zaki, H.A., et al., Is Radiologic Assessment of Alveolar Crest Height Useful to Monitor 
Periodontal Disease Activity? Dent Clin North Am, 2015. 59(4): p. 859-72.
20. Papapanou, P.N., et al., Periodontitis: Consensus report of workgroup 2 of the 2017 Wor-
ld Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditi-
ons. J Clin Periodontol, 2018. 45 Suppl 20: p. S162-S170.
21. Williams, B., et al., 2018 ESC/ESH Guidelines for the management of arterial hypertensi-
on. Eur Heart J, 2018. 39(33): p. 3021-3104.
22. Bucerius, J., et al., Position paper of the Cardiovascular Committee of the European 
Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl 
Med Mol Imaging, 2016. 43(4): p. 780-92.
23. Nagahama, Y., et al., Oxidized low-density lipoprotein-induced periodontal inflammation 
is associated with the up-regulation of cyclooxygenase-2 and microsomal prostaglan-
din synthase 1 in human gingival epithelial cells. Biochem Biophys Res Commun, 2011. 
413(4): p. 566-71.
24. Ter Horst, R., et al., Host and Environmental Factors Influencing Individual Human Cyto-
kine Responses. Cell, 2016. 167(4): p. 1111-1124 e13.
25. Quintin, J., et al., Candida albicans infection affords protection against reinfection via 
functional reprogramming of monocytes. Cell Host Microbe, 2012. 12(2): p. 223-32.
26. Kleinnijenhuis, J., et al., Bacille Calmette-Guerin induces NOD2-dependent nonspecific 
protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad 
Sci U S A, 2012. 109(43): p. 17537-42.
27. van der Valk, F.M., et al., Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall 
Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016. 
134(8): p. 611-24.
28. van der Heijden, C., et al., Catecholamines Induce Trained Immunity In Monocytes In 
Vitro and In Vivo. Circ Res, 2020.
29. Hayashi, C., et al., Pathogen-mediated inflammatory atherosclerosis is mediated in part 
via Toll-like receptor 2-induced inflammatory responses. J Innate Immun, 2010. 2(4): p. 
334-43.
30. Qi, M., H. Miyakawa, and H.K. Kuramitsu, Porphyromonas gingivalis induces murine ma-
crophage foam cell formation. Microb Pathog, 2003. 35(6): p. 259-67.
31. Lamont, R.J., et al., Porphyromonas gingivalis invasion of gingival epithelial cells. Infect 
Immun, 1995. 63(10): p. 3878-85.
32. Bekkering, S., et al., Treatment with Statins Does Not Revert Trained Immunity in Pa-
tients with Familial Hypercholesterolemia. Cell Metab, 2019. 30(1): p. 1-2.
33. Fifer, K.M., et al., Positron emission tomography measurement of periodontal 18f-fluo-
rodeoxyglucose uptake is associated with histologically determined carotid plaque in-
flammation. Journal of the American College of Cardiology, 2011. 57: p. 971-976.
34. Subramanian, S., et al., High-dose atorvastatin reduces periodontal inflammation: A no-
vel pleiotropic effect of statins. Journal of the American College of Cardiology, 2013. 62: 
p. 2382-2391.




In the circulation, monocyte subpopulations and expression markers were determined with flow 
cytometry. 50 µL EDTA blood was stained after the lysis-no-wash strategy (BD Pharm Lyse lys-
ing buffer, Becton Dickinson) by monoclonal antibodies CD45 Krome Orange ([KO], clone J33; 
Beckman Coulter), HLA-DR PE (clone immu-357; Beckman Coulter), CD14 PC7 (clone 61D3 Biosci-
ence), CD16 FITC (clone CB16; eBioscience), CD3 APC-Alexa750 (clone UCTH1; Beckman Coulter), 
CD56 APC (clone N901; Beckman Coulter), CD192 Brilliant Violet421 ([BV421] clone 48607; Bec-
ton Dickinson), CD11b BV785 (clone ICRF44; Biolegend), CD41 PC5.5 (clone Hip8; Biolegend) and 
measured with CytoFLEX flow cytometer (Beckman Coulter). 
Single cells were analyzed by manual gating and unsupervised computational methods in paral-
lel. The gating strategy applied is shown in Appendix Figure 1, gates were set with the fluores-
cence-minus-one method [23, 24]. In short, monocytes were selected based on CD45+ HLA-DR+ 
and monocyte scatter properties, then CD3+ T-lymphocytes and CD56+ NK-cells were excluded, 
and monocyte subsets were identified in the CD14/CD16 plot as percentage of gated. Data was 
analysed with Kaluza 2.1 software (Beckman Coulter). Characterization of monocytes subsets is 
according to current recommendations [23, 24].
For unsupervised computation analyses, data files were randomly down sampled to 10,000 
events per file and subsequently concatenated to a single file containing all events. Controls and 
patients were labelled accordingly to allow separation after analysis. Unsupervised clustering was 
performed on the expression values of all markers using the tSNE plugin in FlowJo v10.6.2 soft-
ware (Becton Dickinson), using 300 iterations and a perplexity of 20. Manual gating of cell popu-
lations (based on gating strategy) was used to identify cell populations and check the separation 
quality of the unsupervised clustering. The contribution of the periodontitis to circulating cell 
populations in the total tSNE was inspected by separating the patient and control group in two 
figures. Visual differences were confirmed by manual gating and statistical analysis.
[18F]FDG PET and low-dose CT scanning
Participants underwent [18F]FDG PET with low-dose non-contrast enhanced CT from skull base to 
the trochanter major on a dedicated Siemens Biograph 40 mCT scanner (Siemens Healthineers, 
Erlangen, Germany). After adhering to a 24-hour low-carbohydrate diet and 6 hours of fasting, 
~2.1 MBq/kg [18F]FDG was administered intravenously, as described previously [25]. Glucose con-
centrations were obtained (5.3±0.5 mmol/L) after injection. Before scanning, participants rested 
in supine position for 2 hours. 
Images were reconstructed according to EARL protocols; using a TrueX algorithm with point 
spread function (PSF) and time-of-flight (TOF) measurements, using 3 iterations, 21 subsets, ma-
trix size 200x200 (pixel spacing of 4.07 mm), Full Width Half Maximum (FWHM) of 3 mm and 
using 2 minutes of PET data. Postprocessing was performed using a 3D Gaussian filter kernel, 3.0 
mm, using the Inveon Research Workspace 4.2 (Preclinical Solutions, Siemens Medical Solutions 
USA, Knoxville, USA). 
Periodontal [18F]FDG-uptake was determined in two volumes of interest (VOI) by two indepen-
dent operators [MPN, AP]: the left and right periodontal tissue. Anatomic landmarks, the fora-
men mentale in the mandible and the sinus maxillaris in the upper jaw, were used to identify 
the periodontal regions of interest (ROI). Next, four ROIs were drawn on the transversal slices 
(2 lower jaw, 2 upper jaw on each side) in the molar/premolar area based on CT imaging. By 
     
auto-interpolation of the layers the selected ROI became volume of interest (VOI) (Appendix Fig-
ure 2). [18F]FDG-uptake in the vascular wall was determined in seven ROI; the aorta ascendens, 
aorta descendens, abdominal aorta, the left and right common carotid arteries, and the left and 
right iliac arteries. ROIs were positioned in uncalcified areas of vascular wall. [18F]FDG-uptake in 
haematopoietic tissue was assessed in the spleen, lumbar vertebrae L2 and L3, and in the left and 
right medullary cavity of the femur. These regions of interest were evaluated using the Inveon 
Research Workspace 4.2. 
Operators that determined the VOIs/ROIs were blinded for all participants’ characteristics (includ-
ing control or patient). The standardized uptake value (SUV) was extracted from each ROI after 
correction for [18F]FDG dose (MBq) and bodyweight using the PyRadiomics toolbox [39]. The SUVs 
of left and right ROIs (e.g. left and right carotid artery) were averaged. Next, the target-to-back-
ground ratio (TBR) was calculated as the ratio of the vascular wall SUV and the mean thoracic 
arterial blood pool SUV. The TBRs of haematopoietic tissue were expressed as ratio of the mean 
liver SUV, as recommended by the European guideline [25].
Supplementary Tables and Figures
Appendix Table 1. Target-to-background values of [18F]FDG PET/CT scan.
Regions of interest Controls Patients
Carotid arteries, TBRmean 1.03 ±0.16 1.10 ±0.16
Carotid arteries, TBRmax 1.28 ±0.19 1.38 ±0.25
Ascending aorta, TBRmean 1.15 ±0.12 1.20 ±0.13
Ascending aorta, TBRmax 1.71 ±0.22 1.71 ±0.23
Descending aorta, TBRmean 1.23 ±0.15 1.24 ±0.15
Descending aorta, TBRmax 1.87 ±0.37 1.92 ±0.27
Abdominal aorta, TBRmean 1.10 ±0.15 1.12 ±0.16
Abdominal aorta, TBRmax 1.52 ±0.23 1.59 ±0.23
Iliac arteries, TBRmean 1.04 ±0.16 1.05 ±0.15
Iliac arteries, TBRmax 1.30 ±0.15 1.40 ±0.16
Vertebrae, TBRmean 1.07 ±0.16 1.07 ±0.26
Vertebrae, TBRmax 1.30 ±0.19 1.33 ±0.33
Medullary cavity of femur, TBRmean 0.31 ±0.14 0.40 ±0.20^
Medullary cavity of femur, TBRmax 0.58 ±0.21 0.68 ±0.26^
Spleen, TBRmean 0.83 ±0.08 0.86 ±0.09
Spleen, TBRmax 0.99 ±0.09 1.01 ±0.13
TBR values of regions of interest in control participants (n=14) and participants with periodontitis 
(n=14). Data are reported as mean ±SD, p-values are age corrected using ANCOVA. ^ indicates 
P<0.10. TBR: target-to-background ratio.
     
Chapter 3 Trained immunity as a link between periodontitis and cardiovascular disease
90 91
Appendix Table 2. Correlation of periodontitis severity with outcomes.
Model +age R2 R2-adj p-value Unst β CI p-value (var)
DPSI
WBC 0.264 0.205 0.022 0.10 0.03-0.17 0.007
IL-1Ra 0.240 0.176 0.037 0.19 0.03-0.35 0.024
IL-6 0.154 0.086 0.123 0.13 -0.07-0.33 0.183
Perio SUVmean 0.225 0.163 0.041 0.06 0.01-0.12 0.022
Iliac TBRmax 0.137 0.068 0.159 0.03 -0.01-0.08 0.113
Carotid TBRmax 0.117 0.046 0.211 0.05 -0.01-0.11 0.094
Femur TBRmean 0.145 0.077 0.141 0.16 -0.01-0.34 0.068
Spleen TBRmean 0.157 0.090 0.118 0.03 0.00-0.07 0.045
PPDmean
WBC 0.044 -0.033 0.570 0.01 -0.02-0.05 0.362
IL-1Ra 0.127 0.055 0.195 0.05 -0.02-0.11 0.170
IL-6 0.234 0.172 0.036 0.08 0.00-0.16 0.041
Perio SUVmean 0.318 0.264 0.008 0.03 0.01-0.05 0.004
Iliac TBRmax 0.051 -0.025 0.519 0.004 -0.01-0.02 0.661
Carotid TBRmax 0.012 -0.067 0.863 0.002 -0.02-0.03 0.848
Femur TBRmean 0.163 0.097 0.107 0.07 0.00-0.14 0.049
Spleen TBRmean 0.180 0.114 0.084 0.02 0.00-0.03 0.031
PPDdeep
WBC 0.061 -0.014 0.454 0.01 -0.01-0.04 0.258
IL-1Ra 0.121 0.048 0.212 0.04 -0.02-0.09 0.190
IL-6 0.243 0.182 0.031 0.07 0.01-0.13 0.034
Perio SUVmean 0.169 0.103 0.099 0.02 0.00-0.04 0.060
Iliac TBRmax 0.083 0.010 0.337 0.007 -0.00-0.02 0.308
Carotid TBRmax 0.011 -0.068 0.866 -0.002 -0.02-0.02 0.864
Femur TBRmean 0.050 -0.026 0.527 0.03 -0.04-0.09 0.388
Spleen TBRmean 0.121 0.051 0.199 0.01 0.00-0.02 0.085
Associations of DPSI score (0-4) and mean and deepest PPD (mm) with circulating markers and 
periodontal, vascular, hematopoietic [18F]FDG-uptake shows strong associations. Linear regres-
sion analyses on log-transformed data accounting for age.
Appendix Figure 1. Gating strategy of circulating cells.
Gating strategy: monocytes were selected based on CD45+ HLA-DR+ and monocyte scatter prop-
erties, then CD3+ T-lymphocytes and CD56+ NK-cells were excluded, and monocyte subsets were 
identified in the CD14/CD16 plot as percentage of gated.
Appendix Figure 2. Volume of interest of periodontal tissue on [18F]FDG PET/CT scan.
Representative figure of periodontal volume of interest based on four regions of interest drawn 
in the transversal slice per side.
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Appendix Figure 3. Cytotoxicity of stimuli.
Cell viability after P. gingivalis and oxLDL costimulation (n=6). oxLDL: oxidized LDL, W83: Pg W83 
strain, ATCC: Pg ATCC strain, RPMI: medium control, + control: positive control for cell death.
Appendix Figure 4. Unsupervised t-Stochastic Neighbour Embedding (tSNE) analysis.
Unsupervised tSNE plots show the contribution of each expression marker in each cell type. A. 
The overview presents the identified circulating cell types, see table for the legend. B. The dis-
tribution of each expression marker per cell type. The colour depicts the MFI expression of each 
marker (blue: low MFI, red: high MFI). C. The difference between control participants and partici-
pants with periodontitis is shown for each cell type. The arrow indicates a visual smaller group of 
platelet-monocyte complexes in the periodontitis’ group compared to the control group.
Appendix Figure 5. Correlation of periodontitis severity with outcomes.
Associations of DPSI score (0-4) and mean and deepest PPD (mm) with circulating markers and 
periodontal, vascular, hematopoietic [18F]FDG-uptake shows strong associations. Linear regres-
sion analyses on log-transformed data accounting for age. Multiple correlation coefficient R2 of 
regression model noted in cells. P-values of each dependent variable are displayed by colour.
Chapter 4
Reprogramming of bone marrow 
myeloid progenitor cells in 
patients with severe coronary 
artery disease
Noz, M.P., Bekkering S., Groh L., Nielen T.M.J., Lamfers E.J.P., Schlitzer A., El Mes-
saoudi S., van Royen N., Huys H.L.P.G., Preijers F.W.M.B., Smeets E.M.M., Aarnt-
zen E.H.J.G., Zhang B., Li Y., Bremmers M.E.J., van der Velden W.J.F.M., Dolstra 
H., Joosten L.A.B., Gomes M.E., Netea M.G., Riksen N.P.
eLife, 2020, Nov 10;9:e60939.
Chapter 4 Reprogramming of BM myeloid progenitors in CAD
96 97
Abstract
Atherosclerosis is the major cause of cardiovascular disease (CVD). Mono-
cyte-derived macrophages are the most abundant immune cells in athero-
sclerotic plaques. In patients with atherosclerotic CVD, leukocytes have a 
hyperinflammatory phenotype. We hypothesize that immune cell repro-
gramming in these patients occurs at the level of myeloid progenitors. We 
included 13 patients with coronary artery disease due to severe athero-
sclerosis and 13 subjects without atherosclerosis in an exploratory study. 
Cytokine production capacity after ex vivo stimulation of peripheral blood 
mononuclear cells (MNCs) and bone marrow MNCs was higher in patients 
with atherosclerosis. In BM-MNCs this was associated with increased gly-
colysis and oxidative phosphorylation. The BM composition was skewed 
towards myelopoiesis and transcriptome analysis of HSC/GMP cell popula-
tions revealed enrichment of neutrophil- and monocyte-related pathways. 
These results show that in patients with atherosclerosis, activation of in-
nate immune cells occurs at the level of myeloid progenitors, which adds 
exciting opportunities for novel treatment strategies.
Introduction
Atherosclerotic cardiovascular disease (CVD), including myocardial infarction 
and stroke, is the leading cause of death worldwide. Major risk factors for CVD 
include dyslipoproteinemia, smoking, hypertension, obesity, and diabetes. 
However, despite optimal pharmacological treatment of these risk factors, a 
considerable residual CVD risk remains. Evidence is rapidly accumulating that 
chronic low-grade inflammation of the vascular wall is a key pathophysiologi-
cal component of atherosclerosis, and that treatment with anti-inflammatory 
drugs, such as canakinumab and colchicine, additionally lowers future CVD risk 
[1-3]. A more detailed knowledge of this inflammatory process and the role of 
individual immune cells would allow to develop more specific and safe anti-in-
flammatory therapies.
Within atherosclerotic plaques, monocyte-derived macrophages are the most 
abundant immune cells, which play a key role in initiation, progression, and de-
stabilization of these plaques, although the mechanisms driving the persistent 
inflammatory activation are poorly understood [4]. In patients with CVD or risk 
factors for CVD, circulating leukocytes show differences in composition and in 
individual cell phenotypes, compared to healthy individuals. Isolated monocytes 
from patients with CVD are characterized by an increased cytokine production 
capacity and higher glycolytic metabolism [5-7]. This also holds true for patients 
with increased CVD risk due to familial hypercholesterolemia [8]. In addition, 
higher circulating levels of granulocytes are associated with an increased CVD 
risk in a general population study [9]. 
Experimental studies in animal models of atherosclerosis have revealed re-
programming of hematopoietic stem and progenitor cells (HSPCs) in the bone 
marrow as a cause of these changes in circulating innate immune cells under 
conditions that predispose to CVD, including hyperlipidemia [10], and stress 
[11]. Western type diet feeding of low-density lipoprotein receptor deficient 
(Ldlr-/-) mice induces inflammatory activation of monocytes by epigenetic re-
programming of HSPCs which persists in normocholesterolemic conditions [10]. 
This resembles the finding of persistent functional and transcriptional hyperre-
sponsive monocytes in patients with dyslipidemia despite cholesterol-lowering 
treatment [8]. In a retrospective analysis of bone marrow samples from cancer 
patients, HSPCs had a higher proliferative potential in patients with known ath-
erosclerotic CVD than in control patients [12]. A detailed assessment, however, 
of HSPC composition and function in patients with atherosclerosis is lacking. 
Here, we performed a comprehensive study in patients with and without cor-
onary artery disease (CAD). We obtained circulating leukocytes and HSPCs and 
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assessed composition with flow cytometry, as well as cytokine production ca-
pacity, metabolism, and the transcriptional profile. In addition, we performed 
2’-deoxy-2’-[18F]fluoro-D-glucose positron-emission-tomography ([18F]FDG PET/
CT) scanning to detect bone marrow and splenic activity. We report that bone 
marrow mononuclear cells in patients with atherosclerosis are characterized 
by enhanced cytokine production capacity and an increased metabolic rate. 
Flow cytometry and RNAseq analysis revealed inflammatory transcriptional re-
programming and myeloid skewing. These results show that in patients with 
atherosclerosis, activation of the innate immune system occurs at the level of 
bone marrow myeloid progenitors, which adds exciting opportunities for novel 
treatment strategies.
Table 1. Group characteristics. 




Age (years) 59.8±9.7 52.2±10.4
Sex (% men, n) 100 (13) 100 (13)
BMI (kg/m2) 27.8±2.8 25.8±2.5
SBP (mmHg) 133±15 126±10
DBP (mmHg) 90±8* 84±6
Hypertension (%, n) 93 (12)** 31 (4)
Current smoking (%, n) 23 (3) 31 (4)
Calcium score (HU) 445 [213-781]** 0 [0]
Total Plaque score (0-16)‡ 14 [9-15]*** 0 [0]
Lipid-lowering therapy (%, n) 77 (10)*** 8 (1)
Acetylsalicylic acid use (%, n) 69 (9)*** 0 (0)
ACE-inhibitor use (%, n) 23 (3) 8 (1)
β-blocker use (%, n) 23 (3) 8 (1)
Glucose (mmol/L) 5.9±0.8 †5.7±0.7
Creatinine (µmol/L) 89±14 91±16
Tchol (mmol/L) 4.51±0.86** 5.61±0.61
LDLc (mmol/L) †2.52±0.97** 3.56±0.64
HDLc (mmol/L) 1.25±0.31 1.51±0.34
TG (mmol/L) 1.98±1.97 1.20±0.38
nHDLc (mmol/L) 3.26±1.06* 4.11±0.75
Data are reported as mean ±SD, as mean (number of participants), or as median [interquartile 
range] and compared with the appropriate statistical tests. ‡ TPS was calculated for participants 




Thirteen individuals with CAD due to severe atherosclerosis with a median Total 
Plaque Score (TPS) of 14[9-15], and thirteen individuals without coronary ath-
erosclerosis (TPS=0) participated in the study (Table 1). 
As expected, individuals with atherosclerosis more often received lipid lowering 
therapy with statins, which was associated with a lower total and LDL-choles-
terol concentration. All outcomes were corrected for the age and BMI because 
these are known modulators of innate immune cell function [13].
Table 2. Circulating immune cells and inflammatory markers in patients and controls.
Cell types Individuals with CAD Individuals without atheroscle-
rosis 
WBC (106/mL) †5.5 [4.9-6.0] 5.4 [4.8-6.7]
Neutrophils (106/mL) †3.2 [2.5-3.6] 3.0 [2.6-4.0]
Lymphocytes (106/mL) 1.7 [1.3-1.9] 1.8 [1.5-2.5]
Monocytes (106/mL) 0.53 [0.42-0.67] 0.55 [0.45-0.66]
Monocytes (%) 9.8 [8.0-11.5] 9.3 [7.7-11.1]
Classical monocytes (%gated) 78.1 [72.8-80.3] 72.8 [70.1-85.5]
Intermediate monocytes (%gated) 9.8 [8.2-14.2] 10.1 [7.6-13.7]
Nonclassical monocytes (%gated) 12.2 [9.3-14.3] 13.1 [6.3-18.2]
CCR2+ monocytes (%gated) 80.5 [73.0-82.3] †77.6 [71.4-86.3]
CD11b expression monocytes (MFI) 10490 [7814-12025]^ ††6978 [6512-10041]
CD41+ monocytes (%gated) 7.8 [6.5-9.7] 8.7 [7.6-8.9]
Inflammatory markers
IL-1β (pg/mL) †0.12 [0.09-0.17] 0.12 [0.06-0.15]
IL-1Ra (pg/mL) 271 [197-338] 212 [165-253]
IL-6 (pg/mL) 2.31 [1.37-2.86] †1.61 [1.23-2.19]
IL-18 (pg/mL) 162 [127-227] 195 [144-236]
hsCRP (pg/mL) 1.66 [0.83-4.87] 1.37 [0.53-3.84]
E-selectin (ng/mL) †11.74 [7.65-15.10]* 8.45 [4.52-14.06]
VCAM-1 (ng/mL) 773 [711-859]^ 769 [643-844]
MMP2 (ng/mL) 354 [264-434] 341 [250-427]
Circulating concentrations of cells and inflammatory markers in individuals with CAD (n=13) com-
pared to individuals without atherosclerosis (n=13). Median with [IQR]. P-values are corrected 
for age and BMI with ANCOVA. Outliers were removed with an SD of >2.5 of Z-scores. † Data is 
missing for 1 participant. *: P< 0.05, **: P<0.01. HSPCs: hematopoietic stem and progenitor cells.
Chapter 4 Reprogramming of BM myeloid progenitors in CAD
100 101
Circulating inflammatory markers
The distribution of immune cells and monocyte subpopulations was similar 
between groups (Table 2). Integrin CD11b expression on monocytes tended to 
be higher in individuals with CAD (P=0.09). Circulating endothelial dysfunction 
marker E-selectin was higher in individuals with atherosclerosis (P<0.05).
Cytokine production capacity of circulating PBMCs is higher in atherosclerosis
Previously, we showed in a comparable study cohort that the LPS-induced pro-
duction of IL-6, TNFα, IL-1β, and IL-8 in PBMCs was higher in patients with CAD 
compared to controls [5]. We could confirm this in the current study for IL-8 
(P<0.01), with a similar pattern for IL-6 (P=0.08) and TNFα (P=0.13) (Figure 1A). 
There were no significant differences in response to TLR2 agonist Pam3Cys stim-
ulation (Figure 1B).
Figure 1. Cytokine production capacity of circulating PBMCs. (A) Cytokine production capacity of 
circulating PBMCs after LPS stimulation in control participants (white bars, n=13) and participants 
with CAD (grey bars, n=13). Geometric mean with 95% CI. (B) Table of cytokine/chemokine pro-
duction (x-axis) after stimulation with LPS or P3C (y-axis) of PBMCs showing statistical differences 
between groups. The p-values are corrected for age and BMI with ANCOVA. Outliers were re-
moved with an SD of >2.5 of Z-scores. * indicates P<0.05, **: P<0.01.
Figure 2. Progenitor cell populations in the bone marrow compartment (A-G) and in the circula-
tion (H and I). Control participants (white bars, n=13) and participants with CAD (grey bars, n=13). 
HSC and MPP cell populations were combined as the CD90 expression marker was not available 
for n=6 in each study group. Geometric mean with 95% CI. The p-values are corrected for age and 
BMI with ANCOVA. * indicates P<0.05, **: P<0.01. In top-down order: HSC indicates hematopoi-
etic stem cell, MPP: multipotent progenitor, CLP: common lymphoid progenitor, CMP: common 
myeloid progenitor, GMP: granulocyte macrophage progenitor, MEP: megakaryocyte erythrocyte 
progenitor. This article includes the following figure supplement(s) for figure 2: Figure supple-
ment 1. Gating strategy of circulating immune cells. Figure supplement 2. Gating strategy of he-
matopoietic stem and progenitor cells in the bone marrow.
HSPC composition is changed patients with CAD
We assessed the HSPC composition using flow cytometry. Although the total 
percentage of HSPCs was similar between groups, the percentage of multi-
potent progenitors (HSC/MPP, P<0.05) was higher in CAD participants (Figure 
2A,B). Trends for a higher percentage of common myeloid progenitors (CMP, 
P=0.06) and common lymphoid progenitors (CLP, P=0.08) were observed in in-
dividuals with CAD (Figure 2C,D). In addition, the percentage of pre-monocytes 
was higher (P<0.05), which was associated with a lower megakaryocyte eryth-
rocyte progenitor percentages (MEP, P<0.05) (Figure 2F,G). Within bone mar-
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row, no difference in the percentage of monocytes (3.3 [3.1-4.4]% in patients 
versus 3.4 [3.0-4.6] in controls), and monocyte subpopulations, i.e. classical 
(87 [82-88]% versus 82 [79-89]), intermediate (7.5 [7.1-10.8]% versus 9.3 [6.1-
11.5]) and non-classical monocytes (5.1 [4.2-8.1] % versus 8.1 [3.6-11.4]), was 
observed. Interestingly, the percentage of circulating multipotent progenitors 
(HSC/MPP) was higher in participants with CAD (P<0.05) (Figure 2I). Similar pat-
terns were found using absolute cell counts of progenitor populations.
Functional and metabolic reprogramming of bone marrow MNCs in athero-
sclerosis
The immune response of BM-MNCs was determined after ex vivo 24-hour stim-
ulation with TLR agonists. TNFα production after LPS stimulation was higher in 
individuals with atherosclerosis (P<0.05), with similar patterns for IL-6 (P=0.12), 
Figure 3. Cytokine production capacity of BM-MNCs. (A) Cytokine production capacity of BM-
MNCs after LPS stimulation incontrol participants (white bars, n=13) and CAD patients (grey bars, 
n=13). Geometric mean with 95% CI. (B) Table of cytokine/chemokine production (x-axis) after 
stimulation with LPS or P3C (y-axis) of BM-MNCs showing statistical differences between groups. 
The p-values are corrected for age and BMI with ANCOVA. Outliers were removed with an SD of 
>2.5 of Z-scores. * indicates P<0.05, **: P<0.01.
Figure 4. Metabolism of BM-MNCs assessed with Seahorse respirometry in unstimulated condi-
tion and 2 hours after IFNγ+LPS stimulation. (A, B) Oxygen consumption and extracellular acidifi-
cation rates over time using treatment with Oligomycin, FCCP and Rotenone/Antimycin A. (C, D) 
Bar graphs of control participants (white bars, n=13) and participants with CAD (grey bars, n=13).. 
Geometric mean with 95% CI. The p-values are corrected for age and BMI with ANCOVA. * indi-
cates P<0.05, **: P<0.01. IFNγ+LPS: 2 hours IFNγ and LPS stimulation.
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IL-8 (P=0.10), and IL-1Ra (P=0.11) although these differences did not reach 
statistical significance (Figure 3A). There were no significant differences in re-
sponse to Pam3Cys stimulation (Figure 3B).
Seahorse respirometry revealed that both the basal and maximal OCR was 
higher (P<0.01 and P<0.05) in BM-MNCs from CAD patients compared to con-
trol subjects (Figure 4A,C), as well as the basal and maximal ECAR (P<0.01 and 
P<0.05) (Figure 4B,D). The measurements were repeated 2 hours after IFNγ/LPS 
pre-incubation, in order to assess metabolic function during activation. Again, 
the maximal OCR (P<0.01) and maximal ECAR (P<0.05) was higher in individuals 
with CAD.
Proliferation of BM-MNCs
Proliferation assays of BM-MNCs did not reveal significant differences in eryth-
roid-, myeloid-, or granulocyte-macrophage progenitor proliferation rates be-
tween patiens with CAD and healthy controls (Figure 5).
Figure 5. Proliferation capacity of bone marrow MNCs. Counted colonies per 103 cultured BM-
MNCs of control participants (white bars, n=13) and participants with CAD (grey bars, n=13). 
Geometric mean with 95% CI. The p-values are corrected for age and BMI with ANCOVA. BFU-E 






























































































































































































































































































Bone marrow progenitors of CAD patients are primed to differentiate into an 
inflammatory myeloid lineage
To further understand the functional changes in HSPCs, we explored the tran-
scriptional signature of HSC, MPP and GMP cell populations. Differential ex-
pression analysis was applied to each population separately and a combined 
population to identify differentially expressed (DE) genes between patients and 
control samples. This identified 1747 genes that were differentially regulated in 
at least one of the cell populations (P ≤ 0.05). A PCA analysis based on DE genes 
of HSC populations revealed a clear separation between patients and controls 
(Figure 6A). This was less pronounced for the MPPs and GMPs (Figure 6 – figure 
supplement 1). Among those DE genes, we observed that four genes were sig-
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nificantly upregulated in the patients compared to the controls in a combined 
analysis of HSCs, MPPs, and GMPs (Figure 6B, Padj <0.1), including CCR2, EPB42, 
FNDC3B, and RBMS1. For individual log Fold Change (FC) and adjusted P-values, 
please see Supplemental dataset 1 and the combined and separated heatmaps 
for the top 50 DE genes for each population (Figure 6 – figure supplement 2 
and 3). Seven genes were differentially downregulated in the patients, includ-
ing PFKP, CCDC163P, ARMCX4, PTK7, WDR90, ROBO3, and FAM84B. Within the 
HSC population, only PROK2 showed a significant upregulation (Figure 6 – figure 
supplement 3), whereas in the MPPs and GMPs no genes showed significantly 
differential upregulation (Figure 6 – figure supplement 3). 
Subsequently, we performed pathway enrichment analyses on disease-specific 
DE genes. The differentially upregulated genes of HSCs (P<0.05) showed sig-
nificant enrichment for neutrophil and monocyte biological processes. These 
include neutrophil activation pathways, cytokine production pathways, and 
macrophage activation pathways (FDR<0.05) (Figure 6C). Transcriptional signa-
tures of the genes enriched in the neutrophil-related pathways indicated up-
regulation of genes involved in the development and activation of neutrophils, 
such as insulin like growth factor 2 receptor (IGF2R), S100A11, and TNFRSF1B 
(Supplementary dataset 2). Additionally, there was an upregulation of signalling 
genes in the myeloid lineage, such as CCR2, innate immune signal transduction 
adaptor (MYD88), IL1RN, IL18R1, and Toll-like receptors TLR2 and TLR4. The 
differentially upregulated genes in the GMPs showed a similar enrichment for 
neutrophil-related pathways, and pathways related to myeloid cell differentia-
tion and migration (Figure 6C). Upregulated genes in myeloid cell differentiation 
and regulation of hematopoiesis pathways revealed upregulation of important 
signalling and transcription factors, such as colony stimulating factor 3 receptor 
(CSF3R), NFKB inhibitor alpha (NFKBIA), signal transducer and activator of tran-
scription 1 (STAT1), STAT3, and transforming growth factor beta 1 (TGFB1). Re-
peating these analyses using P<0.01 showed that the observed enriched terms 
were robust (FDR<0.05). RNA-seq data have been deposited in the ArrayExpress 
database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number 
E-MTAB-9399.
Vascular wall inflammation and hematopoietic tissue activation measured 
with  [18F]FDG PET/CT is not higher in patients with CAD
Vascular wall inflammation and hematopoietic tissue activity, as determined by 
[18F]FDG PET/CT-scan, was similar between individuals with CAD and subjects 
without atherosclerosis (Figure 7). Correction for age, BMI, and glucose concen-
trations did not influence the results.
Interestingly, although the splenic activity was not significantly higher in CAD 
Figure 7. Vascular wall inflammation and hematopoietic tissue activation on [18F]FDG PET/CT scan. 
Standard uptake value of each region in control participants (white bars, n=13) and participants 
with CAD (grey bars, n=13). Geometric mean with 95% CI. The p-values are corrected for age and 
BMI with ANCOVA.* indicates P<0.05, **: P<0.01. TBR: target SUV / mean blood pool SUV or 
mean liver SUV as background.
patients, the splenic [18F]FDG-uptake correlated with HSPCs and with circulat-
ing immune cells (Figure 7 – figure supplement 1). Splenic [18F]FDG-uptake cor-
related positively with CCR2 expression on HSPCs (rs=0.604, P<0.01), with GMPs 
(rs=0.405, P<0.05), and with circulating leukocyte (rs=0.393, P<0.05) and mono-
cyte counts (rs=0.588, P<0.01). 
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Discussion
The role of activated innate immune cells in the development of atherosclerotic 
plaques is well-established. In the current paper we add an important dimen-
sion to this pathophysiological framework by showing for the first time that 
inflammatory reprogramming of innate immune cells in humans with coronary 
artery disease occurs at the level of HSPCs in the bone marrow. In patients with 
chronic CAD due to severe coronary atherosclerosis, isolated bone marrow 
mononuclear cells showed a higher cytokine production capacity and increased 
metabolic rate compared to individuals without coronary atherosclerosis. Tran-
scriptional signatures of HSPCs were enriched for neutrophil and monocyte re-
lated pathways, indicating that the HSPCs are primed to differentiate into an 
inflammatory myeloid lineage. These findings add an additional layer of inflam-
matory regulation in atherogenesis which potentially offers novel targets for 
pharmacological strategies to prevent or treat atherosclerotic CVD. 
Our findings align with previous studies in animal models in atherosclerosis that 
show increased myelopoiesis in specific conditions that promote CVD. Accu-
mulation of cholesterol in HSPC increases proliferation and mobilization from 
the bone marrow and a differentiation bias towards the myeloid lineage, which 
is associated with accelerated atherosclerosis [14]. In an animal model of dia-
betes, higher circulating numbers of inflammatory Ly6-Chi monocytes and neu-
trophils are present, which is due to increased myelopoiesis. In this model, the 
increased myelopoiesis is driven by the increased expression of S100A8 and 
S100A9 in neutrophils [15]. Interestingly, expression of one of the S100 proteins 
(S100A11) was also increased in the HSCs in patients with CAD in our study. 
Chronic psychological stress and disturbed sleep have also been reported to 
increase myelopoiesis, which is associated with elevated circulating levels of 
neutrophils and Ly6Chigh monocytes and augmented atherosclerosis compared 
with control mice [11, 16].
Since we did not include patients with specific cardiovascular risk factors, but 
rather with established symptomatic coronary atherosclerosis, we cannot con-
clude which factors are responsible for the HSPC reprogramming in our pa-
tients. BMI and blood pressure were slightly higher in the patients compared 
to the controls. Cholesterol concentrations were lower at the moment of inclu-
sion in our study, but might well have been higher previously, since the patients 
also used more statins. We do not have information about stress and sleep pat-
terns. Another mechanism that might contribute to the HSPC functional repro-
gramming is trained immunity. Trained immunity describes the phenomenon 
that brief stimulation of innate immune cells leads to the development of a 
long-term hyperresponsive phenotype. This is mediated by profound intracel-
lular metabolic and epigenetic reprogramming and occurs both at the level 
of mature circulating monocytes as well as at the level of their bone marrow 
progenitors [17]. Christ et al have recently described that a four week period 
of Western type diet feeding in atherosclerosis prone Ldlr-/- mice induced a 
functional, transcriptional and epigenetic reprogramming of circulating myeloid 
cells and their bone marrow progenitors, which persisted for at least for weeks 
after switching back to a chow diet [10]. This was associated with increased 
circulating concentrations of inflammatory monocytes and granulocytes. Func-
tional enrichment analysis of GMPs showed overrepresentation of TNF and Toll-
like receptor signaling pathways, which align with our observations. In contrast, 
although monocytic signature genes were enriched, most of the granulocytic 
signature genes were downregulated, including S100A8 and S100A9, in GMPs 
isolated from WD-fed as compared to CD-fed mice [10]. Patients with hyper-
cholesterolemia also have circulating monocytes with augmented cytokine pro-
duction capacity, increased glycolytic metabolism, and enrichment of activating 
histone modifications, which persist for three months despite cholesterol low-
ering with statin therapy. Circulating monocyte and neutrophil numbers how-
ever, were not increased in these patients [8]. In our current patient cohort, it 
remains to be established whether trained immunity is present since we did not 
assess epigenetic markers in the HSPCs. 
The observation that absolute numbers of myeloid progenitors and circulating 
monocytes and neutrophils are not increased, despite functional and transcrip-
tional inflammatory programming, fits with the effects of alternative inducers 
of trained immunity in humans. Vaccination with the Bacille Calmette-Guérin 
(BCG) vaccine induces trained immunity in humans in vivo [18]. This is accompa-
nied by an increased cytokine production capacity of bone marrow mononucle-
ar cells, comparable to the result in patients with CAD in the current study [19]. 
Also, 90 days post-BCG administration, HSPCs showed myeloid skewing with ac-
tivation of neutrophil-associated pathways and pathways associated with reg-
ulation of immune responses, comparable to our patients. This functional and 
transcriptional reprogramming was accompanied by an increase in numbers of 
circulating myeloid cells in a large cohorts of infants vaccinated with BCG [19]. 
In the patient group with CAD, the increased cytokine production capacity of 
the bone marrow mononuclear cell fraction was accompanied by an upregula-
tion of both glycolytic metabolism as well as oxygen consumption by oxidative 
phosphorylation. It is important to realize that the bone marrow mononuclear 
fraction also contains large amounts of mature monocytes, so we cannot con-
clude on the metabolic landscape of HSPCs and specific progenitor subtypes. 
Isolated monocytes and monocyte-derived macrophages from patients with 
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atherosclerosis are characterized by increased glycolysis, which is coupled to 
the hyperresponsiveness in terms of cytokine release [5, 6]. Also, HSPCs of mice 
after induction of trained immunity with β-glucan have an upregulation of the 
glycolytic pathway [20].
Analysis of the differentially upregulated genes transcriptome of the flow-sorted 
HSCs and GMPs showed significant enrichment for neutrophil activation path-
ways. This further supports a role for neutrophils in the pathophysiology of ath-
erosclerotic CVD, which is suggested by various recent findings in the literature. 
Although neutrophils are the most abundant circulating white blood cell type, 
neutrophils only recently received attention in the context of cardiovascular in-
flammation. A large epidemiological study shows that circulating granulocyte 
counts are strongly associated with the occurrence of CVD [9]. During athero-
genesis, platelet- derived chemokines, such as CC-chemokine ligand 5, promote 
neutrophil activation and recruitment [21]. At the luminal side, these activat-
ed neutrophils secrete granule proteins, including cathepsin G, which further 
promotes myeloid cell recruitment. Several actions further fuel atherosclerotic 
plaque formation, including secretion of reactive oxygen species and myeloper-
oxidase, which mediates oxidation of LDL, promoting foam cell formation [21]. 
Also, neutrophils can form neutrophil extracellular traps (NETs) [22] and they 
can secrete pro-inflammatory microvesicles which further fuel vascular wall in-
flammation and atherosclerosis [23]. Interestingly, a recent study used plasma 
proteomics analysis to explore the mechanism by which colchicine lowers car-
diovascular risk in patients with CAD and showed mainly a downregulation of 
neutrophil activation pathways [24].  
Analysis of the individual significantly differentially expressed genes in the 
HSPCs showed that the glycolytic enzyme phosphofructokinase (PFKP) was 
downregulated in individuals with CAD. Quiescent HSCs depend mainly on 
anaerobic glycolysis to sustain survival, quiescence, and retention within the 
bone marrow [25]. Once stimulated to divide, HSCs start to activate OXPHOS 
to meet metabolic demands of proliferation and differentiation [26]. Therefore, 
the downregulation of PFKP might be related to activation of HSCs. This finding 
is in contrast to the higher extracellular acidification rate of the bone marrow 
mononuclear cells which points to activation of glycolysis. We speculate that 
this finding is dominated by the inflammatory activation of bone marrow mono-
cytes, which constitute a large percentage of the bone marrow mononuclear 
cells. The chemokine receptor CCR2 showed significant upregulation in the 
HSPCs of the patients with CAD. CCR2 is critical for monocyte egress from the 
bone marrow and for recruitment of circulating monocytes to the arterial wall 
[27]. The upregulation of CCR2 in our study might contribute to the increased 
circulating HSC percentage in the CAD patients. In mice, increased levels of 
circulating HSPCs are found after myocardial infarction, which migrate to the 
spleen for extramedullary hematopoiesis [28]. In humans, splenic extramed-
ullary hematopoiesis can occur in response to extreme physiologic stress (e.g. 
sepsis or hematologic malignancies), but has not been described yet during the 
development of CVD. Indirect evidence shows that splenic activity in humans is 
increased after myocardial infarction assessed with PET/CT scanning [12], sug-
gesting increased immune cell activation. In our study, we observed a  correla-
tion between splenic activity and CCR2 expression on circulating HSPCs which 
might suggest that the spleen performs a role in human atherosclerosis.
Our study has several limitations. First, the sample size is relatively small. How-
ever, this sample size needs to be considered in the context of the invasive and 
complex nature of the study, and this sample size usually allows to detect rel-
evant differences [19, 29]. The sample size might also be an explanation for 
the lack of a significant difference in FDG uptake in the large arteries, which 
has been shown previously in patients with CVD. [30, 31]. Another possible ex-
planation for our results is that our patients had severe mature coronary ath-
erosclerotic plaques with calcium deposits, which are known to have less FDG 
uptake than uncalcified arterial plaques at early stage of atherosclerosis [32]. 
In addition, lipid-lowering therapy is effective in reducing vascular wall inflam-
mation [33]. A second limitation is that we did not explore epigenetic programs 
of the HSPCs. As such, we cannot conclude whether the mechanism of trained 
immunity contributes to our findings. This should be the focus of future studies. 
Thirdly, in a study on symptomatic patients with CVD, it is inevitable to have 
differences in medication use compared to the healthy control group. 
To summarize, our study is the first to prospectively assess HSPC phenotype in 
patients with CAD and is unique in providing a comprehensive phenotype by the 
integration of powerful tools such as RNAseq on flow sorted HSPC populations, 
functional parameters, Seahorse respiratory, and PET imaging of vascular wall 
and hematopoietic activity. These results show that in patients with CAD, acti-
vation of the innate immune system occurs at the level of bone marrow myeloid 
progenitors, which adds exciting opportunities for novel treatment strategies.




Participants (men, 18-75 years) were recruited among patients who were ad-
mitted for the evaluation of chest pain and underwent cardiac imaging at the 
Cardiology department of the Canisius Wilhelmina hospital or the Radboud Uni-
versity Medical Centre, Nijmegen, The Netherlands after 01-01-2015. Severe 
coronary atherosclerosis was defined as a calcium score >400 HU on computed 
tomography (CT), or a total plaque score (TPS) >4 on coronary CT angiography 
(CCTA), according to previously described standards [5, 34]. Control partici-
pants, with a calcium score and TPS of zero, were matched for age, body mass 
index (BMI) and smoking. 
Criteria for exclusion were previous cardiovascular events, malignancies, au-
to-immune or auto-inflammatory diseases (including diabetes mellitus), chronic 
immunomodulatory drug use, chronic kidney disease (MDRD<45 ml/min), liv-
er disease (ALAT>135 U/l), or thrombocytopaenia (<50x106/mL). Additionally, 
participants were excluded if they had an infection (>38,5°C or antibiotic treat-
ment), hospital admission, or vaccination within 3 months prior study entry. The 
study protocol was approved by the Institutional Review Board Arnhem/Nijme-
gen, the Netherlands and registered at the ClinicalTrials.gov (NCT03172507). All 
individuals gave written informed consent.
Evaluation of atherosclerotic burden
CCTA total plaque score was calculated as previously described [34]. Briefly, a 
64-slice MDCT scanner (Philips) was used to obtain CAC and MDCT Image ac-
quisition using an ECG-synchronized axial scan protocol and post-processing CT 
and CAC studies using IntelliSpace Philips software. Prior to image acquisition, 
beta-blockers were administered targeting a heart rate of <60 beats per minute, 
and patients received nitroglycerin 0.8 mg sublingually. Prospective electrocar-
diographically gated step-and-shoot contrast-enhanced MDCT imaging was 
performed, initiated from 10 mm above the level of the left main artery to 10 
mm below the inferior myocardial apex with scan parameters being 64 x 0.625 
mm sections (2.5 mm), collimation tube currents of 350 to 780 mAs and tube 
voltage of 100 or 120 kV. In the rare event that prospective scanning was not 
possible, retrospective or helix scanning was used. 
Reconstruction of the MDCT scans was performed with reconstructed images 
obtained, using an ECG-triggered protocol, at 75% from the previous RR-inter-
val, or at 75% and 40% from the previous RR-interval if a helix scan-protocol was 
used. The TPS was determined by summing the number of evaluable coronary 
segments with calcific or non-calcific plaque, or mixed plaque, where non cal-
cified and mixed plaque was assigned with 1 point and calcified plaque with 0 
(maximum score = 16). Two independent experienced operators scored all CT 
images and both operators were blinded for all clinical information. In case of 
disagreement the opinion of a third independent observer was asked.
Study design
Participants underwent [18F]FDG PET/CT scanning, follow by venepuncture and 
bone marrow aspiration within 2-14 days. The participants were invited in pairs 
(1 patient:1 control) for blood sampling and bone marrow aspiration from De-
cember 2017 till July 2018.
Cardiovascular risk assessment
Medical history, smoking status, medication use, BMI and fasting glucose con-
centrations were obtained from all individuals. Blood pressure was measured 
three times by a manual sphygmomanometer after 5 minutes seated rest ac-
cording to AHA guidelines. Fasting total cholesterol (Tchol), high-density lipopro-
tein cholesterol (HDLc), and triglycerides (TG) were measured using standard-
ized methods, and low-density lipoprotein cholesterol (LDLc) was calculated 
with the Friedewald formula.
Blood sampling and bone marrow aspiration
Bone marrow was aspirated from the posterior iliac crest according to standard 
practice by an experienced physician assistant. Blood was sampled through ve-
nous puncture. Sample collection was performed at 8.00-10.00 to avoid inter-
ference of circadian rhythms of immune parameters, and sample processing 
occurred within 2 hours. Plasma and serum were stored at -80°C until further 
use. Total blood cell counts were determined with an automated Sysmex-XN 
450 haematology analyser (Sysmex, Hamburg, Germany).
 
Mononuclear cell enrichment and stimulation
Before mononuclear cell (MNC) enrichment, the bone marrow aspirate was 
filtered and washed with sterile PBS. Thereafter, the same procedures were 
followed for peripheral blood MNCs (PBMCs) and bone marrow MNCs (BM-
MNCs). PBMCs/BM-MNCs were isolated by Ficoll-Paque density gradient cen-
trifugation (GE Healthcare, Chicago, USA). Cell composition was evaluated by 
Sysmex analyser (Sysmex) and with flow cytometry (Table 3, see key resource 
table (KRT) for RRIDs). PBMCs/BM-MNCs were resuspended in Roswell Park 
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Memorial Institute 1640 Dutch-modified culture medium (RPMI) (Life Technol-
ogies/Invitrogen, Waltham, USA) supplemented with 2 mmol/L glutamine (In-
vitrogen), 10 mg/mL gentamicin (Centrafarm, Etten-Leur, The Netherlands) and 
1 mmol/L pyruvate (Invitrogen). Per well, 5x105 PBMCs/BM-MNCs were stim-
ulated for 24 hours in duplicate in round-bottom 96-well plates (Corning, New 
York, USA) with the following stimuli: RPMI, 10 ng/mL Escherichia coli lipopoly-
saccharide (LPS) (serotype 055:B5 Sigma-Aldrich, St. Louis, USA), and 10 μg/mL 
Pam3CysK4 (P3C) (EMC Microcollections, Tübingen, Germany). After 24-hour 
incubation, supernatants were stored after plate centrifugation at −80°C until 
cytokine assessment.
Table 3. Cell composition of PBMC and BM-MNC fraction.
Cell types in PBMC fraction Controls Patients
Lymphocytes (%) 73 [68-79] 65 [62-75]*
Monocytes (%) 25 [19-31] 32 [23-35]
Neutrophils (%) 0.7 [0.6-1.1] 1.2 [0.6-1.7]
Cell types in BM-MNC fraction
HSPCs (%) 1.6 [1.2-2.0] 1.4 [1.2-4.7]
Cellular composition after mononuclear cell enrichment of peripheral blood and bone marrow. 
Median with [IQR]. Mann-Whitney U test. *: P< 0.05, **: P<0.01. HSPCs: hematopoietic stem and 
progenitor cells.
Cytokine measurements
Cytokine and chemokine concentrations were determined in supernatants us-
ing Human Cytokine Magnetic Magpix 25-plex panel (Invitrogen) on the MAG-
PIX platform (Luminex). Circulating IL-1β, IL-1Ra, IL-6 and IL-18 concentrations 
were measured with the SimplePlex cartridge on the Ella platform (ProteinSim-
ple, San Jose, USA). Additional circulating cytokines/chemokines concentrations 
were measured using ELISA (see KRT).
Flow cytometry
In the circulation, monocyte subpopulations and expression markers were de-
termined with flow cytometry. 50 µL EDTA blood was stained after the lysis-
no-wash strategy (BD Pharm Lyse lysing buffer, Becton Dickinson) by mono-
clonal antibodies CD45 Krome Orange ([KO], clone J33; Beckman Coulter, Cat# 
B36294, RRID:AB_2833027), HLA-DR PE (clone immu-357; Beckman Coulter, 
Cat# IM1639U, RRID:AB_2876782), CD14 PC7 (clone 61D3 eBioscience, Cat# 
25-0149-42, RRID:AB_1582276), CD16 FITC (clone CB16; eBioscience, Cat# 11-
0168-42, RRID:AB_10805747), CD3 APC-Alexa750 (clone UCTH1; Beckman 
Coulter, Cat# AA66329, RRID:AB_2876783), CD56 APC (clone N901; Beckman 
Coulter, Cat# IM2474U, RRID:AB_2876784), CD192 Brilliant Violet421 ([BV421] 
clone 48607; Becton Dickinson, Cat#564067, RRID:AB_2738573), CD11b BV785 
(clone ICRF44; Biolegend, Cat#301346, RRID:AB_2563794), CD41 PC5.5 (clone 
Hip8; Biolegend, Cat# 303719, RRID:AB_2561731) and measured with CytoFLEX 
flow cytometer (Beckman Coulter, RRID:SCR_017217). The gating strategy ap-
plied is shown in Figure 2 – figure supplement 1, gates were set with the fluo-
rescence-minus-one method [35, 36]. In short, monocytes were selected based 
on CD45+ HLA-DR+ and monocyte scatter properties, then CD3+ T-lymphocytes 
and CD56+ NK-cells were excluded, and monocyte subsets were identified in 
the CD14/CD16 plot as percentage of gated. Data was analysed with Kaluza 3.1 
software (Beckman Coulter, RRID:SCR_016182). Characterization of monocytes 
subsets is according to current recommendations [35, 36].
Bone marrow progenitors were identified with Navios flow cytometer (Beck-
man Coulter, RRID:SCR_014421). 5x106 bone marrow cells were washed, lysed, 
and stained for 20 minutes with the monoclonal antibodies:  CD90 FITC (Clone 
5E10; Biolegend, Cat#328107, RRID:AB_893438), CD123 PE (Clone 9F5; BD 
Biosciences, Cat#555644, RRID:AB_396001), CD19 ECD (Clone J3.119 ; Beck-
man Coulter, Cat# IM2708U, RRID:AB_130854), CD38 PC5.5 (Clone LS198-4-
3 ; Beckman Coulter, Cat# IM2651U, RRID:AB_131166), CD117 PEC7 (Clone 
104D2D1 ; Beckman Coulter, Cat# IM3698, RRID:AB_131184),  CD45RA APC 
(Clone 2H4LDH11LD89; Beckman Coulter, Cat# B14807, RRID:AB_2876787), 
DRAQ7 (Biostatus), CD34-APC A750 (Clone 581; Beckman Coulter, Cat# A89309, 
RRID:AB_2876786), CD192 PB (Clone 48607; Becton Dickinson, Cat# 564067, 
RRID:AB_2738573),  CD45 KO (Clone J33; Beckman Coulter, Cat# B36294, 
RRID:AB_2833027). The target input was set at 1x106 measured events, pan-
els were balanced with the fluorescence-minus-one method to determine spill 
over, spectral overlap, and nonspecific binding. 
The gating strategy is displayed in Figure 2 – figure supplement 2. In short, 
HSPCs were defined as CD45+CD34+CD38dim/+ cells, after selecting for singlets 
and alive cells. Next, the lymphoid lineage was excluded by gating of CD19-
CD117+ cells. In CD45RAdimCD38+ gated cells, CMP, GMP, MEP and R1-3 pro-
genitor populations were identified using CD123 and CD45RA expression. CD90 
expression in CD38-CD45RA- cells determined MPP and HSC populations. Data 
were analysed with Kaluza 2.1 software.
Proliferation assays
2.5x104 BM-MNCs were cultured in Methylcellulose medium containing eryth-
ropoietin, G(M)-CSF, IL-3 and IL-6 (MethoCult GF H84435, Stemcell technolo-
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gies, Vancouver, Canada) and 2% foetal bovine serum (Integro B.V., Zaandam, 
The Netherlands) in Petri dishes for 14 days in 37°C 5% CO2 incubator. After 14 
days, erythroid progenitor (BFU-E), common myeloid progenitor (CFU-GEMM), 
and granulocyte-macrophage progenitor (CFU-GM) cell colonies were counted 
in duplo by an experienced haematology operator.
Mitochondrial respiration and glycolysis assays
Using a modified protocol from [6], 2×106 BM-MNCs were plated per well in 
fivefold to overnight-calibrated cartridges in assay medium (DMEM with 1mM 
L-Glutamine, 11mM glucose and 1 mM pyruvate [pH adjusted to 7.4]) and in-
cubated for 1 hour in a non-CO2-corrected incubator at 37°C. In addition, BM-
MNCs were stimulated with 50ng/mL interferon gamma (IFNγ) (Immukine, 
Boehringer Ingelheim BV, Alkmaar, The Netherlands) and 10ng/mL LPS (Sig-
ma-Aldrich) for 2 hours. Oxygen consumption rate (OCR) and extracellular acid-
ification rate (ECAR) were measured via XFp Analyzer (Seahorse Bioscience), 
with final concentrations of 1 mM oligomycin, 1 mM FCCP, and the combination 
of 1.25 mM rotenone and 2.5mM antimycin A. 
RNA sequencing of sorted progenitor populations and circulating monocytes
HSPCs were sorted by BD FACSAria II SORP flow cytometer sorter (Becton Dick-
inson, RRID:SCR_018091), using the flow cytometric panel as described above 
(Figure 2 – figure supplement 2). BM-MNCs stored in liquid nitrogen were gently 
thawed in foetal calf serum (in house) containing 1.25mM MgCl2 and 0.1 mg/
mL DNase I (Sigma). HSCs, MPPs and GMPs populations were directly sorted in 
100µL TRIzol (ThermoFisher) before processing for RNA sequencing. 
Total RNA was extracted using the standard TRIzol (ThermoFisher) protocol and 
used for library preparation and sequencing. mRNA was processed as described 
previously, following an adapted version of the single-cell mRNA seq protocol of 
CEL-Seq [37, 38]. In brief, samples were barcoded with CEL-seq primers during 
a reverse transcription and pooled after second strand synthesis. The result-
ing cDNA was amplified with an overnight In vitro transcription reaction. From 
this amplified RNA, sequencing libraries were prepared with Illumina Truseq 
small RNA primers (Illumina, San Diego, USA). Paired-end sequencing was per-
formed on the Illumina Nextseq500 platform (RRID:SCR_014983). Read 1 was 
used to identify the Illumina library index and CEL-Seq sample barcode. Read 
2 was aligned to the hg19 human RefSeq transcriptome using BWA [39]Reads 
that mapped equally well to multiple locations were discarded. RNA input for 
all samples was normalized, and libraries for each progenitor population were 
sequenced in a single run.
Bioinformatics, differential gene expression and pathway analysis
Reads were mapped to hg19 human reference genome using BWA [39]. Mul-
tiQC (RRID:SCR_014982) was used to quality check all the samples [40]. In total, 
107,565,838 reads were mapped in 59 progenitor populations, with one GMP 
population failed to pass quality control. Raw read counts provided the input for 
differential gene expression analysis with DESeq2 (RRID:SCR_015687) [41] after 
excluding genes with less than 50 reads. Internal variance stabilizing transfor-
mation was used for regressing out age and to normalize the data (Benjamini–
Hochberg correction was used to adjust p-value for multiple testing correction). 
In the differential expression analyses within HSC populations, one HSC pop-
ulation was marked as outlier and further filtered out as it located 3 standard 
deviations away from mean values in principle component analysis of this study.
Differential gene expression analysis was carried out after regressing out age 
with DESeq2 v1.22.0 in R (RRID:SCR_001905) [41], with internal statistical and 
normalization method (i.e. correction for multiple testing with Benjamini–Hoch-
berg). The average expression between individuals with atherosclerosis (n=10) 
and matched individuals without atherosclerosis (n=10) was analysed for each 
progenitor population. Enrichment analysis were performed using R package 
clusterProfiler (RRID:SCR_016884) [42] with Gene Ontology terms [43]. After 
BH adjustment, a FDR <0.05 in enrichment analysis was considered significant.
[18F]FDG PET and low-dose CT scanning
Participants underwent [18F]FDG PET with low-dose non-contrast enhanced CT 
from skull base to the trochanter major on a dedicated Siemens Biograph 40 
mCT scanner (Siemens Healthineers, Erlangen, Germany). After adhering to a 
24-hour low-carbohydrate diet and 6 hours of fasting, ~2.1 MBq/kg [18F]FDG 
was administered intravenously, as described previously [44]. Glucose concen-
trations were obtained (5.3±0.5 mmol/L) after injection. Before scanning, par-
ticipants rested in supine position for 2 hours. 
Images were reconstructed according to EARL protocols; using a TrueX algo-
rithm with point spread function (PSF) and time-of-flight (TOF) measurements, 
using 3 iterations, 21 subsets, matrix size 200x200 (pixel spacing of 4.07 mm), 
Full Width Half Maximum (FWHM) of 3 mm and using 2 minutes of PET data. 
Postprocessing was performed using a 3D Gaussian filter kernel, 3.0 mm, us-
ing the Inveon Research Workspace 4.2 (Preclinical Solutions, Siemens Medical 
Solutions USA, Knoxville, USA). 
[18F]FDG-uptake in the vascular wall was determined in seven regions of interest 
(ROI) by a single investigator (MPN); the aorta ascendens, aorta descendens, 
abdominal aorta, the left and right common carotid arteries, and the left and 
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right iliac arteries. [18F]FDG-uptake in haematopoietic tissue was assessed in the 
spleen, lumbal vertebrae L2 and L3, and in the left and right femurs. These re-
gions of interest were evaluated using the Inveon Research Workspace 4.2. The 
standardized uptake value (SUV) was extracted from each ROI after correction 
for [18F]FDG dose (MBq) and BMI using the PyRadiomics toolbox [45]. The SUVs 
of left and right ROIs (e.g. left and right carotid artery) were averaged. Next, the 
target-to-background ratio (TBR) was calculated as the ratio of the vascular wall 
SUV and the mean thoracic arterial blood pool SUV. The TBRs of haematopoietic 
tissue were expressed as ratio of the mean liver SUV. The primary outcome is 
the TBR, as recommended by the European guideline [44].
Statistical analysis
This study is an exploratory study, hence no sample size calculation is per-
formed. Normal distribution of the data was checked with the Shapiro-Wilk 
test, when the P-value reached <0.05 this assumption was violated and 
non-parametric tests were used. Data are reported as mean ±SD with inde-
pendent samples T-test according to Levene’s test for equality of variances, as 
mean (number of participants) with Χ2 test for categorical data, and as median 
[interquartile range] with Mann-Whitney U test for non-parametrical data. Out-
liers were removed with a standard deviation >±2.5 of Z-scores. All outcomes 
were log(10)-transformed and thereafter corrected with ANCOVA for confound-
ing demographics such as age and BMI. SPSS V25.0 (SPSS Inc, Chicago Illinois, 
RRID:SCR_002865) and Graphpad Prism v6.0 (GraphPad software, La Jolla, 
California, RRID:SCR_002798) were used for data analysis and visualization. A 
two-sided P-value <0.05 was considered statistically significant.
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Figure 6
Figure supplement 1. Transcriptome of HSC, MPP and GMP populations. (A) PCA analysis based 
on DE genes of the GMP and MPP cell population; (B) Volcano plot showing differential expressed 
genes between CAD patients and controls, controlled for age, in the HSC, MPP, and GMP cell pop-
ulations. Genes with an FDR <0.1 are called out.
Figure supplement 2. Combined heatmap showing the top 50 DE genes for the HSC, MPP, and 
GMP cell populations in the patients and the control subjects. Genes with an FDR<0.1 are colored 
in red and blue for up- and down-regulated respectively.

























































































































Figure supplement 1. Splenic activity correlates with progenitor cells and circulating immune cells. 
Linear regression with 95% CI (n=26). Spearman correlation coefficient (rs). * indicates P<0.05, **: 
P<0.01. HSPCs: hematopoietic stem and progenitor cells, GMP: granulocyte macrophage progen-
itor cells, WBC: white blood cells.
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Abstract
Background. Low-grade inflammation, largely mediated by monocyte-de-
rived macrophages, contributes to atherosclerosis. Sedentary behaviour 
(SB) is associated with atherosclerosis and cardiovascular (CV) diseases. 
We examined whether reducing SB and improving walking time improves 
monocyte inflammatory phenotype in subjects with increased CV risk. 
Methods and Results. Across two waves, sixteen individuals with in-
creased CV risk performed a 16-week intervention study (age 64±6 years, 
BMI 29.9±4.3 kg/m2), using a device with vibration feedback to promote 
physical activity. Before and after intervention, we objectively examined 
physical activity (ActivPAL), cytokine production capacity after ex vivo 
stimulation in peripheral blood mononuclear cells (PBMCs), metabolism of 
PBMCs, circulating cytokine concentrations, and monocyte immunophe-
notype. 
Overall, no significant increase in walking time was found (1.9±0.7 to 
2.2±1.2 hours/day, P=0.07). However, strong, inverse correlations were ob-
served between the change in walking time and the change in production 
of IL-1β, IL-6, IL-8 and IL-10 after LPS stimulation (rs=-0.655, -0.844, -0.672, 
and -0.781, respectively, all P<0.05). After intervention optimisation based 
on feedback from wave 1, participants in wave 2 (n=8) showed an increase 
in walking time (2.2±0.8 to 3.0±1.3 hours/day, P=0.001) and attenuated 
cytokine production of IL-6, IL-8 and IL-10 (all P<0.05). Glycolysis (P=0.08) 
and maximal OXPHOS (P=0.04) of PBMCs decreased after intervention. 
Lower IL-6 concentrations (P=0.06) and monocyte percentages (P<0.05), 
but no changes in monocyte subsets were found.
Conclusion. Successfully improving walking time shifts innate immune 
function towards a less pro-inflammatory state, characterized by a lower 
capacity to produce inflammatory cytokines, in individuals with increased 
CV risk. 
This study is registered at the Netherlands Trial Register (NTR6387): 
https://www.trialregister.nl/trial/6215.
Clinical Perspective
1) What is New?
•	 We showed that effectively reducing sedentary behaviour 
and improving walking time attenuates cytokine pro-
duction capacity of circulating mononuclear cells  with a 
strong inverse correlation between the change in walking 
time and the change in production of IL-1β, IL-6, IL-8 and 
IL-10 of isolated mononuclear cells after ex vivo LPS stim-
ulation.
2) What are the clinical implications?
•	 Our results identify a novel mechanism by which less 
sitting and increased physical activity contributes to im-
proved cardiovascular outcomes. 
•	 By attenuating cytokine production capacity of circulating 
innate immune cells, interventions that reduce sedentary 
behaviour could be of benefit in patients in with chronic 
inflammatory diseases.
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Introduction
Atherosclerotic cardiovascular diseases (CVD), including myocardial infarction 
and stroke, are the major cause of death worldwide [1]. Although regular exer-
cise training is a potent strategy to reduce risk for future CVD [2], only 50-60% of 
the Western population meet these guidelines [3] with even lower prevalence 
rates in those at risk for CVD [4]. In the past decade, an increasing number of 
studies explored the role of sedentary behaviour (i.e. any waking behaviour in a 
sitting, reclining or lying posture with energy expenditure below 1.5 metabolic 
equivalents) in the context of CVD. Interestingly, high levels of sedentary be-
haviour, independent of exercise performance, are associated with an increased 
risk for all-cause mortality and CVD [5-7]. Cross-sectional studies have linked 
sedentary behaviour to higher blood pressure [8], BMI [9], waist circumference 
[9, 10], glucose intolerance [10], and lower high density lipoprotein cholester-
ol (HDLc) [9]. Despite these cross-sectional observations, little work explored 
potential underlying mechanisms of the detrimental impact of sedentary be-
haviour on development of future CVD.
Atherosclerosis is a low-grade inflammatory disorder of the arterial wall, in 
which monocyte-derived macrophages orchestrate the development of athero-
sclerotic plaques [11]. We and others have recently described that circulating 
monocytes of individuals with atherosclerosis have a long-lasting pro-inflam-
matory phenotype. This is characterised by an enhanced cytokine production 
capacity and a switch to an increased glycolytic metabolism [12, 13], suggesting 
that functional and metabolic alterations in circulating monocytes contribute 
to atherogenesis. Individuals with increased risk for CVD due to dyslipoprotein-
emia are also characterized by a pro-inflammatory monocyte phenotype [14]. 
Importantly, a previous study found that a Western type diet in atherosclero-
sis-prone mice is capable of inducing a persistent pro-inflammatory phenotype 
of circulating monocytes and their bone marrow progenitors [15]. Furthermore, 
pharmacological therapy inhibiting interleukin-1β (IL-1β) in the innate immu-
nity pathway successfully reduced the risk of future cardiovascular events in 
patients with CVD [16]. This suggests that interventions, including pharmaco-
logical and environmental strategies that impact on innate immune function, 
may alter the process of atherosclerosis.
Sedentary behaviour is associated with markers of chronic low-grade inflam-
mation (e.g. high concentrations of C-reactive protein (CRP), IL-6, neopterin, 
leptin, adiponectin and tumor necrosis factor alfa (TNFα)) [17, 18]. However, no 
previous study directly examined whether a change in sedentary behaviour (or 
physical activity) results in modulation of the innate immune function. There-
fore, we examined the impact of a 16-week intervention to reduce sedentary 
time and increase physical activity levels on the innate immune function in sub-
jects with increased risk for CVD. For this purpose, we explored the functional 
and metabolic phenotype of innate immune cells in terms of ex vivo cytokine 
production capacity and intracellular metabolism.
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Methods
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request.
Subjects
Individuals with an increased cardiovascular risk were recruited by newspaper 
and internet advertisement in Nijmegen, The Netherlands. Individuals aged 
above 55 years with at least 40 hours per week of self-reported sedentary be-
haviour were eligible for participation. Criteria for inclusion were the presence 
of one or more cardiovascular risk factors, consisting of high blood pressure 
(SBP >160 mmHg, DBP >90 mmHg), anti-hypertensive medication use, or BMI 
>28 kg/m2. Exclusion criteria were presence of diabetes mellitus, autoimmune 
diseases or autoinflammatory diseases, and daily immunomodulatory drug use. 
Moreover, individuals were excluded if they were not able to perform light-in-
tensity physical activity (e.g. standing and walking) or when unable or not al-
lowed to provide informed consent. The study protocol was approved by the In-
stitutional Review Board Arnhem/Nijmegen, the Netherlands and registered at 
the Netherlands Trial Register (NTR6387).  All individuals gave written informed 
consent.
Study design
Subjects reported to our laboratory on four measurement days; two test days 
before and two test days after the 16-week intervention (Figure 1). At each 
Figure 1. Study design. Measurements were performed across 2 waves (n=8 per wave). Partici-
pants visited our laboratory four times; two test days before and two test days after the 16-week 
intervention.
measurement day, participants were instructed to refrain from caffeine and al-
cohol intake at least 12 hours prior to the test. Moreover, participants were in-
structed to refrain from vigorous exercise 24 hours prior to the measurements. 
At the first visit, participant characteristics were assessed and blood was drawn 
for immunological assessment. In the subsequent week, baseline sedentary be-
haviour characteristics of the subjects were measured using an activity monitor 
combined with an inclinometer (ActivPAL, PAL technologies Ltd, Glasgow, UK). 
At a second visit, participants handed in the activity monitor, received written 
and oral information about the reduced sitting intervention, and participants 
started the 16-week intervention. Physical activity patterns were assessed 
during the last week of the intervention and thereafter all other measurements 
were repeated.
Intervention
The 16-week mHealth reduced sitting intervention involved prevention of pro-
longed sitting behaviour (>30 minutes) throughout the day and promotion 
of low-intensity physical activity (e.g. walking, standing). Subjects received a 
pocket pedometer Activ8sit (2M Engineering, Valkenswaard, the Netherlands) 
which recorded physical activity patterns using an inclinometer and tri-axial ac-
celerometer. This combination of information allows for recognizing prolonged 
periods of sedentary behaviour and physical activity. A vibrating signal was pro-
vided after 30 minutes of SB and served as a reminder to break up sitting by 
low- to moderate-intensity physical activity for at least 2 minutes. Next to di-
rect feedback, participants were able to review their physical activity patterns 
in a web-based environment. Furthermore, subjects had a phone meeting with 
their personal coach periodically to evaluate their participation in the reduced 
sitting intervention. The intervention study was performed in two groups. The 
intervention for wave 1 was performed in September 2017 to January 2018 (i.e. 
group1.0, n=8) and wave 2 from March to July 2018 (i.e. group2.0, n=8). Based 
on feedback from the participants in group1.0, coaching and support was in-




Medical history, smoking status, medication use and BMI were assessed in all 
participants. Capillary blood was used to measure fasting glucose concentra-
tions. Blood pressure was measured twice by a manual sphygmomanometer in 
sitting position after 5 minutes rest according to AHA guidelines [19].
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Sedentary behaviour
A validated activity monitor (ActivPAL3 micro, PAL technologies, Glasgow, Unit-
ed Kingdom) was used to measure number of steps, sedentary time, standing 
and walking time [20]. The ActivPAL was attached to the ventral side of the right 
thigh. The monitor was coated in a waterproof sleeve to enable assessment for 
8 days continuously. The first day was excluded for data analyses, leaving 7 days 
of sedentary behaviour measurements. ActivPAL data was processed using an 
analysis script in Matlab R2014b (The Mathworks, Inc., Natick, Massachusetts). 
This allowed distinguishing between wake times and bed times per day for each 
subject and calculated sedentary time, sedentary breaks, number of prolonged 
sedentary bouts (>30 minutes), standing,  walking time and number of steps 
per day [21].
Blood sampling
Directly before and after intervention, non-fasting blood was collected in EDTA 
vacutainers. Sample collection was performed at 8.00-9.00 in the morning to 
avoid interference of circadian rhythms of immune parameters, and sample 
processing occurred within 2 hours. Plasma and serum were stored at -80°C 
until further use. Total cholesterol (Tchol), high-density lipoprotein cholester-
ol (HDLc), and triglycerides were measured in fasting Lithium Heparin plasma 
using standardized methods, and low-density lipoprotein cholesterol (LDLc) 
was calculated with the Friedewald formula. Total blood cell counts were deter-
mined with an automated Sysmex-XN 450 hematology analyser (Sysmex, Ham-
burg, Germany).
PBMC isolation and stimulation
Human peripheral blood mononuclear cells (PBMCs) were isolated by Fi-
coll-Paque density gradient centrifugation (GE Healthcare, Chicago, IL, USA). Cell 
composition was evaluated by Sysmex analyser (Sysmex). PBMCs were concen-
trated in Roswell Park Memorial Institute 1640 Dutch-modified culture medium 
(RPMI) (Life Technologies/Invitrogen, Waltham, MA, USA) supplemented with 2 
mmol/L glutamine (Invitrogen), 10 mg/mL gentamicin (Centrafarm, Etten-Leur, 
The Netherlands) and 1 mmol/L pyruvate (Invitrogen). To evaluate cytokine pro-
duction capacity, 5x10^5 PBMCs per well were stimulated in triplicate for 24 
hours in round-bottom 96-well plates (Corning, New York, NY, USA) with the 
following stimuli: RPMI, 10 ng/mL lipopolysaccharide (LPS) from Escherichia coli 
serotype 055:B5 [22] (Sigma-Aldrich, St. Louis, MO, USA), 10 μg/mL Pam3CysK4 
(P3C) (L2000, EMC microcollections, Tübingen, Germany), 10 µg/mL Resiquim-
od (R848) (Invivogen, San Diego, CA, USA; Catalog#tlrl-r848-5), 50 μMol C16.0 
conjugated with Albumin (Sigma-Aldrich resp. Sanquin, Amsterdam, the Neth-
erlands), and 50 μMol C16.0-Albumin in combination with 300 μg/mL sonicated 
monosodium urate (MSU) crystals (in house). The preparation of C16.0-Albu-
min and MSU crystals is previously described [23]. Simultaneously, to assess 
the adaptive immune response, PBMCs were stimulated in triplicate for 7 days 
in RPMI, 1×10^6/mL Candida albicans conidia (UC820 strain), and 1x10^6/mL 
Staphylococcus aureus (ATCC 29213 strain) both with 10% human pool serum. 
After the incubation periods of 24 hours and 7 days, supernatants were stored 
after plate centrifugation at −80°C until cytokine assessment.
Cytokine measurements
In stored supernatants cytokine concentrations were measured using ELISA 
(Supplemental Table I). Circulating cytokine concentrations were determined 
using ELLA cartridges for IL-1RA, IL-1β, IL-6 and IL-18 on the ELLA platform (Sim-
pleplex, San Jose, CA, USA). Thiobarbituric Acid Reactive Substances (TBARs) 
were measured in plasma as measure for oxidative stress (OXitek TBARs Assay 
kit, ZeptoMatrix, New York, NY, USA).
Flow cytometry
Monocyte subpopulations, platelet complexes and expression markers were 
identified with flow cytometry. Using the lysis-no-wash strategy (BD Pharm Lyse 
lysing buffer, Becton Dickinson, Franklin Lakes, NJ, USA), 50 µL EDTA blood was 
stained by monoclonal antibodies (CD45 Chrome Orange clone J33 Beckman 
Coulter, HLA-DR PE clone immu-357 Beckman Coulter, CD14 PC7 clone 61D3 
Bioscience, CD16 FITC clone CB16 eBioscience, CD3 APC-750 clone UCTH1 
Beckman Coulter, CD56 APC clone N901 Beckman Coulter, CD192 BV421 clone 
48607 Becton&Dickinson, CD11b BV785 clone ICRF44 Biolegend, CD41 PC5.5 
clone Hip8 Biolegend) and measured with CytoFLEX flow cytometer (Beckman 
Coulter, Brea, CA, USA). The gating strategy applied is shown in Supplemental 
Figure I, gates were set with the fluorescence minus one method [24, 25]. Data 
was analysed with Kaluza 3.1 software (Beckman Coulter). Characterization of 
monocytes subsets is according to current recommendations [24, 25].
Metabolic measurements
Lactate levels were measured in unstimulated PBMCs after 24 hours. In a sub-
group of subjects oxygen consumption rate was measured in freshly isolated 
5×10^6 PBMCs collected in RPMI. Oxygen consumption was measured at 37°C 
using polarographic oxygen sensors in a two-chamber Oxygraph (OROBOROS 
Instruments, Innsbruck, Austria). First, basal oxygen consumption was mea-
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sured over a period of ≥10 minutes. Then, leak respiration was measured by 
adding oligomycin A (2.5 μM), a specific inhibitor of mitochondrial complex V. 
Next, the mitochondrial uncoupler p-trifluoromethoxy carbonyl cyanide phenyl 
hydrazone (FCCP) was added at increasing concentrations (ranging from 0.2 μM 
to 1.0 μM final concentration) to determine maximal electron transport chain 
capacity. Finally, non-mitochondrial oxygen consumption was established by 
adding the mitochondrial complex I inhibitor rotenone (0.5 μM) and the mito-
chondrial complex III inhibitor antimycin A (2.5 μM).
Statistical analysis
Data are presented as mean ±SD for continuous variables, as number (percent-
age) for categorical variables and as median [interquartile range] for skewed 
distributed data. All data were analysed using Wilcoxon signed-rank tests, un-
less stated otherwise. A 2-sided P-value <0.05 was considered statistically signif-
icant. Data were analysed using Prism version 6.0 (GraphPad software, La Jolla, 
CA, USA) and SPSS version 21.0 (SPSS Inc, Chicago, IL, USA).
Table 1. Participants’ characteristics.
† data is missing for 8 participants. * indicates P< 0.05, **: P<0.01. Paired samples T-test, mean, 
SD, or Χ2 test for categorical data, mean (n). First and second group were matched (age, sex, BMI, 
smoking). SBP indicates systolic blood pressure, DBP: diastolic blood pressure.
Baseline characteristics Total (n=16) Group1.0 (n=8) Group2.0 (n=8)
Sex (% male, n) 31 (5) 25 (2) 38 (3)
Age (years) 64±6 66±5 62±6
Current smoking (%, n) 13 (2) 0 (0) 25 (2)
Hypertension (%, n) 69 (11) 50 (4) 88 (7)
Lipid lowering therapy (%, n) 25 (4) 25 (2) 25 (2)
B-antagonist use (%, n) 31 (5) 38 (3) 25 (2)
Intervention outcomes Pre Post Pre Post Pre Post
SBP (mmHg) 132±10 131±9 128±11 134±8 136±7 128±10**
DBP (mmHg) 82±7 84±7* 80±7 84±6* 83±7 83±8
BMI (kg/m2) 29.9±4.3 30.0±4.2 30.2±2.6 30.6±2.6* 29.5±5.7 29.4±5.4
Glucose (mmol/L) 6.17±0.77 5.78±0.74* 6.43±0.67 5.96±0.72** 5.91±0.82 5.61±0.76
Tchol (mmol/L) 5.11±0.74 4.88±0.61 5.04±0.76 4.94±0.48 5.18±0.78 4.83±0.75*
HDLc (mmol/L) 1.43±0.35 1.39±0.32 1.37±0.40 1.33±0.33 1.49±0.31 1.45±0.33
LDLc (mmol/L) 2.85±0.72 2.77±0.60 2.74±0.74 2.80±0.64 2.96±0.72 2.74±0.60
Triglycerides (mmol/L) 1.84±1.11 1.63±0.93 2.06±1.14 1.82±1.00 1.62±1.12 1.43±0.87
Non-HDLc (mmol/L) 3.67±0.69 3.51±0.52 3.66±0.82 3.63±0.43 3.68±0.60 3.40±0.61
Sedentary time (hours/day) 10.1±1.3 9.8±1.5 10.4±1.7 10.3±1.5 9.9±0.6 9.3±1.4
Sitting time >30 min (#/day) 6±2 6±2 7±2 7±1 5±1 5±1
Walking time (hours/day) 1.9±0.7 2.2±1.2 1.5±0.5 1.4±0.4 2.2±0.8 3.0±1.3**
Total step count (#/day) 8864±4138 10656±6821 7069±2243 6402±2181 10659±4930 14909±7321**
Estimated physical fitness 
(ml O2/ml/kg)
27.7±7.4 27.7±8.8 25.3±5.4 22.6±4.9 30.0±8.6 32.8±9.1
Central vascular stiffness† 7.8±1.7 7.6±2.9 n.a. n.a. 7.8±1.7 8.1 ±2.8
Peripheral vascular stiffness† 9.1±1.0 9.0±2.4 n.a. n.a. 9.1±1.0 9.8 ±1.3
Results
Subject characteristics
Sixteen participants (age 64±6 years, BMI 29.9±4.3 kg/m2) participated in the 
study. After 16 weeks, the increase in walking time (1.9±0.7 to 2.2±1.2 hours/
day, P=0.07) and step count (8864±4138 to 10656±6821 #/day, P=0.06) did not 
reach statistical significance. The intervention was performed in two waves. 
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Based on feedback from participants in group1.0, coaching and support was 
intensified for subjects in group2.0 to optimise the intervention. No differences 
were found between both groups at baseline (Table 1).
Importantly, group2.0 (n=8) significantly increased walking time (2.2±0.8 to 
3.0±1.3 hours/day, P<0.01) and step count (10659±4930 to 14909±7321 #/day, 
P<0.01). No changes were seen in estimated physical fitness. Total cholesterol 
levels (P=0.05) and systolic blood pressure (SBP) (P<0.01) decreased in group2.0, 
whilst group1.0 (n=8) showed a decrease in glucose (P<0.01), an increase in BMI 
(P=0.01) and in diastolic BP (P=0.01) (Table 1).
In addition to analysis of the entire group, sub-analyses on group2.0 (n=8) were 
performed to specifically examine the impact of reducing sedentary behaviour 
on innate immune function. All data for group1.0 are reported in Supplemental 
Tables II-IV.
Figure 2. Circulating cytokines. Individual changes in circulating cytokines before (pre) and after 
(post) intervention (n=8). Mean is represented in black. Lowest detection limit for IL-1β is 0.31 pg/
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Circulating inflammatory markers 
A trend for a decrease in circulating IL-6 concentration was observed in group 
2.0 (n=8) (3.21 to 2.62 pg/mL, P=0.08) (Figure 2). The concentrations of inflam-
matory markers CRP, IL-1β, IL-1RA and IL-18 did not change significantly after in-
tervention. In addition, levels of adiponectin and leptin, both adipokines; TBAR, 
a marker of  oxidative stress; E-selectin and VCAM-1, markers of endothelial 
dysfunction; and MMP-2, a matrix metalloproteinase, were not affected by the 
intervention (Supplementary Table V).
Cytokine production capacity of PBMCs
After the intervention a significant reduction in the innate cytokine production 
capacity of PBMCs was observed in group2.0 (n=8) (Figure 3A). We found an 
attenuated production of IL-6, IL-8 and IL-10 in PBMCs stimulated for 24 hours 
Figure 4. Cytokine production capacity correlated with walking time per day (n=16). The change 
in cytokine concentration after LPS (black) and R848 (red) stimulation correlated with the change 
in walking time. Linear regression with 90% confidence interval. * indicates P<0.05, ** P<0.01, rs: 
Spearman correlation coefficient.
with LPS, P3C and R848 (TLR4, TLR2 and TLR7/8 ligands respectively) after the 
16-week intervention (all P<0.05). For C16.0 stimulation (i.e. a saturated fatty 
acid) an attenuated production in IL-1β, IL-6 and IL-8 (all P<0.05) was seen after 
intervention. After C16.0-MSU stimulation, which induces inflammasome acti-
vation, IL-6 and IL-8 production was significantly attenuated after intervention 
(all P<0.05). Correction for monocyte count in the PBMC fraction did not alter 
the results for cytokine production after LPS and R848 stimulation, and IL-1β 
production after C16.0 stimulation (see Supplementary Table VI for cell per-
centages in the PBMC fraction). To  study the adaptive immune function, 7 day 
stimulation of PBMCs with C. albicans and S. aureus was performed. After in-
tervention, a significant increase in the cytokine response of IFNγ was observed 
after C. albicans stimulation (P=0.05), and of IFNγ, IL-22 and IL-17 after S. aureus 
stimulation (P<0.05, P=0.08, and P<0.05, respectively) (Figure 3B).
We examined the correlation between the change in walking time and the 
change in cytokine production capacity during the intervention on the data of 
both groups (n=16) as all individuals possess data on a change in walking time 
and consequent changes in cytokine production capacity (Figure 4). This anal-
Table 2. Circulating cell counts and immunophenotyping of monocytes (n=8).
Cell counts Pre Post
WBC (10^6/mL) 5.3 [4.4-6.1] 5.0 [4.5-6.2]
Neutrophils (10^6/mL) 2.9 [2.6-3.3] 2.8 [2.4-3.2]
Lymphocytes (10^6/mL) 1.7 [1.3-2.2] 1.7 [1.6-2.5]
Monocytes (10^6/mL) 0.50 [0.37-0.60] 0.39 [0.27-0.54]
Monocytes (%) 9.0 [7.3-10.3] 7.9 [6.1-8.7]*
Lymphocyte monocyte ratio 3.47 [2.95-4.51] 4.59 [3.90-6.13]*
Neutrophil lymphocyte ratio 1.54 [1.41-2.46] 1.61 [1.21-1.83]
Immunophenotype monocytes
Monocyte subsets (% total) 7.5 [6.0-7.9] 5.7 [3.8-6.6]
Classical Mo (% gated) 78.5 [76-81] 79.0 [75-84]
Intermediate Mo (% gated) 7.3 [4.4-8.1] 7.0 [4.1-8.0]
Nonclassical Mo (% gated) 14.1 [13.0-16.1] 12.7 [10.4-18.4]
CD41+ Mo (% gated) 8.0 [7.0-8.7] 8.5 [8.0-9.2]
CCR2+ Mo (MFI) 5255 [4607-5932] 4385 [3894-6873]
CD11b+ Mo (MFI) 8872 [6721-10893] 10743 [7924-10978]
WBC indicates white blood cell counts, Mo: monocytes, MFI: mean fluorescence intensity. * indi-
cates P< 0.05. Median, IQR.
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ysis shows a strong, inverse correlation between IL-1β, IL-6, IL-8 and IL-10 pro-
duction after stimulation with LPS and R848 versus walking time (all rs>-0.51 
and P<0.001, except IL-8 after LPS P=0.01).
Immunophenotyping of monocytes
A reduction in the percentage of circulating monocytes (P<0.05) was observed 
together with an increase in the lymphocyte-to-monocyte ratio (P=0.01) after 
intervention in group2.0 (n=8) (Table 2). The distribution of the monocyte sub-
populations, i.e. the classical, intermediate and nonclassical monocytes, did 
not change during the intervention. Also, CCR2 and CD11b expression in mono-
cytes, and monocyte-platelet complexes were not altered (Table 2).
Figure 5A-E. Metabolism of PBMCs: A. Extracellular lactate production in unstimulated PBMCs 
(n=8). B. Representative result of the OROBOROS. C. Oxygen consumption is presented as basal 
respiration (basal) (n=6), proton leak after inhibition of ATP synthase (leak) (n=4),  maximal ox-
ygen consumption (max) (n=4), residual oxygen consumption or non-mitochondrial oxygen con-
sumption (rox) (n=6). D-E. Absolute and relative oxygen consumption reserve (n=4). Data before 
(white) and after intervention (grey) are shown in boxplots (median ± interquartile range). Whis-
kers represent 90% confidence interval. * indicates P<0.05.
Metabolism of PBMCs
A trend for a decrease in lactate production was observed (P=0.08) after 24 
hours in unstimulated PBMCs (Figure 5A). Oxygen consumption in freshly iso-
lated PBMCs tended to decrease after intervention for both basal (P=0.06; n=6) 
and maximal (P<0.05; n=4) respiration (Figure 5B-C). However, no changes were 
observed for relative and absolute reserve capacity (P>0.20) (Figure 5D-E).
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Discussion
Our main finding is that a 16-week intervention to reduce sedentary behaviour 
and improve walking time alters the innate immune function towards a less 
pro-inflammatory state in individuals with increased CV risk. In support of this 
observation, we found a strong, inverse correlation between the increase in 
walking time and attenuated cytokine production capacity that followed a 
dose-response like pattern. In other words, individuals who had the highest 
increase in walking time, demonstrated  the strongest reduction in cytokine 
production capacity of circulating PBMCs. The reduction in inflammatory state 
after the 16-week intervention coincided with a trend to decreased glycolysis 
and oxidative phosphorylation rate. Together, our study provides a mechanistic 
explanation of the cardiovascular benefits of long-term reductions in sedentary 
behaviour.
Given the current lack of validated strategies to reduce sedentary behaviour, 
we have co-developed a physical activity-monitor with the capacity to provide 
tactile feedback for the purpose of a “reduce sedentary behaviour”-interven-
tion. During this process, data from group1.0 showed no significant improve-
ment in physical activity patterns. Based on feedback from these participants, 
we adjusted the intervention, largely through an increased frequency and more 
detailed feedback to the participants (including weekly online or oral feedback). 
As a result, successful improvement of physical activity after the 16-week in-
tervention in participants from group2.0 was achieved, as supported by the 
increase in walking time of 45 minutes/day. The difficulty of changing daily sed-
entary behaviour is illustrated by previous 3-4 month intervention studies, also 
using mHealth-devices, that failed to markedly improve walking time [26] or 
sedentary time [27]. This emphasises the importance for (co-)developing inter-
ventions, using participants’ feedback, to successfully alter sedentary behaviour 
patterns. Another important observation in our study was that the reduction 
in sedentary behaviour was achieved through elevation in walking time rather 
than via increased engagement in exercise training and/or physical fitness. Pre-
vious work linked regular exercise training and/or higher fitness to mechanisms 
of cardiovascular protection and prevention of atherosclerosis [28]. Therefore, 
the absence of changes in physical fitness and/or exercise training, allows us 
to relate the improved innate immune response to the reduction in sedentary 
behaviour.
The key finding of our study is that reducing sedentary behaviour across a 16-
week intervention is associated with a significant reduction in cytokine produc-
tion capacity of PBMCs (i.e. attenuated innate immune response). In previous 
cross-sectional studies, sedentary behaviour or physical inactivity was found to 
be associated with several circulating markers of systemic inflammation (CRP, 
IL-6, TNF-α, neopterin) [17, 18], but the effect on innate immune cell function 
was unexplored. Our observations confirm these previous findings in that we 
found a trend for reduction in circulating IL-6 concentrations within individuals 
after the 16-week intervention. 
Next, one could hypothesize about the potential underlying mechanisms driv-
ing the attenuated innate immune state. Previous work on the acute impact of 
sedentary behaviour found marked reduction in vascular function, which was 
linked to an decreased in arterial blood flow  and presence of oxidative stress 
[29]. More specifically, vitamin C supplementation prevented the impact of 3h 
sitting on vascular function. However, the investigators found no changes in the 
circulating oxidative stress markers [30]. In our study we examined a circulating 
marker of oxidative stress, but neither did we observe significant changes af-
ter intervention. Additional markers of antioxidants and oxidative damage are 
needed to fully exclude a role of oxidative stress. In addition, it is important to 
note that we cannot exclude the potential presence of local changes of oxida-
tive stress in tissues (e.g. active areas). 
Another explanation for our observations, might relate to the metabolic effects 
of sedentary behaviour versus low-intensity physical activity. A previous study 
found that an acute sedentary bout impaired glucose metabolism [31]. Interest-
ingly, we found a trend for decreased glycolysis and oxidative phosphorylation 
rates in PBMCs after our intervention. Recent studies have shown that the hy-
per-responsiveness of circulating monocytes in terms of cytokine production in 
patients with atherosclerosis coincides with an increased glycolytic metabolism 
[12, 13]. Therefore, metabolic changes during our intervention might contrib-
ute to the attenuated inflammatory innate immune function. Moreover, the 
leptin/adiponectin pathway seems related to the level of physical (in)activity in 
cross-sectional observations [17, 32, 33]. In contrast to these studies, we found 
no change in the ratio after the intervention. Together, the decrease in cellular 
metabolism is one mechanism driving the attenuated immune response after 
intervention. Still future studies are warranted to better understand our novel 
observation of the capacity of low-intensity physical activity to attenuate innate 
immune responses of PBMCs in humans.
Interestingly, in conjunction with an attenuated innate immune response of 
PBMCs after the intervention, we observed an enhanced production by the 
adaptive immune cells, as IFNγ and IL-17 production after S. aureus stimulation 
significantly increased after the 16-week intervention. A similar counter-regula-
tory mechanism has been reported previously. A decreased production capacity 
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of IFNγ was found in patients with cerebral small vessel disease in conjunction 
with an increased innate immune cytokine production [34]. This increase in the 
adaptive immune response may represent a counter-regulatory mechanism to 
compensate for the attenuate innate immune response.
Our results are in line with recent studies that have demonstrated that environ-
mental factors can persistently modulate the inflammatory function of circulat-
ing monocytes and, consequently, contribute to changes in risk for future CVD 
[35]. For example, sleep fragmentation leads to an increase in pro-inflammatory 
monocytes and subsequently to larger atherosclerotic lesions in mice [36]. In 
addition, chronic stress induces monocytosis via accelerated haematopoiesis 
that subsequently promotes vulnerable plaque lesions [37]. Furthermore, a 
Western-type diet modulates towards long-lasting innate immune reprogram-
ming in myeloid cells and progenitor cells in Ldlr-/- mice [15]. In agreement 
with these earlier observations, our results imply that changes in lifestyle may 
reduce the risk to develop CV disease through their effects on innate immune 
function in humans.
Our study may have implications for public health. The ability to successfully 
reduce sedentary behaviour, in a population at risk for CVD and a priori high 
levels of sedentary behaviour, and the associated diminished pro-inflammatory 
phenotype of innate immune cells is of potential clinical relevance. More im-
portantly, our work shows that the detrimental effects of sedentary behaviour 
on atherosclerosis and CVD may, at least partly, be explained through the direct 
effects on the innate immune function. However, some limitations must be con-
sidered. 
A potential limitation of this study is that, due to the design of our study, we 
cannot exclude the impact of external modulators of immune function, e.g. sea-
sonality. Previously, annual seasonal variability in cytokine production has been 
described to significantly peak in summer for several cytokines (e.g. TNF-α, 
IL-1β, and IL-6) after stimulation [38]. We observed a decreased cytokine pro-
duction after the physical activity intervention in July, which is exactly opposite 
effect of the annual seasonal summer peak. Moreover, no seasonal effect was 
found for the cytokine production after P3C and LPS stimulation, the stimuli ap-
plied in our study. This suggests that the effect of the intervention unlikely can 
be explained by seasonality per se. Also, the strong correlation between walking 
time and cytokine production capacity strongly argues for a direct effect of the 
intervention on cytokine production capacity. Fluctuations of immune cells over 
time might have influenced our results, however correction for the monocyte 
percentage of the PBMC fraction did unalter our strongest findings, namely the 
cytokine production capacity after LPS and R848 stimulation. 
Our relatively small sample size should be considered, although power analy-
sis revealed intermediate (β>0.65) to good (β>0.80) power for most outcomes, 
except for IL-8 which is underpowered (see Supplemental table VII) and there-
fore has a larger chance of a type II error (i.e. false negative results). Still we 
were able to detect a significant difference in IL-8 before and after intervention. 
Nevertheless, caution should be taken extrapolating our results to other groups 
and/or physical activity interventions.
This study is the first to reveal a diminished pro-inflammatory phenotype of 
innate immune cells after a successful 16 weeks reduced sitting intervention in 
subjects with increased cardiovascular risk. These findings, combined with the 
within-subject approach of our study, support the presence of a dose-response 
relationship between sedentary behaviour and innate immune response. Given 
the central role for activated monocytes in atherosclerosis and development 
of cardiovascular diseases, our observations may have important clinical impli-
cations. These data improve our understanding of the link between sedentary 
behaviour and cardiovascular disease and support the concept that targeting 
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Supplemental Tables II-IV show data of group1.0.
Table II. Circulating cytokines in group1.0 (n=8).
Circulating cytokines Pre Post
IL-1RA (pg/mL) 263 [215-377] 260 [199-371]
IL-1β (pg/mL) 0.15 [0.09-0.17] 0.15 [0.08-0.27]
IL-6 (pg/mL) 2.66 [1.90-4.26] 3.43 [1.82-5.62]
IL-18 (pg/mL) 172 [112-193] 173 [117-226]
* P< 0.05, ** P<0.01. Wilcoxon signed rank test, median, IQR. IL: interleukin.
Supplemental Tables
Table I. Product details of cytokines and chemokines measured with ELISA.
Item Manufacturer Category number
24 hour stimulation Human TNFα duoset R&D DY210
Human IL-1β duoset R&D DY201
Human IL-6 duoset R&D DY206
Human Pelipair IL-8 Sanquin M9318 
Human Pelipair IL-10 Sanquin M9310
7 day stimulation Human PelipairIFNγ Sanquin M9333
Human IL-17 duoset R&D DY317 
Human IL-22 duoset R&D DY782 
Plasma Human VCAM-1 duoset R&D DY809
Human E-selectin duoset R&D DY724
Human MMP-2 duoset R&D DY902
Human Leptin duoset R&D DY398
Human Adiponectin duoset R&D DY1065
MMP-2 indicates matrix metalloproteinase-2; VCAM-1, vascular cell adhesion molecule 1.
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Table III. Cytokine production capacity in group1.0 (n=8). A. Innate cytokine production 
after 24 hour stimulation, B. Adaptive cytokine production after 7 day stimulation. 
A. Innate cytokine production Pre Post
Unstimulated
IL-1β (pg/mL) 78 [78-78] 78 [78-78]
IL-6 (ng/mL) 0.5 [0.5-0.5] 0.5 [0.5-0.5]
IL-8 (ng/mL) 1.6 [1.6-1.6] 1.6 [1.6-1.6]
IL-10 (pg/mL) 47 [47-47] 47 [47-47]
TNFα (pg/mL) 78 [78-127] 78 [78-110]
LPS stimulated
IL-1β (pg/mL) 3478 [1689-6317] 12187 [6393-16901]*
IL-6 (pg/mL) 12.6 [7.0-27.7] 23.4 [21.6-25.9]*
IL-8 (ng/mL) 55.6 [27.7-87.7] 88.1 [67.7-123.2]*
IL-10 (pg/mL) 930 [804-1920] 1606 [974-1926]
TNFα (pg/mL) 447 [182-1117] 787 [489-1590]*
P3C stimulated
IL-1β (pg/mL) 2637 [1234-4333] 3552 [2617-5441]
IL-6 (ng/mL) 16.4 [10.9-22.6] 20.1 [17.1-26.7]*
IL-8 (ng/mL) 84.4 [70.7-114.6] 123.3 [89.4-157.6]*
IL-10 (pg/mL) 170 [106-768] 200 [128-440]
TNFα (pg/mL) 135 [115-297] 493 [110-923]
R848 stimulated
IL-1β (pg/mL) OFR OFR
IL-6 (ng/mL) 24.5 [18.7-40.6] 34.3 [26.9-50.1]
IL-8 (ng/mL) 37.7 [24.4-51.5] 67.7 [44.7-85.1]* 
IL-10 (pg/mL) 1249 [1050-2642] 1299 [784-3837]
TNFα (pg/mL) 6093 [2811-7898] 5148 [2871-7435]
C16.0 stimulated
IL-1β (pg/mL) 39 [39-145] 176 [39-372]*
IL-6 (pg/mL) 94 [94-225] 252 [94-1061]*
IL-8 (ng/mL) 2.1 [1.6-4.5] 6.3 [1.6-20.1]*
TNFα (pg/mL) 272 [168-363] 322 [183-555]
C16.0-MSU stimulated
IL-1β (pg/mL) 39 [39-374] 299 [46-798]
IL-6 (pg/mL) 94 [94-1542] 882 [166-1723]
IL-8 (ng/mL) 3.0 [1.6-20.6] 22.9 [1.7-31.2]
TNFα (pg/mL) 98 [78-119] 124 [78-730]
B. Adaptive cytokine production Pre Post
Unstimulated
IFNγ (pg/mL) 12 [12-12] 12 [12-12]
IL-22 (pg/mL) 78 [78-78] 78 [78-78]
IL-17 (pg/mL) 39 [39-39] 39 [39-39]
Candida stimulated
IFNγ (pg/mL) 448 [179-1032] 293 [110-553]
IL-22 (pg/mL) 4396 [803-9046] 2755 [1132-7182]
IL-17 (pg/mL) 556 [350-819] 444 [373-897]
S. aureus stimulated
IFNγ (pg/mL) 44 [18-150] 75 [61-1161]*
IL-22 (pg/mL) 158 [78-464] 101 [78-754]
IL-17 (pg/mL) 147 [39-810] 63 [39-262]
* P< 0.05, ** P<0.01. Wilcoxon signed rank test, median, IQR. OFR indicates out of range. LPS, 
lipopolysaccharide; P3C, Pam3CysK4; R848, Resiquimod; C16.0+MSU, C16.0 with monosodium 
urate crystals.
Table IV. Metabolism: Lactate and oxygen consumption in group1.0 (n=8). 
Oxygen consumption (O2/10^6 cells) Pre Post
Basal (pmol/sec) 2.5±0.2 1.9±0.5
Leak (pmol/sec) 0.6±0.2 0.6±0.2
Max (pmol/sec) 9.0±1.0 7.1±1.7
ROX (pmol/sec) 0.1±0.1 0.1±0.1
Absolute reserve (pmol/sec) 6.5±0.9 5.2±1.3
Relative reserve (%) 72±2 73±3
Lactate production (pg/mL) 854 [708-986] 1321 [1046-1339]
* P< 0.05, ** P<0.01. Wilcoxon signed rank test. Basal respiration (basal), proton leak after inhibi-
tion of ATP synthase (leak), maximal oxygen consumption (max), residual oxygen consumption or 
non-mitochondrial oxygen consumption (ROX).
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Table V. Circulating markers of fat tissue, inflammation, oxidative stress and endothelial 
dysfunction (n=8).
Circulating markers Pre Post
Adiponectin (pg/mL) 4.17 [3.78-4.99] 4.18 [2.75-5.50]
Leptin (µg/mL) 16.2 [10.2-20.0] 14.4 [12.3-31.0]
Leptin adiponectin ratio 5.1 [2.1-7.8] 5.6 [2.3-12.0]
CRP (pg/mL) 2.72 [1.62-3.69] 3.07 [2.22-3.54]
TBAR (nmol/L) 1.38 [1.33-1.72] 1.41 [1.34-1.94]
MMP-2 (ng/mL) 377 [374-421] 383 [360-404]
VCAM-1 (ng/mL) 908 [828-978] 938 [781-978]
E-selectin (ng/mL) 10.3 [7.8-12.8] 10.8 [7.7-12.8]
* P< 0.05, ** P<0.01. Wilcoxon signed rank test, median, IQR. MMP-2 indicates matrix metallo-
proteinase-2; VCAM-1, vascular cell adhesion molecule 1.
Table VI. Cell types in PBMC fraction (n=8).
Cell types in PBMC fraction Pre Post
Neutrophils(%) 1.1 [0.7-1.4] 0.9 [0.6-1.3]
Lymphocytes (%) 71 [69-74] 73 [67-81]*
Monocytes(%) 28 [24-30] 26 [18-30]*
* P< 0.05, ** P<0.01. Wilcoxon signed rank test, median, IQR.
Table VII. Power analysis of cytokine production capacity. 
Stimulus Cytokine Difference ±SD r Power (1-β) Sample size needed 
for β=0.80
LPS IL-6 (ng/mL) -8.1±7.3 0.46 0.68 10
IL-10 (pg/mL) -611±468 0.55 0.81 8
IL-8 (ng/mL) -27±41 0.21 0.31 24
R848 IL-6 (ng/mL) -22.4±5.9 0.93 0.99 4
IL-10 (pg/mL) -959±337 0.92 0.99 4
IL-8 (ng/mL) -16.9±18.2 0.40 0.53 13
Power calculations of cytokine production capacity using Wilcoxon-signed ranked test. Difference 
±SD indicates the difference in cytokine production capacity before and after intervention. R 
indicates correlation coefficient, LPS, lipopolysaccharide; R848, Resiquimod.
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Abstract
Background and Purpose: Cerebral small vessel disease (cSVD) is the ma-
jor vascular cause of cognitive decline and dementia. The pathogenesis 
of cSVD remains largely unknown, although several studies suggest a role 
for systemic inflammation. In certain pathophysiological situations, mono-
cytes can reprogram towards a long-term pro-inflammatory phenotype, 
which has been termed trained immunity. We hypothesize that trained 
immunity contributes to the progression of cSVD.
Methods: Individuals with mild to severe cSVD participated in the study. 
Severity of cSVD was determined by the white matter hyperintensities 
(WMH) volume (mL) on MRI in 2006, 2015 and the progression between 
2015-2006 (∆WMH). Cytokine production was assessed after ex vivo stim-
ulation of peripheral blood mononuclear cells (PBMC’s) and monocytes. 
Additionally, monocyte subsets were identified by flow cytometry.
Results: Fifty-one subjects (70 ±6 years, 60% men, 5.1 ±6.4 mL ∆WMH) 
were included. Circulating high sensitivity interleukin 6 (hsIL-6) correlated 
with cSVD (p=0.005, rs=0.40). Cytokine production capacity by monocytes 
was associated with cSVD progression. Basal IL-8 and IL-17 production 
(p=0.08, rs=0.25; p=0.03, rs=0.30) and IL-6 production after Pam3Cys stim-
ulation in monocytes was associated with cSVD (n=35: p=0.008, rs=0.44). 
Conversely, interferon-γ (IFNγ) production in C. albicans stimulated PB-
MC’s was negatively correlated with cSVD (p=0.009, rs= -0.36). Flow cy-
tometry revealed a correlation of the intermediate monocyte subset with 
cSVD (p=0.01, rs=0.36).
Conclusions: Severity and progression of cSVD is not only correlated with 
systemic inflammation (hsIL-6), but also with trained immunity character-
istics of circulating monocytes, in terms of an altered cytokine production 
capacity and a shift towards the pro-inflammatory intermediate monocyte 
subset.
Introduction
Cerebral small vessel disease (cSVD) is the major vascular contributor to cogni-
tive decline and dementia and ultimately results in loss of independence [1]. It 
accounts for 25% of all ischemic strokes with limited therapeutic options avail-
able, apart from modification of classical cardiovascular risk factors [2-4]. cSVD 
refers to pathological processes affecting the small arteries, arterioles, venules 
and capillaries of the brain. It is characterized by so called MRI markers of cSVD 
including white matter hyperintensities (WMH), lacunes, microbleeds, enlarged 
perivascular spaces, gray and white matter atrophy, acute (micro)infarcts and 
microstructural white matter degeneration [5, 6]. Classical cardiovascular risk 
factors such as hypertension, diabetes mellitus and smoking are risk factors for 
cSVD [7]. cSVD typically progresses slowly over years [8], while progression ac-
celerates during aging and in the presence of cardiovascular risk factors [9-11].
In contrast to large artery disease, which is caused by atherosclerosis, the main 
pathological basis of cSVD is arteriolosclerosis of the small arteries in the brain. 
The pathophysiological processes that regulate the development and progres-
sion of cSVD remain enigmatic, yet, similar to large vessel atherosclerosis, in-
flammation has been suggested to play a role. Indeed, observational cohort 
studies indicate that circulating inflammatory markers, such as interleukin-6 
(IL-6), are consistently associated with cSVD [12, 13]. Besides, cSVD shares risk 
factors with atherosclerosis suggesting a common pathophysiological mecha-
nism. Atherosclerosis is a low-grade inflammatory disorder of the arterial wall 
with the innate immune system, specifically monocyte-derived macrophages, 
as major driver of disease initiation and progression [14]. Therefore, we now 
aim to test the hypothesis that the innate immune system is also involved in the 
pathophysiology of cSVD. 
We and others have recently described that, in contrast to the traditional immu-
nological paradigm, cells of the innate immune system can also build immuno-
logical memory, which has been termed ‘trained immunity’, and is characterized 
by an enhanced cytokine response [15]. Brief exposure of monocytes to various 
micro-organisms or to endogenous atherogenic substances, such as oxidized 
low-density lipoprotein (LDL) or lipoprotein(a) induces the development of 
a long-lasting pro-inflammatory phenotype, which is characterized by an en-
hanced cytokine production capacity [16, 17]. This is mediated by epigenetic 
and metabolic reprogramming and, in vivo, occurs at the level of hematopoietic 
progenitor cells in the bone marrow [18-20]. Recent studies demonstrated that 
monocytes from patients with established atherosclerosis or risk factors for ath-
erosclerosis indeed have a trained immunity phenotype [17, 21].
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Given the overlapping findings of systemic inflammation and shared risk factors 
between atherosclerotic cardiovascular disease and cSVD, we now aim to test 
the hypothesis that trained immunity also contributes to the pathophysiology 
of cSVD. Therefore, we performed extensive phenotyping of circulating mono-
cytes, using flow cytometry to determine monocyte subsets, and assessing cy-
tokine production capacity after ex vivo stimulation, in a well-defined cohort of 
patients with cSVD who underwent consecutive cerebral MRI scanning.
Materials and Methods
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request. Expanded Materials and Methods 
are available in the online-only Data supplement, please see http://stroke.aha-
journals.org.
Study participants
Individuals with mild to severe cSVD were included in the RUN DMC – InTENse 
study [22]. Subjects of the RUN DMC – InTENse study were selected from the 
prospective Radboud University Nijmegen Diffusion tensor and Magnetic res-
onance imaging Cohort (RUN DMC) study. This study collected MRI and clin-
ical data in 2006, 2011 and 2015 among elderly subjects with cSVD [23]. The 
aim of the RUN DMC – InTENse study was to investigate the progression and 
prognosis of cSVD in individuals without any other cause of cerebral ischemia. 
Therefore, we applied the following stringent exclusion criteria: the presence of 
large artery disease defined as carotid artery stenosis (>50% assessed by carotid 
ultrasound), atrial fibrillation or the use of oral anticoagulants, previous cortical 
ischemic stroke or transient ischemic attack, intracranial haemorrhage, large 
artery vasculitis, dementia or Parkinson’s disease. All individuals gave written 
informed consent. The study protocol was approved by the Institutional Review 
Board Arnhem/Nijmegen, The Netherlands. 
Baseline measurements
At baseline of the RUN DMC – InTENse study medical history, current drug use, 
and cardiovascular risk factors including body mass-index (BMI), blood pressure 
(measured three times), and random glucose level were determined. 
Blood sampling
Between August 2016 and February 2017 blood was obtained in the morning in 
EDTA vacutainers after overnight fasting. Plasma and serum was stored in -80C 
until further use. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), 
and triglycerides were measured using standardized methods, and LDL choles-
terol was calculated with the Friedewald formula. Total blood cell counts were 
measured with an automated Sysmex-XN 450 hematology analyser.
PBMC and monocyte isolation and stimulation
Human peripheral blood mononuclear cells (PBMC’s) were isolated by Fi-
coll-Paque density gradient centrifugation (GE Healthcare, UK). Subsequently, 
monocytes were isolated by magnetic activated cell sorting (MACS) using neg-
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ative bead selection with the Pan Monocyte Isolation kit according to manu-
facturer’s instructions (Miltenyi Biotec, Leiden, The Netherlands). For both cell 
suspensions purity and cell composition were evaluated by Sysmex analyser 
and flow cytometry (Figure I in the online-only Data supplement).
Purified monocytes were concentrated to 1x106/ml in Roswell Park Memorial 
Institute (RPMI) 1640 Dutch-modified culture medium (Life Technologies/Invi-
trogen, Breda, The Netherlands) supplemented with 2 mM glutamine (Invitro-
gen), 10 mg/mL gentamicin (Centraform) and 1 mM pyruvate (Invitrogen). Per 
well 1x105 monocytes were seeded on flat-bottom 96-well plates (Corning, New 
York, USA) and stimulated in triplicate for 24 hours with RPMI (negative con-
trol), 10 ng/ml lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO; from E. 
coli serotype 055:B5, further purified as previously described [24]) and 10 ug/
ml Pam3CysK4 (EMC microcollections, Tübingen, Germany; L2000).
Simultaneously, 5x105 PBMC’s were stimulated in triplicate for 7 days in RPMI 
(negative control), and 1x10^6/ml C. albicans conidia (UC820/In house) both 
with 10% human pool serum. After the incubation periods of 24 hours and 7 
days, supernatants were collected after plate centrifugation and stored at -80 C 
until cytokine assessment.
Cytokine measurements
Cytokine levels were measured in collected supernatants and in plasma with 
Enzyme Linked Immuno Sorbant Assay (ELISA) as described in the Supplemen-
tary materials.
Flow cytometry 
Monocyte subpopulations were identified with flow cytometry using the lysis-
no-wash strategy (BD Pharm Lyse lysing buffer, Becton Dickinson) with 100uL 
fresh EDTA blood. Cells were stained by monoclonal antibodies (CD16 FITC 
Leu11a Becton&Dickinson, CD14 ECD RM052 Beckman-Coulter, CD45 PC5 J.33 
Beckman-Coulter) and subsequently measured using FC500 flow cytometer 
(Beckman Coulter) and analysed with Kaluza software version 1.5a (Beckman 
Coulter). The full gating strategy is displayed in Figure 1. In short, monocytes 
were gated in SSC/CD45+ plot, identifying monocytes as CD45+ cells with mono-
cyte scatter properties. Exclusion of lymphocytes and natural killer cells was 
performed by excluding CD14/CD16 negative cells. Percentages of monocyte 
subsets (CD14++CD16−, CD14++CD16+, and CD14+CD16++) were identified in the 
CD14/CD16 plot. For determination of the gates setting the fluorescence minus 
one method was applied. Identification and characterisation of monocytes sub-
sets follows current recommendations of the European Society of Cardiology 
(ESC) Working Groups and the International guidelines of Immunology [25, 26].
Figure 1. Gating strategy of monocyte subsets. Flow cytometric gating strategy of monocyte sub-
populations: percentages of the CD14++CD16−, CD14++CD16+, and CD14+CD16++ monocyte subsets. 
FS= forward scatter, SS= site scatter, Lf= lymphocytes, Mo= monocytes, Gr= granulocytes.
MRI acquisition and evaluation of cSVD progression
Participants were scanned with the MRI protocol as described in the Supple-
mentary materials. Severity of cSVD was determined by the WMH volume (mL) 
in 2006 and 2015 while progression was the calculated difference (mL) between 
2015 - 2006 (∆WMH).
Statistical analysis
Data are presented as mean (standard deviation) for continuous variables, num-
ber (percentage) for categorical variables and median (IQR) for skewed distrib-
uted data. Spearman correlation (rs) was performed to correlate cSVD parame-
ters with inflammatory measurements. In addition, scatter diagrams with Loess 
regression curves were plotted to visualise the significant correlations found 
between baseline and ∆WMH with inflammatory parameters.
In the cSVD cohort (n=51), co-morbidities that could potentially act as a con-
founder were not uncommon (Table 1). Therefore, all analyses were also per-
formed after exclusion of 16 participants with one or more of the following: 
auto-immune diseases (n=4) (rheumatoid arthritis, ankylosing spondylitis, and 
Crohn’s disease), diabetes mellitus (n=5), or the daily use of immunomodulating 
drugs (n=13), including prednisolone, methotrexate, and NSAID’s or corticoste-
roids.
A two-sided p-value <0.05 was considered statistically significant. All data were 
analyzed using Prism version 5.0 (GraphPad software, La Jolla, California) or 
SPSS version 21.0 (SPSS Inc., Chicago, Illinois).
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Table 1. Baseline characteristics of cSVD cohort.
Demographics n = 51
Age, y (SD) 69.9 (6.3)
Sex, % male (n) 60.8 (31)
BMI (kg/m2) 25.88 (3.90)
SBP (mmHg) 142 (20)
DBP (mmHg) 82 (10)
CVD last year, % (n) 2.0 (1)
Hypertension, % (n) 82.4 (42)
Diabetes mellitus, % (n) 9.8 (5)
Smoking, % active (n) 7.8 (4)
Smoking in pack years 12 (16)
Statin use, % (n)* 46 (23)
Acetylsalicylic acid use, % (n) 41 (21)
Corticosteroids drug use, % (n)† 13.7 (7)
NSAID use, % (n) 11.8 (6)
Laboratory measurements
TChol, mmol/L 4.9 (1.2)
HDLc, mmol/L 1.5 (0.5)
TG, mmol/L 1.4 (0.6)
LDLc, mmol/L 2.9 (1.0)
nHDLc, mmol/L 3.5 (1.1)
Non-fasting glucose, mmol/L 6.2 (1.3)
WBC, 10^6/mL 6.1 (1.6)
Neutrophils, 10^6/mL 3.4 (1.2)
Lymphocytes, 10^6/mL 1.9 (0.7)
Monocytes, 10^6/mL 0.6 (0.2)
Monocytes, % 9.5 (2.5)
Eosinophils, 10^6/mL 0.2 (0.2)
Basophils, 10^6/mL 0.04 (0.02)
Neuroimaging characteristics
WMH volume 2006, ml 5.24 (9.43)
WMH volume 2015, ml 10.30 (13.87)
∆WMH 2015-2006, ml 5.06 (6.42)
Data are reported as mean with SD, and percentages with number of participants. * Information 
is missing for 1 participant. † including inhalation corticosteroids (n=4). BMI: body mass index, 
SPB: systolic blood pressure, DPB: diastolic blood pressure, CVD: cardiovascular disease defined 




Fifty-one elderly subjects (70 ±6 years, 60% men) were included (Table 1). The 
mean increase in WMH was 5.06 ±6.42 mL over nine years. Within the cohort, 
age and sex were evenly distributed across the spectrum of WMH progression 
(supplementary Figure II).
Cytokine production capacity of monocytes and PBMC’s
The cytokine production capacity was assessed in monocytes after 24 hours, 
and in PBMC’s after 7 days of ex vivo stimulation. As shown in Figure 2A, the 
basal IL-8 production by monocytes and IL-17 production by PBMC’s was associ-
ated with cSVD progression (∆WMH for IL-8: p=0.08, rs=0.245; for IL-17: p=0.03, 
rs=0.298). In addition, IFNγ production following C. albicans stimulation in PB-
MC’s was negatively associated with WMH at baseline in 2006 and 2015, and 
∆WMH (p=0.009 rs= -0.362, p=0.02 rs= -0.339, p<0.05 rs= -0.276). In Figure 2B-C 
the non-linear correlation for IFNγ is shown.
In addition, a significant correlation of IL-6 production by monocytes after 
Pam3CysK4 stimulation with WMH volume in 2006 and 2015, and ∆WMH, re-
spectively, was observed in the subgroup of participants without inflammatory 
conditions or immunomodulatory drug use, as described above (n=35; p=0.01, 
rs=0.431; p=0.008, rs=0.439; p=0.01 rs=0.423, respectively).
Circulating inflammatory markers
Circulating high sensitivity IL-6 (hsIL-6) strongly correlated with WMH at base-
line in 2006 and 2015, and with ∆WMH (p=0.005, rs=0.399; p=0.01, rs= 0.363 
resp. p=0.04 rs=0.294) (Figure 3A-C). In the subgroup of subjects free from in-
flammatory diseases and immunomodulatory drugs, hsIL-6 remained signifi-
cantly correlated with baseline WMH in 2006 and 2015 (p=0.009, rs=0.443; 
p<0.05, rs= 0.340).
Circulating monocyte subsets
Flow cytometry analyses revealed that the percentage of CD14++CD16+ inter-
mediate monocytes was significantly associated with both WMH in 2006 and 
2015, and with ∆WMH (p=0.01, rs=0.362; p=0.02, rs=0.338; p=0.02 rs=0.324) 
(Figure 4A). The visual presentation of the percentage intermediate monocytes 
plotted against WMH reveals a linear Loess curve (Figure 4B-C). The correla-
tion between the percentage of intermediate monocytes and WMH remained 
significant in the subgroup of 35 subjects without inflammatory diseases or im-
munomodulatory drug use (WMH 2006: p=0.05, rs=0.339; WMH 2015: p=0.09, 
rs=0.291).
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Discussion
Our study provides the first evidence that trained immunity characteristics of 
circulating monocytes are associated with the severity and progression of cSVD. 
This suggests an important role for the innate immune system not only in ath-
erosclerotic cardiovascular disease, as was previously reported, but also in the 
pathophysiology of cSVD. Flow cytometry analyses identified a shift towards the 
intermediate monocyte subset in patients with rapid cSVD progression, suggest-
ing reprogramming of myelopoiesis at the level of the bone marrow. In addition, 
functional reprogramming of the monocytes occurs, illustrated by the associ-
ation between cytokine production capacity and cSVD progression. Although 
these immunological markers only explain part of the variance in cSVD progres-
sion, this effect is substantial compared to the explained variance of <2% that 
has previously been observed for classical cardiovascular risk factors [27]. These 
findings add an important novel component to the complex pathophysiology 
of cSVD which might yield novel biomarkers for individual risk prediction, and 
might offer novel potential targets for pharmacotherapy.
We focussed on the role of the innate immune system in the progression of 
cSVD for two reasons. First, circulating markers of inflammation have recently 
been associated with cSVD, including IL-6, C-reactive protein (CRP), and neop-
terin, which activates monocytes and macrophages [28-31]. Second, the fact 
that cSVD shares risk factors (hypertension, smoking, diabetes) with atheroscle-
rosis suggests common pathophysiological mechanisms. In the pathogenesis of 
atherosclerosis, monocyte-derived macrophages play a decisive role [14]. 
Although the innate immune system is traditionally regarded as incapable of 
building an immunological memory, we and others have recently reported that 
long-lasting functional reprogramming of monocytes and macrophages can oc-
cur after brief stimulation with a wide variety of stimuli, which has been termed 
trained immunity [15]. Interestingly, brief exposure of human monocytes to 
micro-organisms as well as to endogenous atherogenic substances, such as ox-
idized lipoproteins, induces the development of a persistent pro-inflammatory 
macrophage phenotype [16]. This transition is mediated by profound metabolic 
and epigenetic reprogramming [32]. The long-lasting effect of trained immunity 
is explained by the fact that training occurs at the level of hematopoietic stem 
and progenitor cells in the bone marrow [18]. 
Importantly, the trained immunity hypothesis was recently explored in the 
microglia of the brain. In this study, cytokine production in tissue-resident mi-
croglia was assessed after a repeated peripheral immune challenge with LPS 
[33]. Repeated stimulation with LPS induced a persistently elevated cytokine 
production by microglia, driving disease progression in an Alzheimer’s mouse 
model and modifying pathological features after stroke. This strongly suggests 
that peripheral stimuli can induce long-term changes in the immune function of 
microglia by crossing the blood-brain barrier. 
Based on these recent studies, we hypothesized that circulating monocytes con-
tribute to the progression of cSVD via trained immunity. Therefore, in this study, 
we set out to detailed functional characterization of circulating monocytes in a 
cohort of patients with cSVD, in whom disease progression was well-character-
ized by repeated MRI scans.
First, we measured a set of circulating inflammatory mediators to validate that 
cSVD progression is associated with systemic inflammation. Circulating hsIL-6 
showed a highly significant correlation with cSVD severity in 2006, and the nine-
year progression rate, which is in accordance with multiple previous epidemio-
logical studies [34-38]. However, with regard to progression of the disease, the 
available evidence is less consistent. Although a longitudinal study with 4 years 
follow-up did not find a correlation between baseline circulating IL-6 and CRP 
and WMH progression [35], the Rotterdam Scan Study found that the progres-
sion of periventricular WMH was greater among subjects with high CRP levels 
compared to subjects with low CRP levels [29]. It is important to note that, com-
pared with the previous studies, we used a high sensitive IL-6 assay in our study 
and the follow-up of WMH progression was nine years. 
The main novelty of our study lies in the extensive phenotyping of circulating 
monocytes. We explored the cytokine production capacity of PBMC’s and mono-
cytes after ex vivo stimulation, which is a major hallmark of a trained immunity 
phenotype. We observed significant correlations between cytokine production 
capacity and cSVD progression; the enhanced IL-6 production after Pam3CysK4 
stimulation by monocytes in the subgroup of patients without inflammatory 
diseases or immunomodulating drugs, points towards a trained immunity phe-
notype in patients with severe cSVD progression. In addition, basal IL-8 pro-
duction by monocytes was correlated with cSVD progression. Interleukin-8 is 
a pro-inflammatory chemokine with a well established role in atherogenesis, 
and enhanced levels are found in patients with coronary artery disease [39]. In-
terestingly, we also observed a significant correlation between ex vivo baseline 
PBMC IL-17 production and cSVD progression. IL-17 is produced by the T help-
er (Th)-17 subset of CD4+ T lymphocytes, and it is suggested that IL-17 might 
contribute to atherosclerosis development [40]. Finally, we observed a negative 
correlation between IFNγ production after stimulation with Candida in PBMC’s 
and cSVD extent and progression. The role of IFNγ (produced by CD4+ T lym-
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phocytes) in atherosclerosis is complex. Although most studies point towards 
a pro-atherogenic role of IFNγ [41], IFNγ also has immunomodulatory effects, 
especially the inhibition of IL-1β production [42]. In conclusion, we showed that 
functional reprogramming of circulating monocytes in terms of cytokine pro-
duction capacity is associated with progression of cSVD.
In addition, we characterized the circulating monocyte subsets using flow cy-
tometry. Monocytes are heterogeneous and can be subdivided into three 
subsets: the classical CD14++CD16− monocytes, the intermediate CD14++CD16+ 
monocytes, and the non-classical CD14+CD16++ monocytes. The intermediate 
CD14++CD16+ monocyte subset appears to be of particular importance for ath-
erosclerotic cardiovascular diseases. The role of monocyte subsets in cSVD has 
never been explored. In atherosclerosis, the intermediate monocyte subset is 
strongly associated with unstable plaque characteristics [43] and with the oc-
currence of future cardiovascular events [25, 44, 45]. We observed a significant 
correlation between the percentage of CD14++CD16+ intermediate monocytes 
and WMH volume in 2006, 2015 and WMH progression. Intermediate mono-
cytes are the most pro-inflammatory subset as they have higher expression of 
various inflammatory receptors, a higher phagocytic capacity, and an enhanced 
cytokine production in response to LPS stimulation than the other monocyte 
subpopulations [46-49].
Our study is the first to suggest involvement of the innate immune system in the 
development and progression of cSVD. The study design has several strengths 
that support the significance of our findings. First, the cSVD cohort is unique be-
cause of its long follow-up time with MR imaging in 2006 and 2015. In addition, 
the extensive clinical characterisation of the patients allowed excluding patients 
with chronic inflammatory conditions or the use of immunomodulating drugs, 
after which all associations remained significant. From this we can conclude that 
the effects of the innate immune system are independent from these co-mor-
bidities, including diabetes mellitus. Secondly, we used state-of-the art immu-
nological techniques to investigate innate immune function, including flow cy-
tometric characterisation of monocyte subsets according to current guidelines, 
and assessment of cytokine production capacity after a broad range of stimuli 
in highly purified monocytes that were isolated with negative bead selection. 
The major limitation of our study is that the cross-sectional study design does 
not allow to draw conclusions regarding causality. In line with this, we did not 
have a control group of subjects in whom cSVD was excluded, which narrows 
our conclusion to the role of the immune system in cSVD progression. It is im-
portant to emphasize however, that the lack of this control group does not in-
validate in any way the findings we describe for the patients with cSVD: our 
observation that several characteristics of the innate immune cells are asso-
ciated with progression of cSVD is still valid, novel, and exciting. In addition, 
both our outcome (cSVD) and the determinants showed a distribution from the 
lower to the higher range allowing for the establishment of a dose-response re-
lation, which is one of the causality criteria as formulated by Bradford-Hill [50]. 
A second limitation is the relatively small sample size. Therefore, future studies 
should examine the inflammatory characteristics of immune cells in a prospec-
tive design in a larger cohort of patients, preferable without cSVD at baseline, 
to confirm our findings.
To conclude, elucidation of the pathophysiology of cSVD, as a leading cause of 
dementia and ischemic stroke, is critical for the identification of novel pharma-
cological targets that can prevent or halt this devastating disease. Our prospec-
tive cohort study is the first to combine nine-year follow-up imaging data with 
detailed characterisation of innate immune cell function. We found that the 
progression of cSVD is correlated with various characteristics of trained immu-
nity in circulating monocytes. This is the first study that shows a potential role 
for trained immunity in the pathophysiology of cSVD, indicating that pro-inflam-
matory monocytes either drive or become activated during the initiation and 
progression of cSVD.
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Cytokine levels were measured in collected supernatants and in plasma with Enzyme Linked Im-
muno Sorbant Assay (ELISA). The following biomarkers were assessed in plasma: high sensitivity 
C-reactive protein (hsCRP) (detection limit 0.8ng/mL), high sensitivity IL-6 (hsIL-6) (R&D quan-
tikine) (detection limit 0.2pg/mL), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and 
matrix metalloproteinase-2 (MMP-2) (R&D duoset). Cytokine production capacity was measured 
for tumor necrosis factor alpha (TNFα), interleukin-1β (IL-1β), IL-6 (R&D), IL-8, IL-10 (Sanquin) for 
24 hour stimulation of monocytes, and interferon-γ (IFNγ) (Sanquin), IL-17 and IL-22 (R&D) after 
7 day stimulation of PBMC’s. For detailed materials see supplementary Table I.
MRI acquisition and evaluation of cSVD progression
Participants were scanned on a 1.5-Tesla Siemens Magnetom Sonata in 2006, and a 1.5-Tesla 
Siemens Magnetom Avanto (Erlangen, Germany) in 2015. The MRI protocol has been described 
in detail previously [23]. In short, to detect markers of cSVD we applied 3D T1 magnetization pre-
pared rapid gradient echo (MPRAGE) (voxel size 1.0x1.2x1.0mm), and fluid-attenuated inversion 
recovery (FLAIR) sequence (2006: voxel size 1.0x1.2x6.0mm, slice-gap 1.0mm; 2015: voxel size 
1.2x1.0x2.5mm, interslice gap 0.5mm). Markers of cSVD were evaluated according to Standards 
for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria [6]. WMH volume in mL was 
estimated by a semi-automatic segmentation method [51] and afterwards visually checked for 
segmentation errors. Volumes were corrected for interscan differences and normalized to base-
line intracranial volumes in 2006 (ICV). Severity of cSVD was determined by the WMH volume 
(mL) in 2006 and 2015 while progression was the calculated difference (mL) between 2015 - 2006 
(∆WMH).
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Supplemental Table
Table I. Products details of cytokines and chemokines measured with ELISA.
Item Manufacturer Category number
24 hour stimulation Human TNFα duoset R&D DY210
Human IL-1β duoset R&D DY201
Human IL-6 duoset R&D DY206
Human Pelipair IL-8 Sanquin M9318 
Human Pelipair IL-10 Sanquin M9310
7 day stimulation Human Pelipair IFN γ Sanquin M9333
Human IL-17 duoset R&D DY317 
Human IL-22 duoset R&D DY782 
Plasma Human hs-CRP quantikine R&D DCRP00
Human hs-IL-6 quantikine R&D HS600C
Human VCAM-1 duoset R&D DY809
Human E-selectin duoset R&D DY724
Human MMP-2 duoset R&D DY902
Figure II. Distribution of sex and age within the cohort. Age and sex were evenly distributed across 
the spectrum of WMH progression. The log linear correlation of WMH 2006 with 2015 shows an 
even distribution of sex, which is represented by the colour of the circles (dark grey: male, light 
grey: female), and age, depicted by the size of the circles (see legend) of each individual within 
the cohort. Box plots with interquartile range on each side indicate the distribution of the indi-
viduals within the cohort.
Supplemental Figures and Figure Legends
Figure I. Evaluation of cell composition. Purity and cell composition of PBMC’s after Ficoll isolation 
(panel A) and monocytes selected with MACS negative bead selection (panel B) were evaluated 
by flow cytometry. Representative flow cytometry scatter plots are shown.
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The aetiology of cerebral small vessel disease (SVD) remains elusive, 
though evidence is accumulating that inflammation contributes to its 
pathophysiology. We recently showed retrospectively that pro-inflamma-
tory monocytes are associated with the long-term progression of white 
matter hyperintensities (WMH). In this prospective high-frequency imag-
ing study, we hypothesize that the incidence of SVD progression coincides 
with a pro-inflammatory monocyte phenotype.
Methods
Individuals with SVD underwent monthly magnetic resonance imaging 
(MRI) for 10 consecutive months to detect SVD progression, defined as 
acute diffusion-weighted imaging positive (DWI+) lesions, incident mi-
crobleeds, incident lacunes, and WMH progression. Circulating inflamma-
tory markers were measured, cytokine production capacity of monocytes 
was assessed after ex vivo stimulation, and RNAsequencing was performed 
on isolated monocytes in a subset of participants.
Results
13 out of 35 individuals developed SVD progression (70±6 years, 54% 
men), based on incident lesions (n=7) and/or upper quartile WMH progres-
sion (n=9). Circulating E-selectin concentration (p<0.05) and the cytokine 
production capacity of IL-1β and IL-6 (p<0.01) was higher in individuals 
with SVD progression. Moreover, RNAsequencing revealed a pro-inflam-
matory monocyte signature including genes involved in myelination, 
blood-brain-barrier and endothelial-leukocyte interaction.
Conclusions
Circulating monocytes of individuals with progressive SVD have an inflam-
matory phenotype, characterised by the increased cytokine production 
capacity and a pro-inflammatory transcriptional signature.
Introduction
Cerebral small vessel disease (SVD) is a common condition in elderly individuals 
and is the most important vascular contributor to dementia, lacunar infarcts, 
Parkinsonism, and ultimately loss of independence (1-3). SVD affects the struc-
ture and function of the smallest cerebral blood vessels, including the arteri-
oles, capillaries, and venules of the brain, resulting in brain parenchymal tissue 
changes (4). Tissue alterations thought to arise from SVD are mainly detected 
with magnetic resonance imaging (MRI), and include diffusion-weighted imag-
ing positive (DWI+) lesions suggestive of acute (micro)infarcts, microbleeds, la-
cunes and white matter hyperintensities (WMH), amongst others (5). Imaging 
of small cerebral vessels is difficult and the inability to visualize the initiation of 
arteriolar pathology, has arguably contributed to the fact that the etiology of 
SVD has remained elusive. In the past few years, evidence is compiling on the 
role of inflammation in SVD pathophysiology.
Inflammation is increasingly acknowledged as a risk factor SVD (6). Meta-anal-
yses reported elevated circulating markers of inflammation, e.g. interleukin 6 
(IL-6) and C-reactive protein (CRP), and markers of endothelial dysfunction, e.g. 
E-selectin, in individuals with SVD (7-9). In addition, longitudinal studies demon-
strated that systemic inflammatory markers at baseline predicted subsequent 
SVD severity (10, 11). Inflammation and endothelial dysfunction contribute to 
chronic disruption of the blood-brain barrier, which is thought to aggravate SVD 
(12, 13). Blood-brain barrier disruption enhances leakage of signaling mediators 
and facilitates the communication between circulating and tissue-resident im-
mune cells.
Circulating innate immune cells, capable to produce circulating inflammatory 
markers, might have a significant influence on the development of SVD. We 
recently showed in a retrospective analysis that a pro-inflammatory pheno-
type of circulating monocytes was associated with the progression and severity 
of SVD (14). In detail, the cytokine production capacity of monocytes strong-
ly correlated with the progression of WMH over a nine-year course (14). The 
systemic inflammation marker interleukin-6 (hsIL-6) and the pro-inflammatory 
(CD14++CD16+) intermediate monocyte subset correlated with the WMH pro-
gression rate in individuals with SVD. However, the retrospective approach of 
this study precludes the assessment of a direct relation between pro-inflamma-
tory monocytes and inflammatory markers with the development of SVD. 
In this study, we aimed to further elucidate the role for innate immune acti-
vation in SVD by investigating whether the occurrence of SVD progression is 
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linked to the circulating monocyte phenotype. Therefore, high-frequency serial 
imaging with MRI was performed monthly for 10 consecutive months to detect 
multiple imaging markers of SVD, including the incidence of acute (micro)in-
farcts (defined as DWI+ lesions), microbleeds, lacunes, and WMH. In addition, 
we aimed to provide a deeper understanding of the inflammatory phenotype 
of circulating monocytes by performing RNA sequencing of monocytes from in-
dividuals with SVD progression compared to individuals without signs of SVD 
progression. 
Methods
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request.
Study design and participants
Individuals were enrolled in the RUN DMC – InTENse study (Radboud University 
Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort – Investi-
gating The origin and EvolutioN of cerebral small vessel disease), a longitudinal 
observational study, comprising a pre-visit, 10 MRI visits over a period of 10 
months, and a follow-up visit one year after the pre-visit (15).
The major inclusion criterion was progression of WMH between 2006 and 2015 
as demonstrated on MRI collected within the previous RUN DMC study (16). To 
rule out causes of cerebral ischemia other than SVD, exclusion criteria for the 
RUN DMC – InTENse study were presence of large artery disease defined as 
carotid artery stenosis (>50% assessed by carotid ultrasound), atrial fibrillation 
or the use of oral anticoagulants, previous cortical ischemic stroke or transient 
ischemic attack, intracranial hemorrhage (other than a microbleed) and large 
artery vasculitis. Participants with dementia or Parkinson’s disease (according 
to DSM-IV criteria) were also excluded from participation. Furthermore, in the 
current study we excluded participants with auto-immune/inflammatory dis-
eases including diabetes mellitus, or daily immunomodulatory drug use, be-
cause these conditions interfere with the immune response. All individuals gave 
written informed consent. The study protocol was approved by the Institutional 
Review Board Arnhem/Nijmegen, the Netherlands (NL53939.091.15).
MRI acquisition and incident SVD lesion detection
A detailed description of the MRI protocol and image analysis was recent-
ly published (17, 18). Briefly, individuals were scanned using a single 3 T MRI 
system (MAGNETOM Prisma, Siemens Healthineers, Erlangen, Germany) and a 
32-channel head coil. To detect DWI+ lesions we obtained multi-shell DWI scans 
(90 diffusion-weighted directions including 30×b=1000, and 60×b=3000 s/mm2, 
10 b=0 images, and voxel size 1.7×1.7×1.7 mm). Trace images were created for 
the b=1000 and b=3000 shells and a mean diffusivity map was calculated for the 
b=1000 shell. We acquired 3D multi-echo fast low angle shot images (6 echoes, 
voxel size 0.8×0.8×2.0 mm), which were used to create susceptibility-weight-
ed images to identify cerebral microbleeds. Finally, to assess WMH and la-
cunes we acquired 3D fluid-attenuated inversion recovery images (voxel size 
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0.85×0.85×0.85 mm) and 3D T1-weighted images (voxel size 0.85×0.85×0.85 
mm).
Incident SVD lesion detection
Detection of SVD imaging markers was done according to previously established 
criteria (5). Briefly, DWI+ lesions were manually detected and defined as hyper-
intense lesions on diffusion-weighted trace images (both b=1000 and b=3000), 
accompanied by a hypointense or isointense signal on the mean diffusivity map. 
Microbleeds were detected semi-automatically as hypointense lesions on the 
FLASH images. Incident lacunes (including cavities <3 mm) were manually de-
tected using difference FLAIR and T1-weighted images, generated by subtracting 
registered baseline FLAIR and T1 scans from the last available follow-up scans. 
WMH were automatically segmented based on a deep-learning algorithm uti-
lizing FLAIR and registered T1-weighted images as input images. For each case, 
the WMH volumes extracted from the monthly scans were corrected for white 
matter volume extracted from the corresponding visit. Next, in a simple linear 
regression model on WMH volume over time we calculated the predicted indi-
vidual WMH volume at each time point and progression of WMH (i.e. the slope 
of the regression model).
Individuals with any incident lesion during the study period (DWI+ lesion, mi-
crobleed or lacune) and individuals belonging to the first quartile of WMH pro-
gression were classified as participants with SVD progression.
Cardiovascular risk assessment
At study inclusion, medical history, medication use, and cardiovascular risk as-
sessment, including measurement of the blood pressure three times (according 
to AHA guidelines (19)), smoking status, body mass index (BMI), and capillary 
non-fasting glucose was obtained.
Blood sampling
Parallel to the third MRI appointment (median of 16 [12-23] weeks after pre-vis-
it) overnight fasted blood was obtained in EDTA vacutainers, between August 
2016 and February 2017. Plasma and serum were stored in -80°C. Total choles-
terol (Tchol), high density lipoprotein cholesterol (HDL-C), and triglycerides (TG) 
were measured using standardized methods. Low density lipoprotein cholester-
ol (LDL-C) was calculated with the Friedewald formula. Total blood counts were 
measured with an automated cell counter using Sysmex-XN 450 hematology 
analyzer (Sysmex, Hamburg, Germany).
Monocyte isolation and stimulation
Monocytes were isolated using Ficoll-Paque density gradient centrifugation (GE 
Healthcare, Chicago, USA) followed by magnetic activated cell sorting using the 
Pan Monocyte Isolation kit according to manufacturer’s instructions (Miltenyi 
Biotec, Bergisch Gladbach, Germany). Cell purity of the monocyte fraction (me-
dian 92[88-95] percent monocytes-of-leukocytes) was evaluated with flow cy-
tometry. Monocytes were concentrated in RPMI 1640 Dutch-modified culture 
medium (Life Technologies/Invitrogen, Waltham, USA) supplemented with 2 
mmol/L glutamine (Invitrogen), 10 mg/mL gentamicin (Centrafarm, Etten-Leur, 
The Netherlands) and 1 mmol/L pyruvate (Invitrogen). 1x105 monocytes were 
seeded on flat-bottom 96-well plates (Corning, New York, USA) and stimulated 
in triplicate for 24 hours with RPMI (control), toll-like receptor 4 agonist lipo-
polysaccharide (LPS) from E. coli (10 ng/mL, serotype 055:B5, Sigma-Aldrich, St. 
Louis, USA), and toll-like receptor 2 agonist Pam3CysK4 (P3C) (10 µg/mL, L2000, 
EMC microcollections, Tübingen, Germany). Supernatants were collected after 
plate centrifugation and stored in -80°C freezer until cytokine assessment.
Cytokine assessment
Cytokine and chemokine concentrations were measured in plasma and in su-
pernatants after stimulation with Enzyme Linked Immuno Sorbant Assay (Table 
I).
Flow cytometry 
Monocyte subpopulations, consisting of CD14++CD16- classical monocytes, 
CD14++CD16+ intermediate monocytes, and CD14+CD16+ non-classical mono-
cytes, were identified with the FC500 flow cytometry (Beckman Coulter, Brea, 
USA) using the lysis-no-wash strategy (BD Pharm Lyse lysing buffer, Becton Dick-
inson) with 100uL fresh EDTA blood. Cells were stained by monoclonal antibod-
ies (CD16 FITC Leu11a Becton&Dickinson, CD14 ECD RM052 Beckman-Coulter, 
CD45 PC5 J.33 Beckman-Coulter) and subsequently analysed with Kaluza soft-
ware version 1.5a (Beckman Coulter).
The full gating strategy is displayed in Figure I. In short, monocytes were gated 
in SSC/CD45+ plot, identifying monocytes as CD45+ cells with monocyte scat-
ter properties. Exclusion of lymphocytes and natural killer cells was performed 
by excluding CD14/CD16 negative cells. Percentages of monocyte subsets 
(CD14++CD16−, CD14++CD16+, and CD14+CD16++) were identified in the CD14/
CD16 plot. For determination of the gates setting the fluorescence minus one 
method was applied. Identification of monocytes subsets follows current inter-
national recommendations (20, 21).
RNA isolation and Quantseq 3’mRNA sequencing
RNA sequencing was completed for 4 participants with SVD progression (com-
prising of DWI+ lesions (n=4) of which 2 with microbleeds) and 4 matched con-
trol participants (Table 3). Of the individuals with SVD progression, all subjects 
with DWI+ lesions and monocyte purity >90% were selected to create a ho-
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mogenous subgroup. Participants with SVD progression were matched to those 
without SVD progression based on age, hypertension and BMI. 
Monocytes, with >90% purity in the isolated fraction, were stored in RNApro-
tect (Qiagen, Venlo, The Netherlands) before processing for RNA sequencing 
using a standard RNA isolation protocol. In short, per 1 mL of RNAprotect 200 
µL of chloroform was added, mixed, incubated at room temperature for 5 min 
and spun down for 15 min at 12000 g at 4°C. The upper aqueous phase was 
transferred to an RNA-se free Eppendorf tube, and an equal volume of 70% 
ethanol was added. After thorough mixing the sample was loaded unto RNeasy 
mini columns (Qiagen), after which the manufacturers protocol was followed. 
After the last manufacturer’s step, 15 µL of RNase free water was added to 
the columns, incubated for 5 min, and spun down. The RNA concentration was 
determined using the Qubit RNA HS assay (Qiagen), and the quality using Nan-
odrop technology. 
Library preparation was performed using the QuantSeq 3’ mRNA-Seq Library 
Prep Kit-FWD from Lexogen (Cat#015.96, Lexogen) according to the manufac-
turer’s protocol. RNA input for all samples was normalized to 200 ng. All sam-
ples were processed in a single library preparation. The optimal cycle number 
for the endpoint PCR was determined on a 1:10 aliquot of the double stranded 
cDNA libraries. Subsequent quality assessment, i.e. measuring the cDNA con-
centration using the Qubit dsDNA HS assay (Cat#Q32854, Thermo Fisher Sci-
entific) and the average fragment size with the Agilent 2200 TapeStation (HS-
D1000 ScreenTape, Cat#5067-5582, Agilent), enabled the determination of the 
molar concentration of individual libraries. Equimolar pooling of the libraries 
was set to 100 fmol, and after final dilution to 4 nM, libraries were sequenced 
on a NextSeq 500 instrument (Illumina, 1.4 pM loading concentration).
Bioinformatics, differential gene expression and pathway analysis
Low quality filtering and adapter trimming was performed using Trim Galore!, 
V0.4.5 (Babraham Bioinformatics), a wrapper tool around the tools Cutadapt 
v1.18 and FastQC v0.11.5 (Babraham Bioinformatics). Reads were mapped to a 
human reference genome (GRCh38.95, Ensembl) with Star v2.6.0a (22) result-
ing in BAM files. BAM files were counted (number of reads mapped to a fea-
ture, e.g. a gene) with HTSeq (HTSeq-count tool v0.11.0 (23)) with default pa-
rameters using a complementary .gtf file, containing annotation for GRCh38.95 
(Ensembl). MultiQC (quality control) was used to combine results and quality 
checks of all the samples (24). Total reads were between 8-11 million, of which 
6-8.5 million were uniquely assigned reads, mean aligned reads was 80%. 
Differential gene expression analysis was carried out with DESeq2 v1.22.0 in R 
v3.5.3 (25), with internal statistical and normalization method (i.e. correction 
for multiple testing with Benjamini–Hochberg) using a cut-off value of at least 
5 counts (RPKM) per sample per gene. The average mRNA expression between 
two groups was analyzed: participants with incident DWI+ lesions were matched 
to controls without SVD progression while correcting for sex. Pathway analysis 
was performed with Reactome v.75 (26) selecting differentially regulated genes 
with an unadjusted P-value <0.05 as input. A P-adjusted value <0.05 with log2 
fold change of >±2 was considered significant. For pathway analysis, a false dis-
covery rate (FDR) corrected P-value <0.05 was considered significant.
The data discussed in this publication have been deposited in NCBI’s Gene Ex-
pression Omnibus (27) and are accessible through GEO Series accession num-
ber GSE162790 (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162790).
Statistics
Normal distribution of the data was checked with the Shapiro-Wilk test. When 
the P-value reached <0.05 this assumption was violated, and non-parametric 
tests were used. In normal distributed data, the P-value of the independent 
samples T-test was used according to Levene’s test for equality of variances. 
Normally distributed data are reported as mean ± SD and tested with indepen-
dent samples T-test, categorical data are reported as mean with (number of 
participants) and tested with Χ2 test, and not normally distributed data are re-
ported as median with interquartile ranges [IQR] and tested with Mann-Whit-
ney U test. 
Individuals with SVD progression were compared to subjects without incident le-
sions or WMH progression. In a separate analysis, subjects with incident lesions 
were compared to subjects without SVD progression. Circulating cell counts, 
inflammatory markers, and cytokine production capacity were log(10)-trans-
formed and thereafter corrected with analysis of covariance (ANCOVA) for con-
founding demographics such as age, sex and hypertension. A two-sided P-value 
below 0.05 was considered statistically significant.




Thirty-five participants met the in- and exclusion criteria for this study (70±6 
years, 54% men, median follow-up time 39.3[37.8-40.1] weeks) (see flow di-
agram Figure 1). Over 10 months, the median WMH progression was 0.023 
[0.002-0.078] mL per month (n=35). In total, 13/35 individuals had SVD progres-
sion, based on either incident lesions (n=7) and/or the upper quartile of WMH 
progression (n=9). Out of the seven individuals that developed incident lesions, 
five individuals had a total of thirteen incident DWI+ lesions, three individuals 
had six incident microbleeds, and two individuals had five incident lacunes or 
small incident cavities. Two individuals had both DWI+ lesions and microbleeds 
and/or lacunes. Twenty-two individuals revealed no incident lesions nor WMH 
progression in the highest quartile during 10-months of imaging follow-up (Fig-
ure 1).
Figure 1. Flow diagram of included participants of the RUN DMC – InTENse cohort. Drop-out indi-
cates premature stop before blood sampling, DM2: diabetes mellitus type 2, AID: auto-immune 
diseases, drug use: chronic immunomodulatory drug use, 4Q WMH: highest quartile of WMH.
Individuals with SVD progression were older (p<0.01), had a higher systolic 
(p<0.01) as well as diastolic blood pressure (p<0.05) compared to participants 
without SVD progression (Table 1). Similar results were obtained when analyses 
were restricted to participants with incident lesions. Therefore, all outcomes 
were corrected for the demographics age, hypertension and sex, which are 
known modulators of the immune function (28).
Higher circulating E-selectin in participants with SVD progression
Circulating E-selectin, a marker for endothelial dysfunction, was higher in par-
ticipants with SVD progression (p<0.05) (Table 2). Similar results were found 
when analyses were limited to participants with incident lesions. Cell counts in 
peripheral blood and monocyte subsets were comparable in participants with 
SVD progression to those without progression (Table 2).
Increased cytokine production capacity in participants with SVD progression
The cytokine production capacity of isolated monocytes was significantly higher 
for IL-1β and IL-6 in individuals with SVD progression and was highly consistent 
for all incident lesions (Figure 2A-B). Individuals with SVD progression had high-
Table 1. Participant characteristics
Demographics Without SVD 
progression
SVD progression Incident lesions
Age, years 68±4 73±7** 77±7**
Sex, % men 50 (11) 62 (8) 71 (5)
BMI, kg/m2 25.0±3.7 26.3±4.2 28.6±3.9*
SBP, mmHg 136±15 155±23** 162±23**
DBP, mmHg 79±9 86±8* 89±10*
Hypertension, % 82 (18) 92 (12) 100 (7)
Smoking, % active 5 (1) 8 (1) 0 (0)
Smoking, #packyears 7.8±10.8 11.1±14.9 15.4±17.9
Statin use, % 41 (9) 46 (6) 43 (3)
Acetylsalicylic acid use, % 32 (7) 62 (8) 71 (5)
Tchol, mmol/L 5.1±1.1 4.9±1.3 4.8±1.6
HDL-C, mmol/L 1.6±0.6 1.4±0.4 1.1±0.2*
LDL-C, mmol/L 2.9±1.0 2.9±1.2 3.1±1.4
TG, mmol/L 1.4±0.7 1.2±0.4 1.3±0.3
nHDL-C, mmol/L 3.6±1.0 3.5±1.3 3.7±1.5
Non-fasting glucose, mmol/L 6.2±1.4 6.0±0.8 6.1±0.9
Baseline WMH, mL







WMH progression, mL/month 0.02[0.00-0.04] 0.11[0.01-0.20]* 0.01[-0.04-0.20]
WMH progression, ‰o of WM 0.13 [0.03-0.27] 0.62 [0.07-1.12]* 0.13 [-0.33-1.01]
Participants without SVD progression (n=22), SVD progression (n=13), Incident lesions (n=7). 
Mean±SD, mean(number), and median[IQR]. * indicates p<0.05, **:p<0.01. SBP:systolic blood 
pressure, DBP:diastolic blood pressure, WM:white matter.
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er IL-6 production after P3C stimulation compared to participants without SVD 
progression (median 11.4[9.53-15.7] versus 8.59[7.61-11.4] ng/mL, p<0.01) 
(Figure 2A). Likewise, in participants with incident lesions, IL-6 production af-
ter P3C stimulation was higher (15.2[10.4-18.3] versus 8.59[7.61-11.4] ng/mL, 
p=0.001) (Figure 2B). In addition, IL-1β production after LPS stimulation was 
higher in participants with incident lesions (7.76[5.75-8.23] versus 6.02[3.35-
7.66] ng/mL, p<0.01). Of note, in participants with DWI+ lesions and partici-
pants with microbleeds similar results were obtained. No differences were ob-
served in production of the anti-inflammatory cytokine IL-10. 
Monocyte transcriptome analysis
In a subset of participants with SVD progression due to incident DWI+ lesions 
(n=4) and matched participants without SVD progression (n=4), we performed 
monocyte transcriptome analyses. The demographic and clinical characteris-
tics of the two subgroups were comparable, except for sex (Table 3). Since the 
PCA plot also revealed sex-based clustering (Figure II), we controlled for sex in 
further differential gene expression analysis. This revealed a pro-inflammatory 
gene expression profile in participants with SVD progression due to incident 
DWI+ lesions. 
In the differential gene expression analysis, the two groups were compared in 
an explorative way using genes with a log Fold Change>±2 and a liberate cut 
off P-adjusted<0.25. In this preliminary analysis, 4 genes were differentially up-
regulated and 3 differentially downregulated (Figure 3A, Volcano plot): FABP4, 
SPP1, EGR2, FN1 were upregulated and ISG15, MX1, PTGES were downregu-
lated. For a more detailed overview of the individual expression levels of the 
upregulated and downregulated genes with a P-adj<0.25, we constructed heat-
maps (Figure 3B and 3C).
Subsequently, we performed pathway analysis using all differentially regulated 
genes with an unadjusted p-value <0.05 as input (Table II). This revealed enrich-
ment of several inflammation-related pathways and neuronal development and 
Figure 2A-B. Cytokine production capacity. Cytokine response of participants without SVD pro-
gression (white, n=22), (A) participants with SVD progression (grey, n=13) and (B) incident lesions 
(grey, n=7) are reported log-transformed with mean±SD. p-values are corrected for age, sex and 
hypertension with ANCOVA. **:p<0.01, ***:p=0.001.
Table 2. Circulating cells and inflammatory markers
Circulating cells/markers Without SVD 
progression
SVD progression Incident lesions
WBC, 10^6/mL 5.2[4.7-6.7] 6.2[5.1-7.3] 7.0[4.8-7.7]
Neutrophils, 10^6/mL 2.9[2.3-3.6] 3.2[2.5-4.5] 4.2[2.6-5.0]
Lymphocytes, 10^6/mL 1.8[1.3-2.2] 2.0[1.5-2.3] 1.9[1.6-2.1]
Monocytes, 10^6/mL 0.5[0.4-0.7] 0.6[0.4-0.7] 0.6[0.3-0.7]
Classical monocytes, %gated a82.5[78.0-88.0] 80.2[75.1-88.2] 79.6[73.7-87.1]
Intermediate monocytes, %gated a7.9[4.8-14.1] 8.3[4.5-11.9] 5.6[2.5-11.7]
Nonclassical monocytes,%gated a7.0[5.0-10.0] 5.8[4.5-12.5] 11.7[5.4-13.2]
hsCRP, pg/mL 1.4[0.5-4.1] 1.1[0.8-5.3] 1.3[0.9-12.3]
hsIL-6, pg/mL 5.7[3.3-9.6] a6.6[4.0-11.4] a5.1[3.2-9.2]
E-selectin, pg/mL 13.9[10.7-17.5] 19.4[16.8-24.3]* 20.0[19.3-27.2]*
VCAM-1, pg/mL 392[333-458] 410[344-471] 424[345-527]
MMP-2, pg/mL †898[817-959] 954[863-1058] 968[823-1082]
bCCL2, pg/mL 31.2 [31.2-74.1] 36.8 [31.2-238] 43.5 [31.2-370]
Participants without SVD progression (n=22), SVD progression (n=13), Incident lesions (n=7). Me-
dian[IQR]. P-values are corrected for age, sex and hypertension with ANCOVA. *:p<0.05. a:data is 
missing for 1 participant. b: concentrations of CCL2 were often below the limit of detection of 31.2 
pg/mL. WBC: white blood cell counts.
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signalling pathways. These include the ‘Nerve Growth Factor-stimulated tran-
scription’ (FDR<0.001), the ‘Nuclear events’ (FDR<0.001) pathway that is acti-
vated by neurotrophins, ‘Signalling by Neurotrophic Receptor Tyrosine Kinase 
1’ (FDR=0.02) leading to proliferation of cell types and neuronal differentiation, 
and ‘Signalling by Neurotrophic Tyrosine Kinase’ (FDR=0.05) consisting of the re-
ceptor ligands for neurotrophins (Figure 3D). Downregulated pathways involved 
adaptive immune interferon (IFN) signalling, including IFN α, β, and γ signalling 
(FDR<0.01), the ‘ISG15 antiviral mechanism’ pathway (FDR<0.01) and ‘Immune 
system´ pathway (FDR=0.04) (Figure 3D). Similar results were obtained when 
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Discussion
Our main finding is that a pro-inflammatory monocyte phenotype, character-
ized by an augmented cytokine production capacity, is associated with progres-
sion of SVD, as detected by serial high-frequency MRI scanning. In participants 
with SVD progression, circulating monocytes had a pro-inflammatory transcrip-
tional signature, with significant upregulation of several inflammation-related 
pathways. These findings underscore our hypothesis that pro-inflammatory 
monocytes are closely involved in the development of SVD, uncovering innate 
immunity as novel potential pharmacological targets to prevent disease pro-
gression.
Given the overlap in pathophysiology and risk factors between atherosclerosis 
and SVD, we hypothesized that activation of circulating monocytes also contrib-
utes to SVD progression. The pathophysiology of SVD involves arteriolosclero-
sis, leading to arterial pathology of the smallest brain vessels, a process that is 
to a great extent comparable with large artery atherosclerotic disease. In addi-
tion, SVD shares cardiovascular risk factors with atherosclerotic disease, such as 
hypertension, dyslipidemia and smoking. In atherosclerosis, we and others have 
shown that a pro-inflammatory phenotype of circulating monocytes, character-
ized by an augmented cytokine production capacity, is involved in the patho-
physiology (29, 30).
Using serial MRI, we investigated the acute progression of SVD using imaging 
markers of SVD. We evaluated SVD progression in multiple ways: first by com-
bining all SVD imaging markers (DWI+ lesions, microbleeds, lacunes and WMH), 
then limited to incident lesions (DWI+ lesions, microbleeds and lacunes), and 
finally each incident SVD imaging marker individually. We observed a higher 
cytokine production capacity of IL-6 and IL-1β in isolated monocytes after ex 
vivo stimulation in the individuals with SVD progression, which was consistent 
across subgroups of individuals with each incident SVD imaging marker evalu-
ated separately. Previously, we described that the nine-year WMH progression 
preceding blood sampling, correlated with the cytokine production capacity 
of monocytes, circulating inflammatory marker hsIL-6, and pro-inflammatory 
CD14++CD16+ monocytes in a retrospective cohort study of elderly individuals 
(14). The current high sequential imaging study enabled to increase the res-
olution with monthly imaging and to assess multiple imaging markers of SVD 
during acute progression of SVD. 
To provide a deeper understanding of the pro-inflammatory monocyte phe-
notype, we explored the monocyte transcriptome with RNA sequencing in a 
small number of participants with and without SVD progression, based on inci-
dent DWI+ lesions. We included participants with DWI+ lesions to create a ho-
mogenous subgroup, matched to subjects without SVD progression. The char-
acteristics were comparable between subgroups, except for age, after which 
a sex-stratified analyses were performed. This explorative analysis revealed a 
pro-inflammatory gene expression profile with significant upregulation of sev-
eral inflammation-related pathways together with a downregulation of adap-
tive immune interferon signalling pathways. Specifically, EGR2 was upregulated 
which encodes for a transcription factor which is essential for myelination of the 
nervous system, and defects result in peripheral neuropathies (31). Also, EGR2 
and EGR3 are important for maintaining immune homeostasis (32). In innate 
immune cells, EGR2 expression is essential for naïve or M2-like macrophages to 
respond to inflammatory stimuli (33). In amyloid-β plaque-associated microglia 
a pro-inflammatory phenotype was found with upregulated EGR2 and SPP1 in a 
disease model for Alzheimer (34).
Another interesting observation is that two genes in the upregulated inflamma-
tion-related pathways encode for extracellular matrix components. Fibronectin 
(FN) and osteopontin-1 (SPP1) are principal components in cell matrix interac-
tions, including within the blood-brain barrier. SPP1 also functions as an integrin, 
which mediates cellular adhesion, interaction and is important in maintaining 
endothelial function. Additionally relevant in this context are two upregulated 
genes (FDR<0.25) involved in endothelial-leukocyte interaction. Both dual Spec-
ificity Phosphatase 6 (DUSP6) and serum- and glucocorticoid-inducible kinase 
1 (SGK1) orchestrate endothelial inflammation, increased expression of adhe-
sion molecules in vascular tissue and enhanced endothelial-leukocyte interac-
tion mediating leukocyte recruitment (35, 36). More specifically, damage to the 
extracellular matrix is perpetuated by activated microglia or monocytes in re-
sponse to hypoxia, eventually contributing to disruption of the blood-brain bar-
rier (37). Chronic blood-brain barrier disruption enhances leakage of signalling 
mediators, facilitates the communication between circulating and tissue-resi-
dent immune cells and is thought to aggravate SVD (12). The fourth upregulated 
gene fatty acid binding protein 4 (FABP4) has been shown to be important in 
macrophage cholesterol trafficking, inducing foam cell formation and the devel-
opment of atherosclerosis (38).
Remarkably, in conjunction with the upregulation of several inflammation-re-
lated pathways, we observed a downregulation of adaptive immune interferon 
signalling pathways in the monocyte transcriptome. Two out of three down-
regulated genes are involved in the interferon pathway. Ubiquitin-like protein 
(ISG15) and Interferon-induced GTP-binding protein (MX1) are interferon-in-
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duced proteins that play central roles in the host antiviral response (39). More-
over, the third downregulated gene glutathione-dependent prostaglandin E 
synthase (PTGES) is also a major modulator of immune activation. This finding 
fits with the previously observed negative association between the ex vivo IFNγ 
production capacity and SVD progression (14). We previously described that 
this might point to a counter-regulatory mechanism between innate and adap-
tive immunity.
Pathway analysis revealed several pathways involved in neuronal development 
and differentiation, and signalling by neurotrophins, which are pivotal proteins 
in neuronal survival, growth, differentiation and during development. There are 
several lines of evidence indicating that neurotrophins play important roles in 
the pathophysiology of neurodegenerative and psychiatric disorders (40). It is 
intriguing that circulating monocytes of individuals with SVD show higher ex-
pression of genes in pathways involved in neuronal development. It is relevant 
to gain a better insight in the influence of circulating monocytes through neuro-
trophins on neurons in the brain.
To our knowledge, we are the first to study the monocyte transcriptome in in-
dividuals with SVD. Previously, whole blood gene expression in the Framing-
ham Heart cohort (n=3248) showed that WMH was associated with genes of in-
flammation-related pathways (41). The heightened expression of inflammatory 
genes and pathways of monocytes in our studied cohort fits with their increased 
immunologic activity. Moreover, it reveals possible underlying mechanisms, 
with the EGR2 gene required in myelination, extracellular matrix components 
that mediate blood-brain barrier integrity, DUSP6 and SGK1 that trigger endo-
thelial leukocyte recruitment, and neurotrophins which are essential for neu-
rons, all processes involved in the complex pathophysiology of SVD.
With the current findings, it is tempting to speculate about the mechanisms re-
sponsible for this pro-inflammatory monocyte phenotype. Monocyte activation 
can be due to genetic variation that predisposes to hyperresponsive monocytes 
(42), or due to stimulation of monocytes by circulating stimuli, such as elevated 
levels of lipoproteins. Finally, trained immunity might contribute to persistent 
monocyte hyperresponsiveness (43). Dyslipidemia, either caused by a Western 
type diet or due to familial hypercholesterolemia, induces hyperresponsive-
ness of circulating monocytes, which persists despite normalization of plasma 
cholesterol levels (44, 45). This is, at least in part, mediated by metabolic and 
epigenetic reprogramming of these monocytes. Trained immunity has recently 
been suggested in the context of Alzheimer’s disease; brain-resident microg-
lia can develop immunological memory after repeated administration of LPS in 
the circulation in animal models (46), inducing a persistent elevated cytokine 
production mediated by epigenetic reprogramming. The pro-inflammatory re-
sponses by the trained microglia accelerated disease progression in an Alzhei-
mer’s disease model. Currently, it remains a question for future investigations 
whether the pro-inflammatory monocyte phenotype is due to differences in 
the genetic code, due to persistent stimulation of monocytes with circulating 
factors, or due to epigenetic reprogramming in the context of trained immunity.
A potential limitation of this study is the small sample size due to its complex 
and intensive design. Although in the current study design the monocyte phe-
notyping preceded the progression of SVD, we cannot draw conclusions on cau-
sality, since it is likely that SVD progression was also present in participants with 
incident lesions before inclusion in the study.
In conclusion, a pro-inflammatory monocyte phenotype and transcriptome, 
characterized by an increased cytokine production capacity and augmentation 
of inflammatory pathways, is related to the progression of SVD in elderly in-
dividuals. Future studies are needed to evaluate the mechanisms responsible 
for the monocyte activation, including the potential role for trained immunity, 
and to provide the causality whether these activated monocytes initiate SVD 
progression.
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Contribution to the Field Statement
Cerebral small vessel disease is a common condition in elderly individuals which 
ultimately results in loss of independence. Cerebral small vessel is the leading 
vascular cause of dementia, Parkinsonism, and ischemic stroke, with a large-
ly unknown pathophysiology and limited treatment options available. In this 
manuscript, we provide important novel insights into the pathophysiology of 
cerebral small vessel disease. We performed a prospective high-frequency im-
aging study with MRI to detect the occurrence of small vessel disease imaging 
markers. We found that participants with progressive SVD (i.e. incident SVD 
markers on MRI) have an activated state of the innate immune cell response in 
the circulation. Circulating innate immune cells (monocytes) are characterized 
by an augmented cytokine production capacity and a pro-inflammatory tran-
scriptional signature using deep RNA sequencing. Previously, circulating mark-
ers of inflammation have found to associate with SVD. This is the first study 
to evaluate innate immune function in individuals with cerebral small vessel 
disease during acute disease progression. These findings strongly suggest that 
pro-inflammatory monocytes are linked to acute SVD progression, which could 
offer new targets for pharmacotherapeutic strategies.
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Supplemental Methods
RNA isolation, sequencing and analysis
Low quality filtering and adapter trimming was performed using Trim Galore!, V0.4.5 (Babraham 
Bioinformatics), a wrapper tool around the tools Cutadapt v1.18 and FastQC v0.11.5 (Babraham 
Bioinformatics). Reads were mapped to a human reference genome (GRCh38.95, Ensembl) with 
Star v2.6.0a (1) using a pre-built genome index with fasta and gtf from Ensembl while using the 
parameter “--sjdbOverhang 100”, with STAR (v 2.6.0a). For the alignment the non-default param-
eter “--outSAMtype BAM Unsorted” was used. BAM files were counted (number of reads mapped 
to a feature, e.g. a gene) with HTSeq (HTSeq-count tool v0.11.0 (2)) with default parameters using 
a complementary .gtf file, containing annotation for GRCh38.95 (Ensembl). MultiQC (quality con-
trol) was used to combine results and quality checks of all the samples (3). 
Differential gene expression analysis was carried out with DESeq2 v1.22.0 in R v3.5.3 using the 
packages DESeq2 (v 1.22.2), data.table (v 1.12.8), ggplot2 (v 3.3.2), edgeR (v 3.24.3), ggrepel (v 
0.8.1), pheatmap (v 1.0.12), RColorBrewer (v 1.1-2) and tidyr (v 1.1.2) (4). Internal statistical and 
normalization method (i.e. correction for multiple testing with Benjamini–Hochberg) using a cut-
off value of at least 5 counts per sample per gene. Pathway analysis was performed with Reac-
tome v.75 (5) selecting differentially regulated genes with a P-value <0.05 as input.
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Supplemental Tables
Table I. Products details of cytokines and chemokines measured with ELISA.
Item Manufacturer Category number
24h stimulation Human TNFα duoset R&D DY210
Human IL-1β duoset R&D DY201
Human IL-6 duoset R&D DY206
Human Pelipair IL-8 Sanquin M9318 
Human Pelipair IL-10 Sanquin M9310
Plasma Human hs-CRP quantikine R&D DCRP00
Human hs-IL-6 quantikine R&D HS600C
Human VCAM-1 duoset R&D DY809
Human E-selectin duoset R&D DY724
Human MMP-2 duoset R&D DY902
Human CCL2 duoset R&D DY279
Table II. Input of differently regulated genes for pathway analysis. Differentially regu-
lates genes with an unadjusted p-value<0.05 were included in Reactome pathway anal-
ysis.
Upregulated genes Downregulated genes
FABP4 RIOK2 FOS BCL9L ISG15 RSAD2 SIGLEC1 ADAM15
SPP1 IKBIP ARNTL LARP1B MX1 AL035071.1 PES1 MARCKS
DUSP6 ZNF808 AC010343.1 DHX16 IFITM3 P2RY2 SH3BP2 TMEM160
EGR2 CCDC126 TMTC2 RGS18 AL139022.1 GTPBP1 ADCY9 ZNF789
SGK1 PCNX4 GPATCH11 CR1 IFITM2 AC018628.1 IL18BP ITPK1-AS1
FN1 C14orf119 NDUFS8 SOCS6 EVL GABBR1 RNASEK RNASEH2B
CD52 F11R ZNF614 SGPL1 PTGES HELZ2 LY6E PATL2
SULT1B1 FAM50B BCL9L TLR4 OAS2 AP2A1 SCNM1 AC135178.3
HLCS UTP15 LARP1B ACP5 SERPING1 AC008764.10 USP19 APBB3
NCAPD2 ZNF143 DHX16 DNAJC3 TYMP AC008982.2 AP000695.3 HCST
FABP5 KCNJ15 RGS18 MRPL22 NAPSB AC007365.1 POLG2 RUNX3
HEMGN TMEM38B CR1 ABCD3 TOX2 TBXAS1 FADS3 SPNS1
RGS2 GIHCG SOCS6 RFC5 CMPK2 RAC1P2 APOBEC3A NEDD1
BTG2 TMEM168 SGPL1 CXCR2 U62317.2 PARP12 TMCC1 VPS9D1
TSPYL4 MGME1 TLR4 LRRC37A16P AC008533.1 C7orf50 KLHDC10 DHRS4L2
KIAA1551 TRIB1 ACP5 DUS4L GBP3 ZEB2-AS1 RBM4 DNPEP
CYBRD1 PBDC1 DNAJC3 LRRFIP2 SMPD3 RRN3P2 PTK6 DDX60
TRIP11 SCD MRPL22  IFIT1 USP21 CUL1 TMEM175
ZNF200 TMEM242 ABCD3  AC073869.1 ZNF408 BST2 NME9
ZSCAN29 LIPN RFC5  EIF4A1 TSPAN4 C5orf56 RPL36A
DYNLT3 CDKL5 CXCR2  PARP14 AL731571.1 GON4L RWDD2B
ANKRD28 RSU1 LRRC37A16P  EIF2AK2 PPAN RF00019 ZNF532
EGR1 LPAR1 DUS4L  LENG8 IRF7 CLEC12B NFATC2IP
FMC1 TRIM13 LRRFIP2  TARBP1 MAN2B1 CYP2S1 LGALS2
NAGS AC118549.1 PSD3  FXYD6 ZBP1 MB21D2 CAPN10
CENPW KIAA1328 INTS2  PRMT9 FAM160B2 UROS TARBP2
CREB5 MCCC2 PPT2  BLVRA TMEM91 MED10 RF00019
RHOBTB1 ACSM3 S100A12  PML LY6G5C AP000347.1 ULK4
ENC1 COQ10B TP53I11  ACAP3 OAS3 KCNMB1 RNU6-1016P
TMEM41B PLBD1 PHF10  MX2 C12orf43 MTMR12 CAPNS1
TCTN3 BCAT1 SNAP47  JUN STAT1 OXCT1 MASTL
AC093673.1 MARC1 SGMS1  SPATA20 PNPT1 AC003681.1 AC012368.1
NDUFA12 NFE2L3 TOP1  PLEKHM1P1 FCGR2B NSUN5P1 OSBPL5
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Supplemental Figures and Figure legends
Figure I. Gating strategy. Monocytes were gated in SSC/CD45+ plot, identifying monocytes as 
CD45+ cells with monocyte scatter properties. Exclusion of lymphocytes and natural killer 
cells was performed by excluding CD14/CD16 negative cells. Percentages of monocyte subsets 
(CD14++CD16−, CD14++CD16+, and CD14+CD16++) were identified in the CD14/CD16 plot.
Figure II. PCA plot of monocyte transcriptome analyses. PCA plot of differentially regulated gene 
expression between participants with SVD progression based on DWI+ lesions (n=4, blue dots) 
and without (n=4, red dots). Circles indicate women, triangle: men.
NRG1 SOWAHC PALLD  RNF213 ENGASE NDRG2 TNFAIP3
CTSL S100A12 ARHGEF12  RNU4ATAC SNRPN EPSTI1 DUSP18
ZBTB38 TP53I11 HTRA1  FMNL1 SNHG20 IFI6 OXNAD1
TMEM206 PHF10 ERLEC1  L3MBTL2 CD1E FAHD2A TMC8
TLR1 SNAP47 KCNE3  SUMF2 TRABD SCAMP5 PLEKHG3
ASGR1 SGMS1 FPR2  IFI44L ALG3 IFIT3 UPK3A
THBD TOP1 ATP2A2  LGALS9 LGALS3BP MED17 AP001107.1
DUSP2 PALLD GPRIN3  PDLIM7 DTX3L TRAF5 KMT2E-AS1
DIPK2A ARHGEF12 SLC16A6  NAA40 HSF2 TCEA2 CPEB2
SMIM13 HTRA1 NRBF2  AC025171.1 AD001527.1 ZCCHC2 CCDC57
FADS2 ERLEC1 YWHAE  TMEM220 GMIP UBE2L6 HERC5
METTL9 KCNE3 SOCS3  CCL3L1 SIRT7 SH3PXD2B PPP3CB-AS1
TENT2 FPR2 CRTAM  LILRA6 CHMP4A ZNF296 ZBTB42
ERI1 ATP2A2 CEP19  SNORD13E NUDT4 AP002762.1 AC109460.1
FOLR3 GPRIN3 C17orf51  AC010997.6 ZFAND2A IFI30 MRPS2
ZNF232 SLC16A6 EREG  SHISA5 ADAT2 BCL7A SH3GLB2
SLC23A2 NRBF2 CBX7  DDX58 JUP SAMD4A CCT6B
RPH3A YWHAE ARRDC4  IRF9 OASL ANKRD52 PARP9
FEM1C SOCS3 IFT20  NEAT1 IL11RA TPRG1L CUL9
ZUP1 CRTAM IL7R  ODF3B SELL AC004241.3 EPM2AIP1
CEP170 CEP19 F8A1  LILRA4 ACBD6 ZNF335 CST3
STK38L C17orf51 ANPEP  C19orf66 IFI35 SMARCE1 SPATS2L
ZNF503 EREG ICA1  CMTR1 OSCAR ATF5 LINC00173
ITGAV CBX7 THAP12  VASH1 CENPF AL035587.1 AP2S1
ZNF354A ARRDC4 QARS EIF5 RNU4-2 OAZ2 MVB12B
MOGS IFT20 FOS DNASE1L1 FANCF AC073957.3 CHST13
DSE IL7R ARNTL ID2 IER5 CD1C GPSM3
PTGER4 F8A1 AC010343.1 UCP2 IFI44 SRGAP2C PLEKHM2
GTPBP10 ANPEP TMTC2 C1orf56 AC069549.1 DCAKD SEMA4A
AC005332.6 ICA1 GPATCH11 VSTM1 BHLHE40 RBM3
TMEM176B THAP12 NDUFS8 AC109326.1 AC099343.3 C1orf115
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Summary and discussion
Cardiovascular disease (CVD) is the leading cause of death and morbidity 
worldwide [1]. Moreover, this number continues to increase due to population 
growth, ageing and urbanisation across the globe [2]. In the last decades, re-
search has drastically changed our perspective on the pathophysiology of ath-
erosclerosis. Rather than being a passive lipid-storage driven disease, athero-
sclerosis was discovered to be a chronic low-grade inflammatory disease. As 
a consequence, systemic low-grade inflammation emerged as an independent 
risk factor for CVD [3] and the first clinical trials were initiated with anti-inflam-
matory therapies to lower cardiovascular risk [4-7].
Another paradigm shift occurred in the field of immunology by the discovery of 
memory properties in innate immune cells [8]. Traditionally, the innate immune 
system has been viewed as primitive and generic, lacking the ability to differ-
entiate between distinct pathogens or develop memory. However, a growing 
body of evidence argues that a previous encounter with various ligands can 
functionally reprogram myeloid cells, which augments the subsequent immune 
response. This phenomenon has been called trained immunity [9]. Interestingly, 
trained immunity can be induced by products found within the atherosclerotic 
plaque or in the circulation of individuals with high cardiovascular risk, such as 
oxidized LDL and lipoprotein (a) [10, 11]. It is now hypothesized that trained 
immunity, although beneficial in the context of recurrent infections, induces ad-
verse effects in the context of chronic inflammatory disorders, and contributes 
to hyperinflammation and progression of CVD and neuroinflammation.
Both recent discoveries form the basis for this thesis, in which I aim to investi-
gate the contribution of innate immune cell reprogramming, and in particular 
trained immunity, to the pathogenesis of CVD, specifically atherosclerosis and 
cerebral small vessel disease. Ultimately, this thesis aims to contribute to a bet-
ter understanding of the inflammatory mechanisms in atherosclerosis, in order 
to identify novel drug targets that can be used in the prevention and treatment 
of CVD. In this final Chapter, I summarize and discuss the study findings. 
In Chapter 2, I provide a detailed overview of the concept of trained immuni-
ty. It is focused on the intracellular mechanisms needed for the initiation and 
maintenance of functional reprogramming: shifts in cellular metabolism and 
epigenetic rewiring. We conclude that trained immunity is a fundamental prop-
erty of the mammalian immune response, and is increasingly investigated as 
pharmacological target. Further expansion of our knowledge of the intricate 
and complex regulatory mechanisms is key to successfully develop therapeutic 
strategies modulating trained immunity in chronic inflammatory diseases.
Chapter 8 Summary, discussion and general perspectives
220 221
After this introductory chapter, this thesis is divided in two parts. The first part 
of the thesis describes a series of experiments in which monocyte reprogram-
ming in individuals with atherosclerosis or increased CVD risk is explored. The 
second parts examines whether pro-inflammatory monocytes are also present 
in a related CVD, namely cerebral small vessel disease.
Part 1: Monocyte activation in atherosclerosis
In Chapter 3, I investigated whether a specific immunological stimulus, the 
periodontitis-associated pathogen P. gingivalis, is capable of inducing trained 
immunity in human monocytes in vitro. A well-established in vitro model of 
trained immunity was used to study whether two different P. gingivalis strains 
can induce trained immunity. Transient exposure (24 hours) of human mono-
cytes to relevant concentrations of P. gingivalis resulted in an increased produc-
tion of pro-inflammatory cytokines (TNFα and IL-6) upon re-stimulation 6 days 
later with TLR-agonists, indicating induction of trained immunity. Moreover, 
costimulation with P. gingivalis and oxLDL, both found in low concentrations 
in the periodontium, resulted in a strong amplification of cytokine production 
upon restimulation.
Thereafter, we aimed to translate the immunological effects of P. gingivalis to an 
in vivo situation in subjects with severe periodontitis. In a cohort of individuals 
with severe periodontitis versus sex-, BMI- and smoking-matched, age-correct-
ed controls with no-to-mild periodontal disease, I showed that those with se-
vere periodontitis had systemic inflammation with higher circulating leukocyte 
counts and trends for higher cytokine levels. However, to our surprise we did 
not find heightened ex vivo responsiveness of circulating monocytes. We also 
performed [18F]FDG PET-CT scanning yet the [18F]FDG-uptake in the vascular 
wall was not higher in the patients with severe periodontitis. Nevertheless, we 
found strong, positive correlations between the severity of periodontitis with 
circulating inflammatory markers and periodontal, vascular wall inflammation, 
and hematopoietic tissue activation. 
In summary, the periodontal pathogen P. gingivalis induces trained immunity 
in vitro, and patients with severe periodontitis show systemic inflammation in 
vivo with an association between the severity of periodontitis with systemic 
inflammation and vascular wall inflammation. We conclude that trained immu-
nity by P. gingivalis might fuel a self-perpetuating chronic inflammation in the 
periodontium or within atherosclerotic plaques, yet in patients with periodonti-
tis, trained immunity is not observed in circulating monocytes.
The discrepancy between the in vitro and in vivo results could have several ex-
planations. First, P. gingivalis might induce trained immunity only in local peri-
odontal tissue, but not exert its effect on distant circulating innate immune 
cells. It is important to realize the differences between monocyte-derived mac-
rophages in periodontal tissue, and circulating short-lived monocytes in blood. 
In our in vitro model we stimulated monocyte-derived macrophages, rather 
than circulating monocytes, resembling macrophages within periodontal or vas-
cular tissue in vivo. Possibly, monocyte-to-macrophage differentiation might be 
necessary to induce inflammatory changes. This discrepancy has been reported 
previously by members of our group: although the adrenal hormone aldoste-
rone induces trained immunity in vitro, isolated monocytes from patients with 
hyperaldosteronism did not show a trained phenotype [12, 13].
At first sight, it might seem farfetched to also suggest an effect of trained immu-
nity in macrophages in the atherosclerotic plaque. Yet, P. gingivalis and other 
keystone periodontal bacteria have been found in histological analyses of ath-
erosclerotic plaques [14, 15], revealing the capability of these bacteria to reach 
distant sites. In our cohort study, we observed a positive association between 
the severity of periodontitis and systemic inflammation with [18F]FDG-uptake of 
the vascular wall, suggestive of local inflammation. The [18F]FDG-uptake in the 
vascular wall correlates with macrophage numbers in atherosclerotic plaques 
in previous studies [16]. Together, these observations build the hypothesis that 
monocytes exposed to keystone periodontal bacteria, such as P. gingivalis, 
might develop trained immunity after monocyte-macrophage differentiation in 
periodontium or atherosclerotic plaques.
Secondly, it is relevant to consider the complexity of periodontitis in vivo. Peri-
odontitis is caused by a complex interplay of several bacterial species in the 
oral flora and the host immune response [17]. In addition, P. gingivalis’ mode 
of action is diverse: P. gingivalis resides intracellularly, secretes gingipains, and 
has fimbriae that determines its virulence rate [17], amongst others. Moreover, 
in vitro we studied the effect of P. gingivalis on monocyte-derived macrophages 
alone, whereas in vivo leukocyte subsets are in constant interaction with each 
other. In this context, trained immunity is only one of several mechanisms that 
might play a role in modulating the host response.
The last explanation is that the disease phenotype in our subjects might have 
been too mild, to overcome the influence of potential confounders. This could 
explain the strong correlation between periodontitis severity and circulating in-
flammatory markers and vascular wall inflammation, without significant group 
differences. Periodontitis and CVD share many risk and socio-economic factors 
[14, 18], thereby creating a potential bias which complicates the interpretation 
of findings in a clinical study. In our study, we matched both groups for known 
CV risk factors, including sex, smoking and BMI, and corrected for the significant 
Chapter 8 Summary, discussion and general perspectives
222 223
age difference. The difference between the groups in terms of severity of peri-
odontitis is modest, as participants with severe PD were in supportive periodon-
tal therapy, resulting in a milder phenotype. Together, this may explain the lack 
of differences in cytokine production capacity and vascular wall inflammation 
between both groups. Therefore, future larger studies with untreated forms of 
periodontitis are needed to explore the role of trained immunity in monocytes 
and vascular wall inflammation.
In Chapter 4, I explored whether reprogramming of bone marrow progenitor 
cells is present in patients with established atherosclerotic CVD as a mechanism 
that leads to long-term reprogramming of circulating monocytes. A trained im-
munity phenotype in circulating monocytes has been documented to persist 
at least three months (up to several years) after initial induction of trained im-
munity in humans in vivo [19-21]. This is surprising considering the short lifes-
pan of myeloid cells of only a few days in the circulation [22]. Ground breaking 
work in mice showed that epigenetic and metabolic reprogramming of myeloid 
progenitor cells in the bone marrow underlie the long-lasting pro-inflamma-
tory changes in circulating monocytes [23]. More specifically, a Western type 
diet in atherosclerosis prone mice induced long-term monocyte activation by 
reprogramming progenitor cells in the bone marrow [24]. Because knowledge 
about hematopoietic progenitor cell composition and function in human ath-
erosclerosis is lacking, we investigated whether monocyte reprogramming is as-
sociated with reprogramming of hematopoietic progenitor cells in established 
atherosclerosis. 
We selected individuals with severe coronary artery disease and sex-, age- and 
BMI-matched control individuals without coronary atherosclerosis to study the 
functional, metabolic and transcriptional phenotype of hematopoietic progen-
itor cells (HSPCs) obtained by bone marrow aspiration. We characterized the 
ex vivo response (after stimulation) of circulating leukocytes and bone marrow 
progenitor cells, the composition of circulating cells and bone marrow progen-
itor cells, and the metabolic and transcriptional fingerprint of bone marrow 
progenitor cells. The enhanced ex vivo responsiveness of circulating leuko-
cytes in individuals with atherosclerosis, which was previously reported by our 
group, was validated in our study [25]. Most importantly, we found functional 
and metabolic reprogramming of bone marrow progenitors with higher ex vivo 
responsiveness, an increased oxygen consumption and extracellular acidifica-
tion rates. In the circulation and within the bone marrow, higher percentages 
of multipotent progenitor cells were present in individuals with coronary ar-
tery disease. In combination with lower megakaryocyte-erythroid progenitor 
cells and higher pre-monocytes percentages, this suggested a shift towards 
myelopoiesis. Indeed, transcriptome analysis of hematopoietic stem cells and 
granulocyte-monocyte progenitor cells showed enrichment of neutrophil and 
monocyte pathways, also indicating a myeloid differentiation bias. These find-
ings are in line with a recent study in atherosclerosis prone mice, showing that a 
four-week Western type diet induces reprogramming of granulocyte-monocyte 
progenitor cells and a myeloid differentiation bias in HSPCs [24]. Moreover, the 
results overlap with the myeloid shift in HSPC transcriptome of subjects after 
vaccination with BCG, which is also a powerful stimulus for trained immuni-
ty, with similar enrichment of neutrophil and monocyte related pathways [26]. 
Finally, we assessed vascular wall inflammation and haematopoietic tissue ac-
tivity using [18F]FDG PET-CT scanning. In contrast to earlier findings [10, 12], no 
difference was observed in vascular wall inflammation between patients and 
controls, which will be discussed below. Interestingly, we did find a correlation 
between splenic [18F]FDG-uptake and CCR2 expression on hematopoietic stem 
cells, circulating leukocytes and monocytes. Taken together, we have shown 
that functional, metabolic and transcriptional reprogramming of HSPCs and 
circulating immune cells is present in individuals with coronary artery disease. 
These findings add an additional layer of inflammatory regulation in athero-
genesis which potentially offers novel targets for pharmacological strategies to 
prevent or treat atherosclerotic CVD. Future studies should confirm that this 
trained immunity phenotype is dependent on epigenetic changes as previously 
shown in circulating monocytes of patients with atherosclerosis [25].
It is tempting, although challenging, to speculate which risk factor is responsible 
for the reprogramming of hematopoietic progenitor cells in our patients, as we 
did not select patients with a specific cardiovascular risk factor; the inclusion 
criterium was established coronary atherosclerosis. Coronary atherosclerosis is 
the net result of multiple classical and non-classical CV risk factors, established 
in decades and further modified by pharmacological treatment. Furthermore, 
despite optimal pharmacological treatment, a considerable residual inflamma-
tory CV risk remains: our colleagues showed that lipid-lowering therapy does 
not revert the pro-inflammatory monocyte phenotype in patients with familial 
hypercholesterolemia [27]. This illustrates that previously elevated cholesterol 
levels can influence the current monocyte phenotype and that this phenotype 
persists despite lipid-lowering therapy. A potential confounder in our study is 
that most patients were treated with acetylsalicylic acid in contrast to the con-
trol subjects. It appears that, the effects of acetylsalicylic acid on innate immune 
function are of marginal relevance. When evaluating the innate immune func-
tion in 500 healthy individuals, acetylsalicylic acid prescription did not influence 
the ex vivo responsiveness in leukocytes [28]. Besides the difference in pharma-
cological therapy between the groups, other demographic characteristics were 
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similar, including classical risk factors. Cholesterol concentrations were lower 
in patients with coronary artery disease at time of study inclusion, but might 
well have been higher previously, which might have contributed to the current 
inflammatory phenotype. Interestingly, recent research in murine models has 
shown that several modifiable CVD risk factors are able to modulate haemato-
poiesis in the bone marrow, leading to enhanced atherosclerosis. These studies 
illuminated pathways through which an unhealthy diet (including hyperlipidae-
mia) [29], psychosocial stress [30], insufficient sleep [31], sedentary behaviour 
[32] (which will be discussed in Chapter 5) and obesity [33] increase hematopoi-
etic progenitor cell proliferation and the bone marrow’s myeloid cell output. In 
this study, information about stress, sleep patterns or sedentary behaviour was 
not available. All these CVD risk factors, including previously elevated plasma 
lipoproteins, might have contributed to reprogramming of hematopoietic pro-
genitor cells in individuals with atherosclerosis.
Since monocytes are short lived, the production and mobilisation rates by the 
bone marrow influence systemic cell abundance and recruitment to cardiovas-
cular tissues [22, 34]. Recent studies have provided fascinating new insights 
into the regulatory mechanisms of HSPCs in the bone marrow compartment 
in atherosclerosis. A CV event triggers increased efflux of HSPCs into the circu-
lation via regulation of CCL2 and CXCL12 to populate the spleen and produce 
increased amounts of pro-inflammatory monocytes by extramedullary haema-
topoiesis, in mice [35-37]. The importance of extramedullary haematopoiesis 
in the spleen, at least in mice, is illustrated by the observation that in splenec-
tomised mice atherosclerosis did not accelerate after myocardial infarction. In 
addition, the murine spleen acts as a reservoir that, in the event of myocardial 
infarction or stroke, rapidly deploys large amounts of immune cells [38]. Using 
real-life imaging with an HDL-nano tracer, it was visualised that monocytes that 
originated from the spleen migrated to the vascular wall in a murine atheroscle-
rosis model [39]. After myocardial infarction, a rapid increase of myeloid cells 
from the spleen and bone marrow to the circulation and infarcted myocardi-
um was observed. In humans, indirect evidence with [18F]FDG PET-CT scanning 
revealed increased immune cell infiltration in the spleen after myocardial in-
farction [39]. In our study, we observed that splenic [18F]FDG-uptake positively 
correlated with circulating hematopoietic progenitor cells, including their CCR2 
expression, and with circulating leukocyte and monocyte counts. Future studies 
should elucidate the function of the spleen in innate immune cell reprogram-
ming in the context of atherosclerosis.
In both Chapter 3 and 4, we observed no significant difference in vascular wall 
inflammation using [18F]FDG PET-CT scanning between patients with periodonti-
tis or with established atherosclerosis and matched control subjects. We decid-
ed to use imaging modality in these studies because [18F]FDG-uptake faithfully 
represent macrophage number and activation: [18F]FDG-uptake in the arterial 
wall correlates with high-risk plaque features on CT and MRI and with mac-
rophage numbers in atherosclerotic plaques on histologic assessment [16]. 
Still, this technique is of limited use in detecting and structurally characterizing 
plaques. Previous studies have shown increased arterial wall [18F]FDG-uptake in 
patients with increased CVD risk due to dyslipidemia or diabetes [16, 40]. Why 
was [18F]FDG-uptake not increased in our patient groups? In both studies the 
relatively small sample size might contribute to the lack of a significant differ-
ence in [18F]FDG-uptake in the large arteries, which has been shown previously 
in larger studies of patients with CVD and periodontitis [41-43]. Another possi-
ble explanation for our results is that the cardiovascular patients we included 
had severe coronary atherosclerotic plaques with calcium deposits, which are 
known to have less [18F]FDG-uptake than uncalcified arterial plaques at early 
stage of atherosclerosis [44]. In a large prospective study, a combination of [18F]
FDG-uptake PET and MRI was used to assess arterial inflammation and plaque 
presence in individuals with subclinical atherosclerosis [44]. Plaques were de-
tected in 90% of the cohort, arterial inflammation was present in 50% of all 
participants, and only 11% of plaques showed coincident [18F]FDG-uptake. Con-
sequently, most segments that showed arterial inflammation did not contain 
mature atherosclerotic plaques. Combined with preclinical studies that support 
a role of arterial inflammation in the early stages of atherosclerosis [45], this 
study demonstrated in vivo that arterial inflammation precedes the develop-
ment of mature, calcified atherosclerotic plaques. The final explanation is that 
lipid-lowering therapy is effective in reducing vascular wall inflammation [42]. 
In individuals with CVD, as well as in those with periodontitis, treatment with 
statins was effective in reducing [18F]FDG-uptake in the vascular wall [46-48]. 
In both of our studies patients more often received lipid low-lowering therapy 
than controls, but the numbers were too small to explore in more detail. Fur-
thermore, the [18F]FDG-uptake in the arterial wall reflects the total glucose up-
take, so virtually all metabolically active cells in the vascular wall could contrib-
ute to the [18F]FDG-uptake signal. Still, the largest body of evidence suggests 
macrophages to be the most important contributor [49], but vascular smooth 
muscle cells and endothelial cells have also been suggested to contribute to 
vascular [18F]FDG-uptake [50]. Currently, exciting novel PET radiotracers and 
imaging techniques are being developed to visualize monocyte/macrophages 
recruitment into (cardiovascular) tissue, by targeting chemokine receptors, for 
example CCR2 [51], and the phagocytic and metabolic capacity of macrophages, 
for instance 18 kDa translocator protein (TSPO) [52], radiolabeled Feraheme 
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(FH) [53] or 18F- fluorocholine [54], amongst many others. These innovations 
will give better, real-life insight into the myeloid cell contribution to arterial in-
flammation, and other relevant cardiovascular tissues in vivo.
In Chapter 5, we examined whether physical activity can influence monocyte 
reprogramming in vivo. We used a physical activity intervention study to test 
whether the pro-inflammatory monocyte phenotype can be reversed in indi-
viduals with a sedentary lifestyle and concomitant increased CVD risk. We in-
cluded individuals with either an elevated blood pressure and/or overweight 
(BMI>28). High levels of sedentary behaviour are associated with increased risk 
for CVD [55-57] and systemic inflammation [58, 59], but the effects on the in-
nate immune function are largely unknown. Besides the functional monocyte 
phenotype, we also assessed the effects of the intervention on intracellular 
metabolism of immune cells. In individuals with increased CVD risk, a 16-week 
intervention to reduce sedentary behavior and improve walking time altered 
the innate immune function towards a less pro-inflammatory state, shown by 
a decrease in IL-1β, IL-6, and IL-8 production after stimulation. In support of 
this observation, we found a strong, inverse correlation between the increase 
in walking time and attenuated cytokine production capacity that followed a 
dose-response like pattern. In other words, individuals who had the highest in-
crease in walking time, demonstrated the strongest reduction in cytokine pro-
duction capacity of circulating PBMCs. The reduction in inflammatory state after 
the 16-week intervention coincided with a trend to decreased glycolysis and 
oxidative phosphorylation rate in isolated PBMCs. In addition, a reduction in the 
percentage of circulating monocytes was observed together with an increase in 
the lymphocyte-to-monocyte ratio. Together, our findings suggest that mono-
cyte reprogramming is a likely mechanistic explanation that contributes to the 
link between sedentary behavior and atherosclerotic CVD. This supports the 
concept that targeting sedentary behavior may be an important approach in 
preventing atherosclerotic CVD.
The reduction in circulating monocytes after the physical activity intervention 
suggests that physical activity might have an effect on hematopoiesis in the 
bone marrow compartment. A recent study by Frodermann et al has provid-
ed more insight into the mechanisms of physical activity on the hematopoietic 
progenitor cells in reducing inflammation [32]. Mice were given permanent ac-
cess to a treadmill in their cage for 6 weeks and voluntarily ran approximate-
ly 12 km per day. The authors described that regular physical activity reduces 
hematopoietic progenitor cell proliferation and leukocyte production in mice, 
thereby reducing circulating leukocyte numbers. Mechanistically, they show 
that exercise diminishes leptin production in adipose tissue, consequently low-
ering the levels in circulation and the bone marrow. Reduced leptin signalling to 
leptin-expressing stromal cells in the bone marrow niche elevated HSPCs quies-
cence-promoting niche factors, including CXCL12. The effect of leptin on bone 
marrow niche cells subsequently regulates hematopoietic progenitor cell pro-
liferation and leukocyte production, as well as cardiovascular inflammation and 
outcome. Also, the effects on hematopoietic progenitor cell transcriptome and 
epigenome remained present for several weeks after exercise withdrawal, link-
ing this finding to the concept of trained immunity. Furthermore, using a sepsis 
model, the authors revealed that running mice responded with higher circulat-
ing leukocyte numbers upon induction of sepsis, resulting in improved survival 
compared to sedentary mice. Together, these data show that physical activity 
alters hematopoietic progenitor cells via modulation of their niche, reducing 
hematopoietic output of inflammatory leukocytes, consequently improving 
CVD outcomes without impairing host defence mechanisms that are crucial for 
surviving infections. It remains to be established whether this mechanism also 
contributes to the findings we presented in the human situation.
We have shown that is relevant to improve physical activity and reduce seden-
tary lifestyle to reduce the inflammatory state, which might also reduce car-
diovascular risk. The feasibility of lifestyle change is noteworthy to mention as 
the first group of participants in our study failed to improve walking time. With 
increased weekly motivational support, the second group of participants did 
manage to significantly increase walking time during the 16-weeks intervention, 
pointing out the importance of encouragement and guidance.
Part 2: Monocyte phenotype in individuals with cerebral small vessel disease 
While the first part of this thesis focussed on monocyte reprogramming in the 
context of atherosclerotic CVD, the second part of this thesis examined whether 
pro-inflammatory monocytes are also present in a related cardiovascular dis-
ease, cerebral small vessel disease (SVD). As individuals with SVD have signs 
of systemic inflammation and share risk factors with atherosclerotic CVD, we 
wondered whether a pro-inflammatory monocyte phenotype is also relevant in 
the pathophysiology of this disease. 
In Chapter 6 we examined the circulating monocyte phenotype in a unique and 
well-characterized cohort of elderly individuals with cerebral small vessel dis-
ease (SVD) in relation to the long-term disease progression. SVD is a common 
condition in elderly that is one the major causes of cognitive decline, dementia 
and stroke. Individuals with SVD are characterized by increased systemic inflam-
mation [60], but knowledge on the role of the innate immune system in SVD is 
lacking. In a cohort of individuals with mild to severe SVD, the severity and pro-
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gression of SVD was previously determined by comparing white matter hyperin-
tensities on MRI scans from 2006 and 2015 [61]. We were interested in the as-
sociation of monocyte responsiveness after stimulation and monocyte subsets 
with progression of SVD. Circulating IL-6 levels and intermediate monocyte per-
centages positively correlated with severity and progression of SVD. In addition, 
cytokine production capacity (e.g., IL-6 after TLR2 stimulation by Pam3Cys) by 
monocytes was also associated with SVD progression. In summary, the severity 
and nine-year progression of SVD is correlated with systemic inflammation, and 
with trained immunity characteristics of circulating monocytes, in terms of an 
altered cytokine production capacity and a shift towards the pro-inflammatory 
intermediate monocyte subset. Limitations of this chapter include the retro-
spective design and that only one readout for a trained immunity phenotype 
or functional reprogramming of monocytes was studied. Therefore, in the next 
chapter we validated our findings in a prospective study, also adding RNA se-
quencing for deep phenotyping of the circulating monocytes.
In Chapter 7, we prospectively studied the monocyte phenotype and transcrip-
tome in relation to signs of acute progression of SVD assessed with detailed 
MRI scanning for 10 consecutive months [62]. During follow-up, 13 of the 35 
individuals developed MRI signs of acute progression of SVD, including acute 
micro-infarcts, microbleeds, lacunes, and severe progression of white matter 
hyperintensities [63, 64]. We showed that, at baseline, a pro-inflammatory 
monocyte phenotype, characterized by an augmented production of IL-1β and 
IL-6, was related to this acute progression of SVD as detected by serial high-fre-
quency MRI scanning. RNA sequencing was performed in isolated monocytes 
to provide a better understanding of the underlying mechanisms. We found an 
inflammatory transcriptional signature with upregulation of several inflamma-
tion-related pathways, including genes involved in immune homeostasis, neural 
myelination, extracellular matrix components, and trans-endothelial leukocyte 
migration. In conclusion, we showed that functionally and transcriptionally re-
programmed circulating monocytes associated with the acute progression of 
SVD in elderly individuals.
Together, Chapter 6 and 7 show the potential role for trained immunity in the 
pathophysiology of SVD, indicating that inflammatory monocytes either drive or 
become activated during the initiation and progression of SVD. Combining a ret-
rospective and prospective approach, we were able to follow SVD progression 
over time and relate that to the individual’s circulating monocyte phenotype. 
Future studies are needed to evaluate whether trained immunity is responsible 
for the monocyte activation in SVD, by looking into metabolic and epigenetic 
markers of trained immunity, and to provide a causal link between circulating 
pro-inflammatory monocytes and the pathophysiology of the small vessels in 
the brain. A potential hurdle to intervention studies is the lack of appropriate 
animal models of SVD.
A disadvantage of our observational studies is that we cannot conclude on 
causation but only association. Also, the mechanism of how circulating mono-
cytes impact on brain pathology has yet to be determined. Murine models have 
provided several new insights which might elucidate how circulating stimuli 
and immune cells play a role in neuropathology. It has recently been demon-
strated in a murine model that microglia, the tissue-resident macrophages of 
the brain, have the capacity to develop trained immunity, in terms of long-last-
ing reprogramming, after peripheral stimulation [65, 66]. Systemic adminis-
tration of multiple LPS doses generated reprogramming of resident microglia, 
indicating that a peripheral stimulus can modulate resident microglia across 
the blood-brain-barrier. Thereafter the role of trained immunity in microglia on 
neuropathology was investigated in various ways, involving singular or repeated 
peripheral stimulation with LPS or Bacillus Calmette-Guérin (BCG) in an Alzhei-
mer disease mouse model [65, 67]. All stimuli generated long-term alterations 
in the responsiveness of microglia, and depending on the specific model ap-
plied, either improved or worsened outcomes, such as plaque load, β-amyloid 
levels, and cognitive decline. Moreover, reprogrammed circulating monocytes, 
either induced by in vivo or ex vivo LPS stimulation, modulated inflammatory 
injury and protected brain tissue after cerebral ischemia in mice [68]. In short, 
murine studies have provided fascinating insights in the interplay between cir-
culating monocytes and tissue-resident microglia to affect brain pathology after 
peripheral stimulation. This opens the avenue for future research involving the 
modulation of trained immunity to prevent the development neuropathology. 
In relation to CVD, it was shown that myocardial infarction induces a change 
in tissue-resident macrophage numbers and phenotypes in remote, uninjured 
organs such as the lung, liver and kidney and also the brain [69]. Longitudinal 
human studies are needed to generate more insight in the relation between 
pro-inflammatory monocytes and brain pathology. Improving the understand-
ing of these inflammation-related processes in elderly, might help further to 
prevent or predict the development of neurodegenerative disorders leading to 
the loss of independence, dementia and stroke.




The ex vivo responsiveness of monocytes is one of the most important read-
outs of the studies included in this thesis. An increased cytokine production 
capacity is the hallmark of a trained immunity phenotype; however, it is not 
exclusive to trained immunity. Pro-inflammatory monocytes present a current 
state of the cells for which several mechanisms can be responsible. Monocyte 
activation can be due to genetic variation that predisposes to hyperresponsive 
monocytes. For example, subjects with a deficiency of mevalonate kinase and 
subsequent intracellular accumulation of mevalonate have a comparable ‘en-
dogenous trained phenotype’ which is characterized by enhanced cytokine pro-
duction [70]. In addition, it can be due to continuous stimulation of monocytes 
by circulating stimuli, such as elevated levels of lipoproteins[24, 27]. Finally, 
trained immunity might contribute to persistent monocyte hyperresponsive-
ness [71]. Without knowledge about the metabolic and, most importantly, epi-
genetic programs of the cells or the persistence of the state despite removal of 
the stimulus, one cannot prove that the enhanced cytokine production capacity 
is due to trained immunity. Since we did not address epigenetic reprogramming 
of monocytes or hematopoietic progenitor cells in this thesis, this remains a 
question for future research.
Another limitation concerns the relatively small sample size of the various stud-
ies described in this thesis. Since the studies were of an exploratory nature, we 
did not perform a sample size calculation, but rather designed the studies based 
on previous results from our group and others, where sample sizes comparable 
to ours were able to detect relevant differences in the production of mono-
cyte-derived cytokines in patients with dyslipidemia or atherosclerosis [25, 40]. 
The small sample size increases the risk of type I errors (i.e. false-positive find-
ings), which necessitates confirmation with selected markers for trained immu-
nity in independent cohorts before using this information to guide innovations 
in diagnosis and treatment strategies in patients with CVD.
Last but not least, it is relevant to consider that a multitude of cell types are 
involved in the development of atherosclerotic disease, whereas this thesis 
focusses on the role of myeloid cells alone. Next to monocyte-derived mac-
rophages, various leukocyte classes and other cell types accumulate in the 
atherosclerotic plaque of which we have gained a deeper understanding by 
using new techniques like fate mapping studies and single cell sequencing. In-
novative studies applied single-cell RNA sequencing as unbiased approach to 
classify plaque leukocytes in a murine and human atherosclerosis [72, 73]. In 
both studies unsupervised clustering singled out 13-14 distinct cell populations, 
among which were three different clusters of macrophages. In mice, these mac-
rophages accounted for one third of the CD45+ cells in the early atherosclerotic 
plaques, while CD8+ T-cells accounted for another 20% and monocytes, mono-
cyte-derived dendritic cells/dendritic cells, NK cells, granulocytes, and B-cells, 
among others, formed the remaining leukocyte population. Besides the knowl-
edge that macrophages in the arterial wall can be divided in distinct classes 
based on different phenotypes, they also originate from different sources. Fate 
mapping studies have revealed that tissue-resident macrophages migrate to the 
vascular wall closely after birth, after which they become independent of the 
circulating pool monocytes with a distinct phenotype [74]. In this perspective, 
this thesis adds a piece to the puzzle in the exciting, rapidly evolving research 
field of atherosclerosis.
Future perspectives
A growing body of evidence indicates that innate immune cell reprogramming, 
and in particular trained innate immunity, is a mechanism that contributes to 
the development of atherosclerosis and CVD. My thesis provides several novel 
insights (see Figure 1) that can potentially improve future individualized CV risk 
prediction and (preventive) treatment of patients with CVD or with risk factors 
for CVD. 
Figure 1. Overview of trained immunity in the context of atherosclerosis divided into four cate-
gories; 1. Conditions in which trained immunity has been studied such as familial hypercholes-
terolemia and periodontitis; with a separate condition for sedentary lifestyle, as increased exer-
cise reserved trained immune responses 2. Stimuli that can induce training such as oxLDL and P. 
gingivalis; 3. Mechanisms that underlie trained immunity including metabolic, epigenetic repro-
gramming, and reprogramming of hematopoietic progenitor cells; 4. CVD in which reprogrammed 
monocytes were observed.
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We have shown that monocyte responsiveness, measured by the cytokine pro-
duction capacity, is associated with atherosclerosis and with progression of SVD. 
These findings suggest that innate immune cell reprogramming plays a role in 
atherosclerosis development, possibly mediated by trained immunity. In this 
context, specific markers of trained immunity, such as epigenetic landmarks in 
circulating monocytes, might be able to predict progression of atherosclerosis. 
In order to identify specific markers, a better understanding of the key mecha-
nisms involved in immune reprogramming is needed. This will be an interesting 
topic for future research.
Moreover, the results of this thesis can help to identify novel therapeutic tar-
gets. A targeted approach is needed in CVD for the development of anti-inflam-
matory therapies. Large clinical trials, such as the CANTOS, LoDoCo and COLCOT, 
have shown that immunomodulating agents effectively reduce CVD incidence. 
However, they have not resolved the increased inflammatory risk in CVD and 
are not without considerable side-effects. In order to effectively reduce the in-
flammatory processes in atherosclerosis a more targeted approach is needed. 
Future therapies preventing or reversing immune cell reprogramming by tar-
geting circulating cells, the atherosclerotic plaque, or hematopoietic progenitor 
cells will possibly lower the residual inflammatory CVD risk. The first study that 
has specifically targeted macrophages within the atherosclerotic plaque showed 
promising results in mice. Administration of HDL-nanoparticles containing 
statins reduced atherosclerotic plaque burden and inflammation in atheroscle-
rosis prone mice by directly affecting the inflammatory response of plaque mac-
rophages [75]. The drawback of therapies targeting the atherosclerotic plaque 
or circulating monocytes is that chronic treatment is required, while therapies 
interfering at the level of hematopoietic progenitor cells might be more effec-
tive with long-term effects, although the duration of hematopoietic progenitor 
cell reprogramming is still unknown. Targeting hematopoietic progenitor cells 
demands high specificity and affinity of the compound to prevent unexpect-
ed side-effects. Taking in consideration the complex interplay of cell-intrinsic 
and microenvironmental factors to maintain hematopoietic homeostasis in the 
bone marrow nice, the hematopoietic progenitor cells that enter the blood-
stream could also be a potential target.
A more detailed understanding of the mechanisms that drive immune cell re-
programming is needed to provide a target that is effective and highly specific. 
Moreover, currently there is circumstantial evidence that trained immunity con-
tributes to the non-resolving inflammation in atherosclerosis. Therefore, longi-
tudinal studies in humans are needed to provide causality for the role of trained 
immunity in atherosclerosis. On theoretical grounds all metabolic and epigen-
etic processes that perform an essential role in training are potential targets 
for pharmacological therapies. A combination with targeted delivery is needed 
to reach specific sites as the atherosclerotic plaque or the bone marrow niche. 
Examples of such therapies, are with the use of nanotechnology, siRNA/sgRNA 
delivery or epigenetics pharmaceuticals (BET inhibitors, Chapter 2) targeting 
myeloid (progenitor) cells in the future [76, 77]. These recent developments 
open the avenue for future pharmacological targets at the level of myeloid cell 
reprogramming for prevention and therapy in atherosclerosis. 
The results of this thesis will improve the current understanding of the role of 
the innate immune memory in the development of atherosclerosis, both in the 
context of traditional risk factors for atherosclerosis as well as in the context of 
chronic infections which are associated with atherosclerosis, and related cardio-
vascular diseases.
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Hart- en vaatziekten (HVZ), zoals een hartinfarct, beroerte, of vaatlijden, 
worden meestal veroorzaakt door slagaderverkalking. Slagaderverkalking, ook 
wel atherosclerose genoemd, ontstaat op volwassen leeftijd onder invloed van 
roken, overgewicht, een hoge bloeddruk, een verhoogd cholesterol of suiker-
ziekte. Deze risicofactoren om atherosclerose te ontwikkelen komen veel voor, 
en daarom zijn HVZ doodsoorzaak nummer 1, zowel in Nederland als wereld-
wijd. Met het aanpassen van de leefstijl, door gezonder te eten en meer te be-
wegen, en met medicatie, zoals bloeddruk- en cholesterolverlagende middelen, 
wordt het risico op HVZ verlaagd. Het liefst zou je het ontstaan van HVZ willen 
voorkómen, en daarom heb ik onderzoek gedaan naar het ontstaan van athero-
sclerose (slagaderverklaring) om nieuwe aangrijpingspunten voor medicijnen 
te ontdekken.
In de afgelopen 20 jaar is duidelijk geworden dat atherosclerose (slagaderver-
kalking) niet alleen bestaat uit een opstapeling van cholesterol in de vaatwand, 
maar ook uit een chronische ontsteking van de vaatwand. Atherosclerose 
ontstaat doordat witte bloedcellen, de monocyten, cholesterol opnemen en 
vervolgens verplaatsen naar de vaatwand. De witte bloedcellen (monocyten) 
zorgen vervolgens voor een ontstekingsreactie in de vaatwand. De monocyten 
veranderen in schuimcellen nadat ze cholesterol opnemen (macrofagen) en 
produceren signaalstoffen die andere cellen van het afweersysteem aantrek-
ken. De opstapeling van afweercellen en cholesterol veroorzaakt een (athero-
sclerotische) plaque in de vaatwand. Opvallend is dat bij mensen met slagad-
erverkalking de monocyten in het bloed veel actiever zijn, ze produceren meer 
signaalstoffen dan de witte bloedcellen van gezonde mensen. De gedachte is 
dat dit het ontstaan van slagaderverkalking versneld.
Afweersysteem
Baanbrekend onderzoek heeft laten zien dat monocyten niet zo simpel zijn als 
men eerst dacht. Daarvoor zal ik eerst uitleg geven over ons afweersysteem. 
Monocyten horen bij het aangeboren afweersysteem, met deze soort cellen 
word je geboren. De witte bloedcellen van het aangeboren afweersysteem zijn 
de eerste verdedigingslinie voor bacteriën, virussen, alles wat lichaamsvreemd 
is. Deze cellen reageren snel, maar niet gericht. Het verworven afweersysteem 
is het deel van het afweersysteem met een geheugen. Dit is de tweede verde-
digingslinie van het lichaam, het reageert langzamer maar wel heel gericht. 
Een groot voordeel is dat deze afweercellen een indringer levenslang kunnen 
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onthouden, waardoor je een tweede keer niet of nauwelijks ziek wordt. Deze 
cellen zorgen ervoor dat vaccinatie je beschermt tegen een ernstige ziekte, 
zoals bijvoorbeeld met de vaccins tegen het coronavirus (COVID-19). 
Kortgeleden is ontdekt dat witte bloedcellen van de aangeboren afweer 
ook een vorm van geheugen hebben. Als ze worden blootgesteld aan een li-
chaamsvreemde stof, reageren ze de tweede keer sterker door de productie 
van meer signaalstoffen. Deze reactie is echter niet gericht, er is een sterkere 
activatie tegen verschillende soorten ziekteverwekkers, maar zorgt wel voor 
een snellere klaring van de indringer. Het is bijvoorbeeld aangetoond dat vac-
cinatie tegen tuberculose ook activatie geeft van de aangeboren witte bloed-
cellen, zoals monocyten. Dit vaccin beschermt dan ook niet alleen tegen tuber-
culose, maar tegen meerdere ziekteverwekkers. Dit mechanisme van activatie 
van monocyten na eerdere blootstelling heb ik onderzocht bij het ontstaan van 
atherosclerose.
Mijn promotieonderzoek
In mijn promotie heb ik onderzocht hoe monocyten van patiënten met risico-
factoren voor HVZ, met atherosclerose (slagaderverkalking), en met HVZ in de 
hersenen zich gedragen. Bij zowel patiënten met HVZ als bij patiënten met HVZ 
in de hersenen, gedragen de monocyten zich actiever dan bij gezonde mensen. 
Dit kenmerkt zich door een toegenomen productie van signaalstoffen en een 
hoger energieverbruik (metabolisme) in monocyten. Hieronder zal ik deze 
onderzoeken per hoofdstuk kort uitlichten.
Hoofdstuk 2
In dit hoofdstuk geef ik een overzicht van de kennis tot nu toe over het werkings-
mechanisme waardoor monocyten geactiveerd raken, bijvoorbeeld bij mensen 
met hart- en vaatziekten.
Hoofdstuk 3
Ik heb onderzoek gedaan bij patiënten met een ernstige vorm van tandvlees-
ontsteking (parodontitis), die een groter risico hebben op het krijgen van HVZ. 
De hypothese was dat dit komt doordat de ontsteking in het tandvlees ook in 
het bloed tot meer ontsteking-verhogende signaalstoffen leidt, hierdoor mono-
cyten activeert die vervolgens naar de vaatwand verplaatsen. In het laboratori-
um zag ik inderdaad dat monocyten sterker reageren na blootstelling aan een 
bacterie die tandvleesontsteking veroorzaakt. In de vergelijking tussen mensen 
met een ernstige vorm van tandvleesontsteking en mensen met geen of milde 
tandvleesontsteking was er echter geen verschil te zien in de productie van sig-
naalstoffen door monocyten in het bloed. Waarschijnlijk was er geen verschil 
doordat de groepen te klein waren of in ziekte-ernst te weinig van elkaar ver-
schillen. Daarom is vervolgonderzoek nodig in een grotere groep mensen om de 
activatie van monocyten in het bloed aan te tonen.
Hoofdstuk 4
In patiënten met ernstige slagaderverkalking onderzocht ik naast de monocyten 
in het bloed ook de stam- en voorlopercellen in het beenmerg. Onze hypothese 
was dat in de stamcellen ook veranderingen te zien zijn, die hyperactivatie van 
monocyten veroorzaken.
In stamcellen verkregen uit het beenmerg van patiënten met HVZ waren inder-
daad veranderingen te zien. Deze stamcellen produceren meer witte bloedcel-
len van het aangeboren afweersysteem dan het verworven afweersysteem. Ook 
worden de stam- en voorlopercellen meer geactiveerd dan bij gezonde mensen, 
dit uit zich in een toegenomen productie van signaalstoffen en toegenomen 
energieverbruik. Het is een nieuw en baanbrekend inzicht dat de stamcellen bij 
mensen met HVZ veranderen.
Hoofdstuk 5
In mensen met risicofactoren voor HVZ onderzocht ik of meer bewegen en 
minder zitten de activiteit van monocyten kan veranderen. In een 16-weken 
durende interventie gingen proefpersonen meer bewegen en als gevolg daar-
van minder zitten. Ik vergeleek de productie van signaalstoffen door monocyten 
voor en na de interventie, en wat bleek: er was een daling in productie van sig-
naalstoffen na de interventie. De monocyten werden dus rustiger. Dit geeft aan 
dat meer bewegen een gunstig effect heeft op je afweersysteem, en hiermee 
mogelijk ook de kans op hart- en vaatziekten verlaagt.
Hoofstuk 6 en 7 
Ook onderzocht ik bij mensen met een vorm van HVZ in de hersenen de mono-
cyten in het bloed. Bij HVZ in de hersenen treedt schade op aan de kleinste 
bloedvaten in de hersenen, in het Engels cerebral small vessel disease genoemd. 
In een grote groep mensen werd met MRI-scans de ontwikkeling van de ziekte 
bijgehouden, driemaal in de periode van 2006 tot 2015, en vanaf 2018 maan-
delijks gedurende 10 maanden. Het bleek dat de hyperactivatie van monocyten 
verband houdt met de ernst en de ontwikkeling van cerebral small vessel dis-
ease. Ook hier zag ik dat de witte bloedcellen een belangrijke rol lijken te spelen 




Dit onderzoek levert een belangrijke bijdrage voor het ontwikkelen van nieu-
we medicijnen in de toekomst. Ik heb namelijk laten zien dat monocyten een 
belang rijke rol spelen bij het ontstaan en de ontwikkeling van HVZ. Daarnaast 
weten we nu dat stamcellen van mensen met HVZ veranderingen ondergaan, 
en dat is mogelijk een nieuw aangrijpingspunt voor medicijnen. Ook heb ik laten 
zien dat meer bewegen een gunstig effect heeft op de activiteit van monocyten, 
en dus mogelijk gedane schade (lees slagaderverkalking) om kan keren.
Toekomst
Nu worden hart- en vaatziekten medicamenteus behandeld door het verlagen 
van cholesterol en de bloeddruk. Door nieuwe inzichten in de rol die mono-
cyten spelen bij het ontstaan van slagaderverkalking, zijn nieuwe medicijnen op 
de markt gekomen die aangrijpen op het onderdrukken van het afweersysteem. 
Deze medicijnen verlagen inderdaad het risico op het krijgen van HVZ, maar 
verhogen het risico op het krijgen van een infectie. Ik heb met mijn onderzoek 
bijgedragen aan het vinden van een specifieker aangrijpingspunt. Meer onder-
zoek is nodig om een specifieker medicijn te ontwikkelen dat aangrijpt op de 
monocyt in de vaatwand of zelfs al in het beenmerg. Het uiteindelijke doel is 
om hiermee hart- en vaatziekten te kunnen voorkómen, zonder dat dit leidt tot 
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baar voor de samenwerking, collega’s en morele steun, want onderzoek doe je 
zeker niet alleen. Hiervoor wil ik iedereen die daarbij betrokken was bedanken, 
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dergaan. Zonder jullie was dit proefschrift er niet geweest, en dankzij jullie is de 
wetenschap weer een stap verder. Bedankt voor het vertrouwen in de weten-
schap.
Beste Niels, prof. dr. Riksen, in de wekelijkse meetings heb ik je leren kennen als 
een echte klinisch-onderzoeker die op wonderbaarlijke wijze onderzoek, onder-
wijs en kliniek kan combineren (met het bouwen van een huis). Ik heb respect 
voor je diplomatie, geduld en bescheidenheid. De vriendelijkheid en het ingeto-
gen enthousiasme waren fijn. Bedankt voor het richting geven, door zowel de 
weg te wijzen als de stip op de horizon aan te geven. En zoals je ziet, is de kaft 
natuurlijk okergeel geworden.
Beste Leo, prof. dr. Joosten, je enthousiasme voor de reumatologie, jicht en 
IL-1 is onuitputtelijk, en het was aanstekelijk. Het is geen toeval dat er nu 3 
arts-onderzoekers reumatoloog worden, waaronder ik zelf. Bij jou kwam ik altijd 
met goede verhalen en 10 nieuwe ideeën terug. Ik wens je veel gezondheid.
Beste Mihai, prof. dr. Netea, de beschrijving van Servaas, als ‘een van de slimste 
mensen die ik ken’ was initieel de reden om naar Nijmegen af te reizen. Het 
Mihai-effect is een fenomeen. Je bent een inspiratiebron voor velen, door de 
combinatie van genialiteit met vriendelijkheid. Het is wonderlijk hoe je uit een 
brij experimenten de essentie weet te vatten, en iedere keer weer weet te en-
thousiasmeren met de woorden ‘dat is geweldig!’. Je was cruciaal als we op een 
kruispunt stonden om de juiste weg in te slaan.
Beste Servaas, prof. dr. Morré, bedankt voor het aanwakkeren van mijn interes-
se voor onderzoek en de kansen die je me hebt geboden.
Dear colleagues of experimental internal medicine group (AIG), you are spe-
cial! It was wonderful to be part of a highly talented, international, and diverse 
group of colleagues. Besides the hard work and yearly round of Science/Cell 
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papers, there was always room for cake, laughter and to help each other out. 
Even the terror Tuesdays will be missed. Thanks for the warm welcome and the 
surprise house-warming in Nijmegen. Beste analisten, Helga, Heidi, Liesbeth, 
Cor, Trees, Anneke, Liesbeth, Kiki, en Fieke, bedankt voor al jullie hulp, gezel-
ligheid, kunde, overzicht en orde in het lab.
Siroon, dr. Bekkering, ik stapte net na je vertrek in jouw schoenen. Gelukkig 
keerde je ook weer terug naar Nijmegen, en kon ik ontdekken dat je naast een 
fantastisch onderzoeker ook een heel leuk mens bent. Het was fijn om jou als 
coach, op de voor- en achtergrond, te hebben. Ik hoop op nog veel toekomstige 
brunch/borrel-dagen. Lieve Charlotte, wij startten gelijktijdig als clinici in het 
lab. Het was fijn om het traject samen te doorlopen en de pieken en dalen te 
delen. Van patiëntenstudies opzetten tot het uitvogelen van nieuwe ELISA-pro-
tocollen, samen kwamen we er wel uit. Je bent een fantastisch mens en dokter, 
mede daarom ben ik zo benieuwd waar jouw pad je brengt. Lieve Julia, wat 
ben ik blij dat jij mijn paranimf bent! Het was fijn dat we (met Charlotte) altijd 
bij elkaar konden binnenvallen voor goede koffie, advies, gezelligheid, gedeel-
de hobby of een luisterend oor. Hopelijk zijn beide erfstukken, de FOCUS en 
UNHAPPY FEW studies, baanbrekend. Nog heel veel succes met de afronding, 
maar als marathonloper weet je als geen ander wat volhouden is. Laszlo, you 
are a true scientist, and that is obvious when you present your data or new re-
search ideas. I admire that. I wish you a bright future, and the best of luck with 
your new position. Sam, you taught me a deeper understanding of epigenetics, 
English and so much more. I wish you all the best. De nieuwe PhD studenten, 
Harsh, Daniella, Wieteke en Helin, ik wens jullie veel plezier en succes.
Roomies, Maartje, Rob en Freek, het was gezellig om met jullie een kamer in de 
buitenhoek te delen. De muur van chocola, de onderzoek drang van Rob met 
ons als lijdend voorwerp, Freeks grappen en de gezelligheid en het Venloos dia-
lect van Maartje zal ik niet snel vergeten. Beste Inge, Vera, Jorge, als Utrechters 
deelden we vaak een coupé, vooral om bij te kletsen. Jullie zijn stuk voor stuk 
toppers. Beste Charlotte (de Bree), je bent een warm, hartelijk mens die onwijs 
veel gedaan krijgt in een korte tijd. Beste Wouter, je brengt met je vele verh-
alen veel gezelligheid en kennis met je mee. Lieve Simone, de bootcamps op 
snikhete avonden en etentjes waren altijd fijn. Groetjes aan je vissen ;). Beste 
Ruud, door jou en je vriendengroep werd ik in korte tijd omarmd, en ingeburg-
erd in het bruisende Nijmegen. Ik hoop op snel weer zulke gezelligheid. Dear 
Mariolina and Diletta, I enjoyed your passion and tips for Italy and Italian food. 
Team Lowlands, en Charlotte, Anne, Rob, wat een avontuur om onderzoek te 
doen op Lowlands! Het was een mega-operatie, waarvoor jullie de credits verd-
ienen, maar ook ontzettend gaaf. Het moment dat the XX – Intro speelde tijdens 
onze briefing met 18 man: onvergetelijk. Dank jullie wel!
Beste collega’s van de neurologie, Annemieke, Kim, en Frank-Erik de Leeuw, we 
hebben een mooie samenwerking opgezet die heeft geleid tot meerdere mooie 
publicaties, vervolgonderzoek en veel meetings met kopjes thee. Annemieke 
en Kim, rustig en vastberaden hebben jullie een mega-project voltooid, het was 
een erg prettige samenwerking!
Beste collega’s van fysiologie, Yvonne en Dick Thijssen, jullie zijn een team. 
Samen enthousiasmeren jullie je proefpersonen, studenten, het hele Rad-
boudumc om minder te gaan zitten en meer te bewegen. Dank voor de bevl-
ogen samenwerking.
Beste Adelina, het klikte meteen tussen ons. Het was een bijzonder project 
tussen de parontologie/tandheelkunde en de interne geneeskunde. Ik heb ge-
noten van de gezellige onderzoeksdagen op maandag.
Beste collega’s van cardiologie, Saloua, Mariëlle, Suzette Elias-Smale, het uit-
voeren van de pilotstudie was zo gepiept door jullie strakke organisatie. Het is 
mooi dat deze pilot tot een grote beurs heeft geleid. Saloua, bedankt voor je 
warmte en support tijdens mijn PhD. Beste collega’s in het CWZ, Tim en Marc, 
bedankt voor de soepele samenwerking.
Beste collega’s van de nucleaire, Esther en Erik Aarntzen, bedankt voor jullie 
enthousiasme over alles wat met PET-CT-scans te maken heeft. De ideeën zijn 
eindeloos en het werk wat Esther verzet ook.
Beste collega’s van de hematologie, Erik, Frank Preijers, Manita, Harry Dolstra, 
dank voor het delen van jullie oneindige kennis over hematopoëse, flow cytom-
etrie, sorting en CFU-assays.
Beste collega’s van de intensive care, Guus, Nienke, Jelle, Matthijs Cox, Peter 
Pickkers, onze paden kruisten op verschillende momenten voor een levendige 
discussie, gezamenlijke uitdagend complexe studie, als mentor of als monitor.
Beste collega’s van de interne geneeskunde van het Antonius ziekenhuis, wat 
een feest om hier te werken. Iedere dag leer ik iets nieuws in een gezellig team 
van collega’s. Ik kijk uit naar de borrels in het post-COVID tijdperk om ook buiten 
werktijd de gezelligheid te delen!
Lieve vrienden en vriendinnen, wat fijn dat jullie er zijn! Lieve Rosa, we al zijn 
vriendinnen sinds de peuterklas en het is bijzonder dat we dat nog steeds zijn. 
Ik waardeer onze vriendschap, omdat we elkaar zo goed kennen en ook zo ver-
schillend zijn. Samen steden verkennen door de architectuur, mode (winkelen), 
of kunst te zien, is het leukste. Drieling, Eleanne, Hannah, en Laurens, volgens 
mij waren wij binnen 1 uur vrienden en daarna onafscheidelijk. Na veel gekki-





avond vol gezelligheid vliegt voorbij en geeft zo veel energie. Ik ben zo blij met 
jullie. Na Berlijn en Dublin voel ik weer een nieuwe stedentrip aankomen! Lieve 
Alejandra, het is fijn dat we altijd kunnen kletsen, over alles en over niks, met als 
enige voorwaarde: lekker eten. Onze vriendschap is gegroeid van huisgenoten in 
de Bijlmer, op-en-neer van Amsterdam naar Nijmegen, naar wekelijks lunchen/
koffie drinken en eindeloos rondjes lopen in Utrecht. Studiemaatjes, Wieneke, 
Anneke, Lisanne, en Robbert, ons avontuur in Tanzania was een kers op de 
taart om geneeskunde mee af te ronden. Het is mooi om te zien hoe ieder zijn 
eigen weg heeft gevonden, huizen koopt, en dat de eerste baby eraan komt. Ik 
geniet van onze eetdates en jullie Amsterdamse eigenheid. Lisanne, ik kan echt 
genieten van je passie voor biologie en je interesse in mijn PhD. De Levenden, 
Kris, Quintine, Kelvin, Anouk, Jorrit, Wouter, Charlotte, Jet, Sylvia, Olaf, Lionel, 
Richelle, Martine, Stefan, Geert, Mara, Mila, met Rik kreeg ik er een leuke vrien-
dengroep bij. Vol bruisende energie, openheid en maffe ideeën zijn alle week-
endjes en festivals een groot feest. Dat jullie me vol verwondering uithoren over 
mijn onderzoek met levende cellen, is genieten. De vraag ‘of het al af is’ kan ik 
nu eindelijk met JA beantwoorden.
Lieve schoonfamilie, Wim, Ellen, Jos, Kevin, Kris, Quintine, Trudi, ik weet nog 
goed dat we 9 jaar geleden kennis maakten in een wat vreemd Turks restaurant. 
Ik heb bewondering voor jullie warmte, vrijgevigheid en het feit dat jullie er 
altijd voor iedereen zijn. Jullie voelen als mijn tweede familie, dank daarvoor.
Lieve familie, bedankt voor jullie betrokkenheid op ieders eigen manier. Lieve 
Mien, dankjewel voor het stimuleren van alle creativiteit. Lieve oma, hoe bi-
jzonder is het dat ik mijn thesis aan u kan laten zien. Ik weet zeker dat u trots 
bent, en daar kan ik nu al van genieten.
Lieve pap en mam, Bob en Elly, ik heb veel aan jullie te danken en vooral dat 
jullie er voor me zijn. Bedankt dat jullie me hebben aangemoedigd om nieu-
wsgierig te zijn, eigen ‘wijs’ te worden, en mijn eigen weg te kiezen. Er is geen 
groter geschenk dan om te weten dat er altijd een thuis is, wat er ook gebeurt. 
Moira, ik zal je geen klein pittig opdondertje noemen, maar je bent een perfecte 
aanvulling in ons gezin. Freek, lieve broer, ik denk dat ik me geen leukere broer 
kan wensen. Ik bewonder je om je sociale, geestige, lichtvoetige manier van in 
het leven staan. Ik ben trots op je!
Lieve Rik, mijn liefde en beste vriend. Als iemand weet dat je onderzoek niet 
alleen doet, dan ben jij het wel. Je hebt met me meegeleefd in de ups en downs 
die bij een PhD horen, weet meer van cytokines dan normaal is, en we zijn zelfs 
samen naar Nijmegen verhuisd. Het is fijn dat je er altijd voor me bent, al tien 
jaar lang. Ik hou van je!
Research data management
The data obtained in this thesis are archived according to the Findable, Acces-
sible, Interoperable and Reusable (FAIR) principles (1). Raw and processed in 
vitro and in vivo data were stored digitally on a local server of the department 
of internal medicine, which is backed up daily on the Radboud Server. All human 
studies were conducted according to the principles of the declaration of Helsin-
ki and were approved by the Medical Ethics Committee of the Radboudumc. 
All participants gave written informed consent before participation. The privacy 
of the participants in this study is warranted by use of encrypted and unique 
individual subject codes. Case Report Forms were stored in Castor EDC (2). Data 
where converged from Castor EDC to SPSS (SPSS Inc., Chicago, Illinois, USA). The 
data generated in this thesis are part of published articles and its additional 
files are available from the associated corresponding authors upon request. The 
RNA sequencing data in Chapter 4 and 7 are publicly available at the ArrayEx-
press database at EMBL-EBI data repository and the gene expression omnibus 
(GEO) data repository, respectively.
1. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The 
FAIR Guiding Principles for scientific data management and stewardship. Sci Data 
2016;3:160018.
2. Castor EDC. (2019). Castor Electronic Data Capture. [online] Available at: https://casto-
redc.com.
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Graduate school:    Radboud Institute for
                     Molecular Life Sciences
PhD period:  16-04-2016 until 
                                                27-09-2019
Promotor(s):  Prof.dr. N.P. Riksen,
                                   Prof.dr. L.A.B. Joosten
Co-promotor: Dr. S. Bekkering
TRAINING ACTIVITIES Year(s) ECTS
Courses & Workshops
Introductory course Radboudumc
RIMLS Introductory course “in the lead”
BROK course
Statistics Course
Workshop: how to sell science
EPIC course
Flow cytometry course part 1 and 2, Cambridge
Scientific writing course
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Vascular Damage Research Theme symposium 
Radboud Research Rounds inflammation




Radboud Research Rounds cerebral SVD
Radboud Research Rounds infectious diseases
Radboud Research Rounds vascular damage


























(Inter)national Symposia & Congresses
Radboud Summer Frontiers Systems Biology of Innate Immunity 
Radboud Science Days – Lab internal medicine
Hartstichting vascular damage course#
Innate Immune Memory, Cambridge#
PhD retreat#
Radboud Science Days – Lab internal medicine
European atherosclerosis symposium, Lisbon*
Mennorode retraite*
Heart for women symposium
PhD retreat*


























Weekly: Cytokine Meeting (2 presentations/year)*
Monthly: Vasculometabolic Meeting (2 presentation/year)*
Two-weekly: Vascular Damage Meeting (1 presentation)*
Presentation with collaborators (2 presentations/year)*
















TEACHING ACTIVITIES Year(s) ECTS
Supervision of internship students
N.a.
Teaching & organization 
Teaching skills and development of flow cytometry protocol 2017-2019 0.5
TOTAL 33,85
Oral and poster presentations are indicated with a * and # after the name of the activity, respec-
tively.
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Marlies Noz werd op 25 augustus 1990 geboren in Utrecht en groeide op in 
Driebergen. In 2008 voltooide ze het atheneum aan de K.S.G. De Breul in Zeist, 
en datzelfde jaar begon ze haar studie Biomedische Wetenschappen aan de Vri-
je Universiteit in Amsterdam. 
In 2009 startte Marlies ook de studie Geneeskunde en combineerde dit met 
de studie Biomedische Wetenschappen. Tijdens haar studie Geneeskunde aan 
de Universiteit van Amsterdam/AMC liep zij meerdere stages in het buitenland 
waaronder in Suriname (verpleeghulpstage), Oeganda (keuze-coschap) en Tan-
zania (tropen-coschap). Tijdens de masterfase heeft Marlies haar wetenschap-
pelijk onderzoek in California, Verenigde Staten uitgevoerd onder begeleiding 
van prof. dr. Servaas Morré naar de virulentiefactoren van Chlamydia tracho-
matis.
Na het afronden van haar master Geneeskunde in 2016, is ze meteen gestart 
met een promotieonderzoek op de afdeling Interne Geneeskunde in het Rad-
boudumc in Nijmegen. Onder begeleiding van professor Niels Riksen, professor 
Leo Joosten en professor Mihai Netea deed ze met een vierjarig promotietra-
ject met als hoofdthema de rol van het immuunsysteem bij hart- en vaatziek-
ten. Haar promotieonderzoek besloeg onder andere laboratoriumwerk en pa-
tiëntenstudies waarvan het resultaat van de inspanningen is beschreven in dit 
proefschrift, alsmede in aanvullende publicaties die niet in dit proefschrift zijn 
opgenomen. Tijdens haar promotie groeide haar interesse voor de immunolo-
gie en reumatologie, en besloot ze te solliciteren voor de opleiding reumatolo-
gie. Sinds juni 2020 werkt Marlies als AIOS reumatologie, vooropleiding interne 
geneeskunde in het Sint Antonius Ziekenhuis in Nieuwegein. Marlies woont 
samen met haar vriend Rik van Houten in Utrecht.
